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Abstract
FDA drug approval process takes years to reach manufacturing, development is 2-10 
years, pre-clinical treatment another 3-6, clinical trails 6-7 years and finally FDA review, 
another 1-2 years. This a long process due to the safety concerns for releasing a new 
drug, with unseen side effects often occurring. This said a new drug that is treating a 
disease that has no treatment or no cure is fast tracked, shortening this time substantially. 
The point I am trying to make, is that Alzheimer’s disease has no cure, it has no treatment 
and by 2050 it is expected that 16 million in the US alone will be struggling with the 
disease. Any drug developed for Alzheimer’s disease would be fast tracked, nevertheless 
there are still no drugs available. Many proteins in the amyloid precursor protein (APP) 
pathway have been investigated to better understand Alzheimers disease. Secreted 
amyloid precursor protein alpha (sAPPα) is a candidate for drug design, it’s proven 
function include neuroprotection and eliciting neurone growth and proliferation.
This study aimed to elaborate on the mechanisms of the sAPPα protein. Investigating if 
subsections of the sAPPα protein, RER and the 16mer have a similar level of functionality, 
specifically its neuroprotection. An additional aim is to investigate novel protein synthesis 
caused by sAPPα. This was done through a molecular technique SILAC (Stable Isotope 
Labelling of Amino acids in Cell culture) enabling us to identify a range of proteins that had 
altered levels of expression with the addition of  sAPPα. 
My results showed that protein expression change over time when induce with sAPPα, 
with vastly different spectrum of altered protein expression at 6 and 12 hours. Some of the 
functions purposed to be effected by induction with sAPPα was RNA processing, DNA 
repair, glycolysis and cell growth and proliferation. There were proteins identified with a 
direct link to sAPPα, such a nicastrin and its role in 𝛄-Secretase. The protein analysis also 
brought new questions from which future SILAC experiments could be designed. Data was 
also analyzed for the subsections of sAPPα, showing that each induced a different 
spectrums of proteins, with some correlation observed between the RER/16mer with the 
full length sAPPα. The discovery of the sAPPη allowed an increase understanding and 
practice of biochemical techniques, but functional assessment is for further work. 
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1.1 Symptoms of Alzheimers disease
Alzheimers disease (AD) is the most common form of dementia, an umbrella term for diseases/
conditions characterised by damaged neurons and/or their connections. Dementia  is classified by 
a decline in memory, accompanied by impaired judgment, faulty reasoning, loss of communication 
skills and disorientation. AD is a more specific diagnosis with a more defined list of symptoms such 
as; difficulties in remembering new information, memory loss that disrupts life, challenges in 
planning or solving problems, difficulties completing familiar tasks, confusion with time or place, 
newly acquired problems with words or spoken language, the misplacement of things and an 
inability to retrace steps, increasingly poor judgment and a withdrawal from social interactions and 
significant changes in mood and personality (McKhann et al., 1984). AD prevalence is rising due to 
an ageing population with no cure or treatment, although change in diet and exercise 
demonstrated in the Unites States has shown an apparent short term decline in the rate of 
increase of prevalence (Alzheimers association  2015, 2016). Despite this, there is still a need to 
research therapeutic treatments derived from a deeper understanding of the biology of the disease.  
1.2 Epidemiology of AD
Alzheimers disease is the most common form of dementia accounting for about 71%  of deaths in 
America, making AD the sixth leading causes of death of Americans (Alzheimers association 
2016). Despite the recent reported decline, unlike other cause of death in elderly people, AD is 
estimated to be as high as 13.8 million in the US alone by 2050 due to the baby boomer generation 
(figure 1.1). World wide in 2016 (Alzheimers association  2016) there were 44 million people with 
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Figure 1.1: Predicted amount of people 65+ with Alzhiemers in the U.S 
Amount of people predicted to develop Alzheimers disease if no cure is found take 
from Alzheimers association (2016)   
 
AD is not only a challenge medically for, diagnosis and treatment, but also raises challenges 
economically. In the US in 2016 there was an estimated US $236 billion spent on AD healthcare, 
while globally estimations are at US $605 billion, equivalent to 1% of the entire world’s gross 
domestic profit (Alzheimer’s Disease International 2016) . On top of these costs, there is an 
additional 17 billion hours of unpaid care required by family and caregivers (Fargo and Bleiler 
2014). 
1.3 Characteristics of AD
The underlining cause of the AD is more difficult to understand. Although it manifests as atrophy of 
neural matter this is not sufficient to distinguish sufferers of the disease and the normal ageing 
process. It is only through microscopic images of the brain that have a higher resolution, where the 
pathological characteristics; neurofibrillary tangles and amyloid plaques can be identified. Although 
some normal elderly people exhibit these characteristics as well (Munoz and Feldman 2000).
1.3.1 Senile plaques
Senile plaques have a core of aggregated amyloid beta protein (Aβ), surrounded by microglia and 
fibrillary astrocytes. Frequency is not greatly affected by age, with small levels common in the 
elderly, but they remain at low levels in most individuals (Munoz and Feldman 2000), AD patients, 
in contrast, have higher concentrations of senile plaques. Monomeric forms of the Aβ peptides first 
form a soluble aggregate and eventually, switch to an aggregated fibril, and then to insoluble 
plaque form through an unknown mechanism. It is thought that the enzyme butyrcholinesterase 
may facilitate this change (Greig et al., 2001). This change from disaggregated to soluble 
aggregates and then insoluble Aβ is thought to be central to the disease pathology. 
1.3.2 Neurofibrillary tangles
Neurofibrillary tangles (NT) consist of aggregations of irregularly phosphorylated cytoskeleton tau 
proteins. This causes misshapen neurons as the cytoskeleton proteins no longer function properly 
and can’t support the structure of neuronal cells. Neurofibrillary tangles are also a consequence of 
age, but they are not as frequent in a normal ageing brain as in AD patients, nor concentrated in 
areas of the brain consistent with the disease. NTs are often seen in high concentration in the 
hippocampus, a region of the brain responsible for processing memories.
Plaques and NT’s were first seen under electron microscopy in 1963 and they appeared as fibrous 
deposits of 10nm paired helical filaments (PHFs) (Kidd,1963; Terry, 1963). The deposits were 
discovered via immunocytochemical studies focused on tau, a microtubule-associated protein. This 
observation led to one hypothesis- that the tau protein and its irregular phosphorylation is the 
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underlining cause of AD though this has lost support over the years, with stronger evidence now 
favouring the amyloid hypothesis. 
1.4 Genetic risk factors of AD
Most cases of Alzheimers disease are late onset and sporadic rather than inherited, which makes it 
more difficult to find genetic lesions, that might be associated with disease onset. In early onset or 
familial AD (EOAD or FAD) there are a few genes that have been identified. Most cases of FAD (up 
to 80%) are caused by mutations in presenilin 1 (PS-1); up to 80% (Campion et al., 1996) . The 
gene is located on chromosome 14 and is important in development as is it homozygous lethal. But 
the exact function is unknown. Most of the mutations are missense, which suggests a decrease or 
abnormal function rather than lack of production. Another gene linked to FAD is amyloid precursor 
protein (APP), found in 5% of FAD patients (Goate et al.,  1997). There are a number of mutations 
that have been identified around the α, β, or 𝛄 cleavage sites of APP, that have varied effects. 
Mutations in APP can lead to overproduction of Aβ or an increase in Aβ1-42 peptide which is the 
major component of the amyloid plaques. The last autosomal dominant gene identified is PS-2, 
which is homologous to PS-1, but neither gene product can compensate for the other (Duff et al., 
1996). The issue with focusing on these autosomal dominant genes, is that they only accounts for 
a small percentage of AD cases (10%). The majority of AD is late onset and sporadic in nature and 
is likely to result from a combination of genetic predisposition and environmental factors.   
1.4.1 Apolipoprotein E
One of the most established genes associated with increased risk of AD, is apolipoprotein E 
(APOE). There are three common alleles of this gone ε2,3 and 4 in which ε4 has been shown by 
multiple studies to be a risk factor for AD (Pericak-Vance et al., 1991). APOE has also shown to 
have a dose dependent relationship with the copy number of the risk allele. Such as a 
heterozygous individual of ε4 has a smaller risk of getting AD compared to a homozygous 
individual, assuming no other associated risk, genetic or environmental (Corder et al., 1993). The 
ε4 allele has also been linked to lowering the age of onset, with each copy lowering onset age by 
7-9 years. However the ε2 allele from the same gene is linked to giving a protective effect. 
1.4.2 TREM2
Microglia receptor TREM2 (triggering receptor expressed on myeloid cells 2) acts as a sensor for 
lipids associated with Aβ accumulation. Thereby recognise damage-associated lipid pattern from 
Aβ neuronal damage eliciting a microglial phagocyte response. R47H mutation in TREM2 is a risk 
factor for Alzheimer’s disease with a known biochemical mechanism for its genetic association. 
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R47H mutation in TREM2  impairs recognition of lipids, thus decreasing the phagocytic ability of 
microglial to clear Aβ plaques (Wang et al., 2015).     
1.4.3 α2 macroglobulin
α2 macroglobulin gene (A2M) is a serum pan-protease inhibitor and it has been identified in senile 
plaques. A2M can bind Aβ and attenuates fibril aggregation and neurotoxicity (Tilley, L et al., 1998). 
A mutation in the a splice acceptor site has been associated with AD with an odds ratio of 3.6. 
1.4.4 Butyrlcholinesterase
Butyrlcholinesterase (BCIE) is ubiquitous throughout the body, although its function is unknown. It 
has been investigated in terms of AD for two reasons (Ⅰ) Its levels increase with age in the brain 
and (Ⅱ) histochemistry shows that BCIE is in both neurofibrillary tangles and senile plaques. A 
variant of the enzyme has A123T halves its catalytic capabilities (Adrent et al., 1992). This variant 
BCIE has been shown to have an increased level in LOAD and confer a two-fold increase in 
association risk. 
1.4.5 α1 antichymotrypsin
α1 antichymotrypsin (Act) is another enzyme discovered by protein analysis of senile plaques 
(Tilley, L et al., 1998). Act mRNA is highly expressed in AD patients and the protein is in the core of 
the senile plaques. Mutations in the ACT gene have been shown to increase risk association, but 
only in ε4 carriers. Unfortunately most of the genes discovered to have association with either 
sporadic or inheritable AD and are not well understood. Most of the genes discovered to have 
association with AD have no known function. Without known function a list of genes that are 
associated with the disease could provide some diagnosis benefit, but as yet no therapeutic 
benefit.  
1.5 Environmental risk factors of AD
A large epidemiological study of AD looked at 40 patients and 80 controls. The study looked at 
lifestyle choices, prior illnesses, diet, unrelated medical treatments and family history in terms of 
association with AD (Heyman et al., 1984). Lifestyle choices are environmental factors seen in 
many disease studyies. Such as consuming alcohol on a regular basis, a smoking a pack of 
cigarettes a day or heavy drinking of coffee. In this AD study, no significant differences was seen 
between controls and AD patients. Prior illness was shown to be a far more important 
environmental factor. Head injuries, thyroid disease, World War I Influenza  infections and shingles 
all having a significant association with an increase risk AD (Heyman et al., 1984). Head injuries 
had a odds ratio (OR) of 5.31 shown in Heyman’s study and 3.7 in another study (Mayeux et al., 
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1993). Diet may be a significant environmental factor, as different foods have been be linked to 
multiple diseases, and AD is sometimes referred to as type Ⅲ diabetes. It is not unlikely that some 
diets could be associated with increased risk of developing AD (Scarmeas et al., 2006). 
Consumption of antacids were analysed due to the suggested link of aluminium with onset AD, but 
no association was found (Flaten 2001). The only association found was between thyroid 
medication, although not significant. The association is likely due to the risk factor found with 
thyroid disease and AD. Family illness was examined with patients more often have family 
members with a dementing illness or suffering from some form of mental retardation. The odds 
ratio of a family member having a dementing illness is 7.74, which suggesting undiscovered  that 
there are more genetic factors playing a role above those currently discovered (Heyman et al., 
1984).   
1.5.1 Aluminium links to AD
Aluminium (Al) has been linked to Alzheimer's disease, which isn’t surprising considering its 
neurotoxic effects. The first major link between Al and AD was shown with the addition of 
aluminium phosphate in rabbits giving neurofibrillary degeneration that looked very much like the 
neurofibrillary tangles characteristic in AD (Terry and Pena, 1965). Multiple studies have shown 
that a higher concentration of Al in drinking water correlates to a higher mortality caused by 
dementia (Neiboer et al., 1995; McLachlan 1995; Doll 1993). A higher exposure to Al can cause 
dialysis encephalopathy, while it is suggested that in AD a much lower level of AI over a much 
longer period of time can give an slow accumulation over time. However despite the association 
between AI and AD, the pathology observed in dialysis encephalopathy is only rarely similar to AD 
and often used to argue that Ali is not a risk factor. Nevertheless, there is a lot of evidence that 
does suggest a link between AI and AD, with five major points. 
1. High levels of AI have been been found in both neurofibrillary tangles and senile plaques 
(McLachlan 1995) 
2. AD pathology can be replicated in many animal models through the use of AI treatment (Terry 
and Pena, 1965). 
3. Over 100 toxic effects of AI at the molecular and cellular level have been documented, with 
many applicable to the brain (McLachlan 1995) 
4. Treatment with a metal chelator, desferrioxamine typically used to treat iron or AI poisoning 
may of slowed progression of AD (Flaten 2001). 
5. Epidemiology studies link levels of AI in drinking water with AD- this has been shown in a 
number of different countries (Flaten 2001).    
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1.6 Epigenetics of AD 
Different epigenetic markers can cause a decrease or an increase in gene expression, but there is 
still much we do not understand about epigenetic tagging of the genome. In studying AD, 5-
methylcytosines was examined in various tissues to look at the epigenetic landscape and to 
determine if there were any changes in AD patients (Mastroeni et al., 2009). In the anterior 
temporal neocortex, an area highly affected by AD, there was a decrease in methylation. It is 
unknown whether this causes a decrease in genetic regulation directly as a result of the disease, 
or is an early symptom leading to some of the more aggressive pathological symptoms. Looking 
further into this change in methylation, it was discovered by large scale expression arrays, that 
there were changes in expression levels of multiple pathological pathways associated with AD, 
such as Aβ production and tau phosphorylation and these may of been caused by the change in 
methylation levels. 
1.6.1 miRNA epigenetic differences
There are multiple types of epigenetic changes that have been linked to AD, for examples miRNA, 
DNA-methylation and histone alterations. One of the easiest observed changes are in miRNA 
concentrations, which can be linked to specific brain functions. For example, miRNA-206 has been 
shown to promote neuromuscular synapse regeneration ‘William et al., 2009’. Comparisons 
between AD brains and controls showed variation in miRNA expression patterns. miR-20a 
expression was lowered in AD brains, which lead to an increase in endogenous APP by 50% 
(Mastesteroeni et al., 2011). APP mRNA itself has interaction sites with miRNA, however no 
correlations has been seen in APP levels and miRNA. Another important enzyme is the β-
Secretase (BACE1), which has miRNA target sites in the  untranslated region its mRNA. 
miRNA-107 has been shown to have a significant decrease in concentration in early-onset AD 
patients (Wang et al., 2008). There is a negative correlation between miRNA-107 and the mRNA of 
β-Secretase. miRNA-29a/b-1 also targets the mRNA of β-Secretase and has a negative 
correlation. 
1.6.2 DNA methylation
DNA can be methylated to cause an increase or decrease in transcription by making the DNA 
inaccessible to transcription machinery. Studies looking at epigenetics of AD focused on genes that 
have previously been identified as genetic risk factors or parts of biochemical pathways that link to 
symptoms of AD. A comparison between AD and controls showed that CpG island sites of genes 
related to APP metabolism were hypomethylated. Among these genes were β-Secretase and 
Caspase 5 (Mastesteroeni et al., 2011). The hypomethylation observed in these genes is 
associated with an increase in transcription. This leads to an increase in Aβ production, which in 
turn has been shown to induce both genome-wide hypomethyation and hypermethylation of 
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neprilypsin (Chen et al., 2009). Interestingly this causes two negative feed back loops. The 
hypomethylation of β-Secretase and Caspase 5 results in increase cleavage of APP to produce 
more Aβ, while neprilypsin degrades Aβ and its hypermethylation represses its synthesis.      
Studies show that globally there are different levels of methylation in AD patients compared with 
controls. However, Is the change in methylation a causative effect of the pathology of AD or is it a 
consequence that can accelerate and aggravate the process? One theory discussed above 
suggests that progression of late onset AD is a normal progression of an ageing brain. Comparing 
the epigenetic distance of individual AD patients and controls, AD patients showed a greater 
epigenetic distance from the median methylation profile than their control counterparts. It is 
common for genes to become less regulated with age and thereby methylation becomes more 
varied in old age. However this does not explain the significant differences seen in AD patients, as 
aged brains showed a pattern of greater demethylation, while AD brains had increased 
methylation. Looking specifically at the APOE gene; A 30 year difference in age showed an 
average of 10% decrease in methylation of the CG’s in AD while the same age gap had an 
average of 68% decrease in controls (Wang et al., 2008). In either group, de novo epimutations 
(abnormal transcriptional repression of active genes of vice versa) are at a higher level than would 
be expected, suggesting that as DNA mutations accumulate with age, so do epimutations, but with 
a higher frequency. It is possible that after a threshold of epimutations is breached, then cellular 
pathways start to malfunctions leading to a progression into AD. With accumulation of epimutations 
a natural part of ageing, it would mean that if this theory is true everybody would be pre-disposed 
to AD and get it eventually if their other organs are still functioning.
1.7 Tau hypothesis
The tau hypothesis states that neurofibril tangles are the cause of the AD pathology. Despite 
amyloid hypothesis now being the favoured theory, the tau hypothesis continues to be investigated 
and the model for tau’s involvement in AD pathology continues to be adjusted. The tau hypothesis 
has significant evidence to support it and therefore can not be disregarded. There is still much 
about AD that is not understood and regardless of whether the ‘amyloid hypothesis’ or ‘tau 
hypothesis’ proves to be the more correct model, understanding aspects of both is likely needed to 
treat the disease. There are three important clinical symptoms that support the tau hypothesis (Ⅰ). 
There is a high correlation between NFT’s and severity of the dementia- not evident for amyloid 
plaques (Maccioni et al., 2001) (Ⅱ). Cognitive impairment has a high correlation with the level of 
hyperphosphorylated tau species in the cerebrospinal fluid of AD patients (Ghosha et al., 2002) 
(Ⅲ). Targeted drug relief aimed at decreasing tau filaments diminish cognitive impairment 
(Maccioni et al., 2010).  
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1.7.1 Tau protein
The tau protein is a low molecular weight microtubule-associated protein which the plays a major 
role in the microtubule structural stabilisation and for this reason is a crucial component in axons or 
neurons. Tau protein self assembles as of its function but, under pathological conditions can 
become paired helical filaments (Maccioni et al., 1995). The underlining cause of the tau protein 
becoming pathological is it’s hyperphosphorylation, but the theory does not state how the 
functional tau protein switches to their pathological counterpart.       
1.7.2 Tau model
A New model suggests a neuroimmunomodulation origin of the tau’s hyperphosphorylation. The 
abnormal signalling starts with individual factors such as oxidative stress, iron overload or 
disorders in lipid overload. After such abnormal stress signalling microglia are activated and they 
produce pro inflammatory cytokines, such cytokines being NF-𝛋B. Overproduction of these pro 
inflammatory cytokines leads to a deregulation of protein kinases facilitating tau phosphorylation 
(Fernandez et al., 2008). Hyperphosphorylation of tau leads to neuronal cell death and tau 
oligomers being released into the extracellular environment, which in turn increases microglia 
activation. In this sense a positive feedback loop is set up. Where unnatural phosphorylation of tau 
species, causes more cytokines to be released that in turn cause deregulation of the kinases 
responsible for the phosphorylation of the tau protein. This new model suggests that tau 
hyperphosphorylation is the final common pathway in AD pathology, whereby abnormal signalling 
of microglia/cytokines can arise from a number of different causes. The microglia/cytokine cascade 
can be triggered by a range of variable signals that arise naturally, but an exacerbated state from 
over stimulation may lead to the positive feedback loop, suggested by this new tau hypothesis 
model.
1.7.3 Tau treatment
This new model is supported by some evidence of drug therapies targeting hyperphosphorylation 
of tau that shows some level of relief. Transgenic mice show that regardless of tau mutations, 
pathology of AD only progresses after hyperphosphorylation and aggregation of the tau species. 
Thereby if this is indeed a primary cause of AD pathology and not a consequence, then inhibition of 
hyperphosphorylation and subsequent aggregation could prevent AD from developing. Inhibition of 
a heat-shock protein (Hsp90) demonstrates this principle to a degree. Inhibiting this protein causes 
a reduction in chaperone activity and a higher ratio of degradation of mutant tau over wild type tau- 
consequently reducing levels of sarcosyl-insoluble PHF-tau species; a defining feature of 
pathological NFTs. This is a promising result, but has some notable difficulties. Firstly, despite the 
decreased level of misfolded mutant tau, it has not be correlated to a decrease in NFT’s nor an 
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improvement in cognitive impairment. Second, the drug target is aimed at the mutant tau and does 
not account for correctly folded wild type tau hyperphosphorylated, the more active contributor of 
AD pathology in this model. Thereby treatment aimed at mutant tau, no matter how effective, may 
do very little to the overall pathology of AD, assuming this model is correct. A more effective 
method for drug targeting might be use of lithium, already used in bipolar disorders, to inhibit 
GSK3β, a kinase that has been linked to tau phosphorylation. This has shown a decrease in 
pathology of AD when treated before symptoms arise. 
Another treatment options is to target tau aggregation rather than its hyperphosphorylation levels. 
Methylene blue (MB) is a heterocyclic aromatic compound which is used as a biological dye, but 
has been found to inhibit tau and Aβ aggregation in vitro. In phase Ⅱ clinical trials MB showed a 
significant difference to placebo, or treatment of cognitive dysfunction, and was shown to slow AD 
progression. This type of drug targeting essentially does not require identification of the correct 
model as it treats the symptoms of both. It may reduce impact or slow AD development, but for 
more effective therapeutic treatments, then more understanding is needed on how the disease 
progresses.        
Although this latest model has given new life to the tau hypothesis, the inconsistencies are still 
unresolved. In this model, the underlying cause is suggested to be any number of variable 
individual factors including the accumulation of Aβ in neuronal synapses- essentially this suggests, 
that increasing amyloid concentration causes the tau hyperphosphorylation that is the undermining 
driver of the AD pathology. One could argue that this is cannibalising the amyloid hypothesis to 
make the opposing Tau hypothesis model more attractive, however a key point made is that tau 
hyperphosphorylation is always the final common pathway. Simply put, any number of factors and 
mechanisms could cause the progression to tau phosphorylation, but the accumulation of Aβ in this 
hypothesis at least, is not a necessary pre-requisite. 
1.8 Amyloid hypothesis 
Variations iterations of the amyloid hypothesis proposes that the accumulation of Aβ drives the 
mechanism for of AD pathology (Hardy and Selkoe 2002). The amyloid hypothesis is supported 
with evidence seen in trisomy 21 patients. The same characteristic pathology of AD has been 
observed in the post-mortem examination of patients in their mid twenties with trisomy 21. They 
develop amyloid plaques that look identical to those in AD patients and subsequently have the 
same pathology. This is thought to result from an extra dose of the APP gene, which is located on 
the long arm of chromosome 21 (Selkoe, 1991). In older trisomy 21 patients, the lesions in the 
brain are indistinguishable from that of AD patients, and thereby likely due to deposits of insoluble 
aggregate Aβ.
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Increased levels of extracellular Aβ has also been shown to give Alzheimer like pathology in 
transgenic mice with human APP (Wieniewski, 1978; Games 1995). The mutant APP gave the 
phenotype of increased levels of APP, suggesting a causative relationship between APP gene 
expression and pathology of AD. Nevertheless these transgenic mouse models do not fully 
replicate the human disease phenotype of AD.  A ‘triple AD mouse’ that has both familial defects in 
APP processing as well as hyperphosphorylated tau demonstrated altered synaptic plasticity with 
increased intra-neural Aβ before Aβ plaques or tau tangles developed 
1.8.1 Amyloid hypothesis inconsistencies
The amyloid hypothesis is not without its limitations. However, with some observations difficult to 
explain with the a basic Aβ deposition theory. A commonly voiced concern is the lack of a 
relationship between the concentration of amyloid deposits and cognitive decline in patients 
diagnosed with AD (Hardy and Selkoe 2002), with some individuals identified with many Aβ 
deposits and yet appearing asymptotic. Understanding this is complicated by the difficulties of 
studying Aβ the biophysical properties of oligomers with current biochemistry techniques. The 3D 
structural information of Aβ with NMR and x-ray crystallography is limited to showing Aβ monomers 
as a random coil. Difficulties of providing a 3D structure is new to the small heterogeneity nature of 
the Aβ oligomers (Kirkitadze, M.d et al., 2001). 
Another issue is that the mechanism for the switch from soluble Aβ states to insoluble Aβ deposits 
is unknown. Despite this, soluble oligomers of Aβ have be shown to seed the formation of amyloid 
fibrils. Studies show that Aβ peptides form amyloid fibrils through nucleation-condensation 
polymerisation. Soluble Aβ oligomers can exist as monomers, trimers, 12-mers as well as larger 
aggregates, with no one morphology existing in any amyloid fibril giving it a large level of 
heterogeneity (Shankar, G.M. et al., 2008). Some morphologies are more critical for the pathology 
of AD but the rates of formation are still unknown. While Aβ1-40 and Aβ1-42 both self-assemble into 
fibrils, the less abundant Aβ1-42 protein is more prone to aggregation (Moore, B.D. et al., 2012).  
A third issue is the lack of progression towards a therapy for AD with targeted drug inhibition of key 
enzymes in the Aβ production. There are two key enzymes, β-Secretase and 𝛄-Secretase (1.1.8). 
Semagacestat is a potent 𝛄-Secretase inhibitor (GSI), which has been shown to reduce Aβ 
deposits in transgenic mice that are over-expressing the human APP transgene ‘Ness et al., 
2004’.Semagacestat also gave a significant reduction in newly synthesised amyloid-β in human 
studies (Bateman et al., 2009). Paradoxically though patients administered with semagacestat 
showed decrease cognitive function compared with their placebo-administered counterparts. GSI’s 
such as semagacestat have a complex mode of action and also inhibit other important proteins 
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such as Notch. It is unclear whether the adverse effect seen, are a consequence of toxic effect on 
other pathways or due to the inhibition of the β-Secretase. In fact simply lowering the level of Aβ 
may not be the best course of actions in terms of stopping progression of the amyloid plaques.
1.8.2 Amyloid hypothesis treatment targets
Assuming that the amyloid hypothesis is the best model for AD, there are three potential 
intervention strategies (Ⅰ). reducing amyloid-β production (Ⅱ). facilitating amyloid-β clearance. and 
(Ⅲ). preventing amyloid-β aggregation. GSI’s are able to reduce the amount of Aβ, but possibly not 
enough to stop the progression into plaques. In a transgenic mouse line, called APP23 mice, GSI 
was added from the age of 6-9 months which gave a 77% reduction in the levels of Aβ and the size 
of cortical plaques by 80% (Abramowski et al., 2008). Yet another study demonstrated that radii of 
the plaque grew at the same rate regardless of size and age (Hefendehl et al., 2011). The GSI 
used could reduce the plaque load at the beginning of treatment, but became ineffective after a 
prolonged time, suggesting that inhibiting the production of amyloid plaques may slow down only 
the progression of new plaques, but existing plaques remain. An established plaque even with a 
diminished concentration of Aβ in the interstitial fluid will still increase in size, due to high potency 
for Aβ formation. 
1.8.3 Blood-brain barrier
The blood brain barrier (BBB) is a vascular endothelium which prevents systemic circulation 
molecules transportation unless mediated. Essentially the permeability across this barrier is tightly 
regulated, preventing passage of molecules that would otherwise be released through typical blood 
capillary systems (Tajes et al., 2014) . Although this system is vital for protection from pathogens, it 
provides a difficulty when trying to develop drugs that target neurones. The BBB is more 
permeable to lipid based molecule due to the hydrophobic nature of the cell membrane. One 
method for neurone based drug design is to increase a drugs lipophilicity, thus increasing the 
likelihood of internalisation. A newer approach uses nanotechnology to facilitate the transportation 
of neurological drugs. Peptides have a low level of uptake by the brain, unless facilitated in a 
specific way. However, some small peptides are able to be rapidly internalised, these specialised 
peptides are called cell penetrating peptides (CPP). CPP are short amphipathic cationic peptides 
that allow exogenous cargo transportation (Lalasta et al., 2014). Not much is known about the 
mechanism of how CPP work, however they are peptides that are able to be internalised and 
understanding this system may allow peptide based drug design for neurological diseases, such as 
sAPPα and AD. 
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1.8.4 β-Secretase inhibitors 
Assuming the amyloid hypothesis, the accumulation of Aβ causes the pathology of AD. 
Theoretically, the inhibition of β-Secretase (BACE1) will prevent the formation of any Aβ. With only 
a very low concentration of Aβ required (1.11), then inhibition of β-Secretase would be the most 
direct target for diminishing Aβ formation. BACE1 inhibitors (β-Secretase inhibitor, BSI) have been 
a candidate drug target for years, yet difficulties have risen for any potential drug must be able to 
pass the blood-brain barrier for effective treatment. Recently developed BSI have met this 
requirement and are currently in clinical trials (Yan and Vassar, 2014). However, concerns are 
raised about other BACE1 substrates and the possible mechanism-based side-effects of BSI. 
BACE1 has many putative substrates, which will be effected by its inhibition. With respect to this, a 
question of balance between effective dose (assuming it is therapeutically effective) and potential 
side-effects. Early BSI drugs acted as non-cleavable peptide-based transition state mimics of APP, 
however despite its potency, these large peptidomimics were not favourable due to short serum life 
and difficulties crossing the blood brain barrier. Later drug development design focused on small 
molecule BACE1 inhibitors, which have sufficient brain penetration and are undergoing clinical 
trials. Some showing a decrease in Aβ in the CSF, with no observed adversed side effects, 
although no significant change when dealing high amyloid concentrations in AD patients (Vassar 
2014).  
If reducing Aβ production does not cause a reduction in amyloid plaque formation, then drugs 
targeting amyloid-clearance may be more effective. Naturally amyloid-β is cleared in a number of 
ways. Some is likely degraded by enzymatically such as by neprilysin and insulin degrading 
enzyme (Chen et al., 2009). While there is a bulk clearance method via the interstitial fluid through 
the cerebrospinal fluid, yet this only accounts for a small proportion of the total Aβ produced. The 
majority of the amyloid-β is cleared directly through the blood-brain barrier into the peripheral blood 
circulation. (Wang et al., 2011) This as a therapeutic target is less easy to manipulate than 
amyloid-β production. Inhibition of a particular enzyme can usually be achieved through a drug 
screen and some bio-engineering. Facilitating amyloid clearance would mean using its naturally 
occurring pathways and increase its efficiency to increase the clearance of amyloid-β. Less 
research has gone into this approach, but some progress has been made. Data has shown that 
antibodies that are targeted at the amyloid plaques, drive its active removal from the brain. 
1.8.5 Aggregation inhibitors
Aggregation of Aβ is a precursor to the formation of amyloid plaques, stated in the amyloid 
hypothesis. Inhibition of Aβ aggregation should feasibly stop the progression of AD before it 
begins. Reduction of incident levels has been documented in correlation with polyphenolic 
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compounds. A study by Churches 2014, established two potent inhibitors of Aβ fibril formation, 
luteolin and transilitin. Furthermore, X-ray structural studies propose a mechanism of inhibition. 
Additionally the polyphenol EGCG has been shown to activate sAPPα and consequently shows 
significant neuroprotection (4.2.3), which is currently in clinical trials (Doig and Derreumaux 2015).    
1.9 Amyloid precursor protein 
With the implication of the gene for APP in FAD, sequencing of the APP has shown the presence of 
mutations in the gene that can cause AD, although they only account for only a small percentage of 
early onset familial AD (Levy et al., 1990). This has led to the investigation into other genes that 
may contribute like the presenilins, which are serpentine protein (multi-transmembrane domains). 
This group of proteins is essential for the activity of the α-Secretase complex, one of multiple 
secretases that cleave APP. 
One mutation in presenilins increases the ratio of APP cleaved at position 42(Aβ42) over position 
40(Aβ40), with Aβ42 associated as more neurotoxicity isoform of amyloid beta aggregations (Levy-
Lahad et al., 1995; Sherrington et al., 1995). Mutations in the APP gene give a similar 
characteristic, resulting in a higher frequency of the neurotoxic Aβ42 peptide. A third important 
discussed previously (1.4.1) gene found associated with AD is apoprotein E (APOE), which is 
thought to be important in binding and sequestering Aβ to regulate levels in the brain (Deane et al., 
2004).  Another important gene is TREM2 (1.4.2), found recently (Iliff et al., 2012) , which functions 
as a receptor on microglia cells that help to clear plaques. However unlike mutations in presenilins 
and APP that are fully penetrant, mutations in APOE and TREM2 are associated with AD, but are 
not fully penetrant. All of these genes have important functions in the lifecycle of Aβ and give clues 
about possible therapeutic inventions. 
1.9.1 APP family of genes
Aymyloid precursor protein (APP) is part of a multigene family that includes APLP1 (amyloid 
precursor-like protein 1) and APLP2 (amyloid precursor-like protein 2). Both APP and APLP2 unlike 
APLP1 have three exons that can be alternately spliced allowing for an addition range of functions. 
In vivo and in vitro studies of these three genes that they may function in neural cell migration and 
copper homeostasis (Barnham et al., 2015). To further understand the function of this group of 
proteins, KO mice of the genes were produced and used to study each of their functions. Only 
minor abnormalities were observed in each of the individual knock out mice, suggesting some level 
of compensating redundancy among these genes.  This idea is established more clearly with some 
combinations of double knockouts; APLP2 and APP and, APLP2 and APLP1 give a lethal 
phenotype. APP has also been shown to regulate transthyretin (TTR) and klotho, and these 
transcripts is are maintained by activity of secreted amyloid precursor protein alpha (sAPPα) (Li et 
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al., 2010). TTR encodes transthyretin, which is a carrier protein for thyroid hormones. Mutations in 
this gene have been associated with amyloid deposits.
1.9.2 Processing of APP
Cleavage of APP is separated into at least two pathways, non-amyloidogenic and amyloidogenic 
are the main two. The non-amyloidogenic pathway produces sAPPα as the main product, while the 
amyloidogenic pathway produces a shorter sAPPβ and Aβ that forms the amyloid plaques. Both 
pathways produce a range of different C-terminal peptide fragments with AICD (APP intracellular 
domain) common to both. The importance of AICD has only been recognised recently and only 
through the homology of APP’s to Notch. Both Notch and APP are cleaved by 𝛄-Secretase in the 
final step of processing, which leads to NICD in the case of Notch, analogous to APP’s AICD. NICD 
then forms a complex with other proteins for stability, such as CSL and then the complex 
translocates to the nucleus to regulate transcription. AICD goes through a similar process, binding 
with Fe65 for stabilisation, thereby allowing for transportation to the nucleus and nuclear 
transcription (Kimberly et al., 2001).  
There are multiple proteolytic enzymes (secretase proteins) in the processing of APP that cleave at 
different residues in the APP protein (fig 1.2). In the two major pathways that process APP and five 
Secretase's that cleave at different residues. If the APP is directed down one of the biochemical 
pathways then the action of opposing Secretase’s are prevented.
 
1.9.3 Amyloidogenic pathway
The first Secretase involved in the amyloidogenic pathway is β-Secretase, that cleaves APP in one 
of two cleavage sites (670 or 671) an aspartate which produces a C99 fragment or at a glutamate 
producing a C89 fragment (Zhang et al., 2014). The variation in β-Secretase activity leads to 
different sizes of Aβ fragments that can affect aggregation characteristics. Successive cleavage of 
this fragment by 𝛄-Secretase also has variation with its cleavage site (771 or 773)(Sandgram et al., 
2002). The combination of these two enzymes leads to a heterogeneous population of Aβ 
fragments. Aβ1-40 is the most abundant, with lower levels of Aβ1-42, but which  is more prone to 
aggregation. Alternative secretases exist and act on the amyloidogenic pathway that can disrupt 
Aβ formation. 𝛉-Secretase does not contribute to plaque formation, it’s cleavage site occurs within 
the Aβ peptide at Aβ-Phe19/Aβ-Phe20 (Zhang et al., 2014). While both 𝛉-Secretase and β-
Secretase are regulated distinctively at both transcription and translation levels. It is unknown how 
this occurs. 𝛇-Secretase can occur alternatively to 𝛄-Secretase and produces Aβ1-46 instead of 
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Aβ1-40/1-42 (Zhao et al., 2004). Aβ1-46 is rare in the population of Aβ fragments and not much is 
known about the regulation of its production nor its affect of Aβ plaque formation.
 
1.9.4 Non-amyloidogenic pathway
The non-amyloidogenic pathway has only two proteolytic enzymes that act in succession. α-
Secretase cleaves at residues 687/688 producing sAPPα (1-687) and smaller fragment incapable 
of producing Aβ (Sandgram et al., 2002). The N fragment is cleaved by 𝛄-Secretase, which makes 
an P20 fragment and AICD. 
1.10 Functions of sAPPα
sAPPα has many functions that have been characterised. However there are difficulties involved in 
establishing the differences between the full length APP and sAPPα functions, as there are a lot of 
shared roles between the two proteins. sAPPα has been shown to promote neuronal extensions; 
transformations with B103 cells (that do not naturally produce APP) show twice as many neurites in 
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Figure 1.2: Processing of APP
Non-amyloidogenic pathway shows the production of sAPPα and Secretase involved. Amyloidogenic 
pathway that produces Aβ is shown with the order of Secretase activity.. Alternative Secretase 
activity that disrupt the amyloidogenic pathway are included;𝛉-Secretase and 𝛇-Secretase.   
cells when transformed with APP than that of mutant APP (Li et al., 1998). This neurotropic activity 
of sAPPα has been shown to combat the effects of Aβ. However the 16 amino acid C-terminus of 
sAPPα can not solely negate the effect of Aβ. Addition of sAPPα in PC12 cells compared with 
controls gave the increase neurite length (~120%) and neurite branching (~250%) (Milward et al., 
1992). sAPPα also has a function in adhesion of cells, with approximately 10-fold stimulation in cell 
adhesion than that of laminin (Schubert et al., 1989). As a more broad function, sAPPα is able to 
rescue cells under stress measured in a cell viability assay. This neuroprotection role of sAPPα 
has been shown in a study by Levities 2003, that demonstrated neuroprotection against toxic 
levels of Aβ.   
Short and long term memory was enhanced when sAPPα was administered 
intracerebroventricularly in mice models. Furthermore learning deficits causes by neurotoxic 
substrates were negated by the same procedure (Meziane et al., 1998). Mice underwent 
behavioural test that required remembering the mechanism of the apparatus i.e. pulling lever or 
visual discrimination, which was positively reinforced by food. Mice with sAPPα treatment 
significantly improved there performance over the placebo counterpart, illustrating enhanced 
memory ability. Mice with induced amnesia were unable to improve at the any of the tests, while 
induced amnesia mice with sAPPα treatment were able to improve each successive test.     
sAPPα mediates activation of K+ channels to decrease cellular concentration of Ca2+. Elevated 
levels of Ca2+ are associated with Aβ mediated neuronal damage (Furukawa, Barger et al 1996). 
The system believed to act in this protection measure is a growth factor including a heparin-binding 
domain within sAPPα (597-612). This was shown by sAPPα’s significant decrease in 
neuroprotection after incubation with herparinase (Furukawa et al., 1996). That is, the 
neuroprotection mechanism acting in calcium regulation is suggested to be dependent of the 
heparin-binding domain, which is located before the 16mer (Corrigan et al., 2011).   
1.10.1 16mer
sAPPα full length protein is 595 residues long, produced via the cleavage by α-Secretase (1.9.3). 
An alternative protein sAPPβ is 579 residues long processed via a different pathway (1.9.4), the 
difference between these two proteins is 16 amino acids and 100-fold less potent neuroprotective 
ability of sAPPβ compared to sAPPα (Furukawa et al., 1996b). This principle is the premise behind 
testing the hypothesis that 16mer could elicit the same neuroprotective ability of the full length 
sAPPα. It is worth noting, that this small peptide does not occur naturally by itself, yet is a good 
candidate for peptidomimetics. That is, large peptide mimics have difficulties passing through the 
blood brain barrier as elaborated in BSI (1.8.3), thus smaller peptides are preferable. The 16mer, if 
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able to confer the same neuroprotection as sAPPα, would be more suitable for therapeutic drug 
design as it would have a greater permeability to the BBB then its full length counterpart (sAPPα)   
1.10.2 RER
A study by Roch et al., 1992, mapped active sites of sAPPα, an active site found in this protein had 
a tri-peptide RER, Arg328-Arg330 that has been investigated to also show functions seperate to the 
full protein. The full length sAPPα can increase neurite length and branching (Milward et al., 1992), 
while the RER motif within sAPPα has shown protection against amnesia induced by Aβ in a chick 
model (Mileusnic et al., 2004; Mileusnic et al., 2005). This evidence was used as the foundation for 
the hypothesis that the RER could elicit the same neuroprotection as sAPPα. The RER is in the E2 
domain of sAPPα, while located differently to the 16mer, it offers different possible mechanisms of 
neuroprotection. It has the same suitability for development into therapeutic drugs as the 16mer 
due to its small molecular weight.    
1.10.3 Cell viability assays
Measuring protection of proteins can be preformed through the use of cell viability assays. Using 
neuroblastoma cells and measuring rescue from induced stress can be used in these assays to 
measure neuroprotection. That is, the decrease in viability of neuroblastoma cells under a specific 
stress is lessened with the addition of a neuroprotective molecule, such as sAPPα (Levities et al., 
2003). MTT and Alamar blue are two cell viability assays that work in this way. The MTT assay 
works by the cells reducing a yellow tetrazolium dye to purple insoluble formazen crystals that can 
be dissolved and measured through absorbance spectrum, elaborated more in methods (2.2.6). 
The MTT assay has been used to measure neuroprotection of sAPPα previously (Levities et al., 
2003) and could be used to investigate the 16mer and RER in the same way. Alamar blue 
(Resazurin) works through the cells reducing resazurin, the reduced form gives of fluorescence. 
Thus the level of fluorescence gives a measure of viability of the cell population and an increase in 
fluorescence compared to the control shows neuroprotection (2.2.7). 
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Figure 1.3 Illustration of sAPPα domains and tested variants
E1 domain from reside 16-189; E2 domain from 290-495, includes RER at resides 328-330; 16mer at C-terminus from residue 
1.10.4 SILAC
Previous studies have investigated the gene expression induced by sAPPα (Ryan et al., 
2013). The study tested a range of time frames and measured the change in gene 
expression in response to the addition of sAPPα. Despite the value of this study, it is 
limiting with respect to protein expression. The correlation between changes in gene 
expression and protein synthesis is often low, thereby cannot assume the change in genes 
results in the same change in protein synthesis. SILAC (Stable Isotope Labelling of Amino 
acids in Cell culture) is a biochemical technique that allows measuring of protein synthesis 
levels without the use of radioactive labelling. The method uses stable isotopes of carbon 
and nitrogen incorporated into lysine and arginine. These amino acids isotopes have a 
larger molecule weight that then there common isotope counterparts. When de novo 
protein synthesis occurs, the isotope amino acids are incorporated. The change in protein 
synthesis can then be measured by the change in molecular weight of proteins compared 
to the control with common isotopes. This technique allows for accurate measurements of 
protein changes caused by the addition of any number of molecules. The power of this 
technique means that an infinite number of proteins could be tested to see if they cause a 
change in protein expression. Additionally, this technique can be used to measure change 
in protein expression with respect to time by changing the incubation time with the 
molecule of interest, however incubation time for SILAC has some limitation (elaborated in 
discussion 4.4).   
1.11 Function of Aβ
The antagonist of the amyloid hypothesis Aβ is not an evolutionary by product that becomes toxic 
with age, but itself is hormesis. That is at a low dose is beneficial, but toxic at elevated levels. 
Hippocampal neurons were plated and grown for two days, cells surviving after this was 36%, with 
the addition of Aβ at concentrations of 10μg.ml-1 and 100μg.ml-1, the cell survival increase to 60% 
and 90% respectively (Whitson et al., 1989). With this experiment, low levels of Aβ show 
neuroprotection and prove that the protein is biologically active. In this same study neurite branch 
points and length were also looked at as a function of Aβ. These two characteristic showed a 
positive increase with the addition of Aβ at a low dose.       
 19
1.12 α-Secretase
α-Secretase is activated in the non-amyloidogenic pathway and is different mechanistically 
from β-Secretase activity, and acts at a site close by so in sense is is regulator, to control 
levels of Aβ which is thought to produced in picomole concentration and pathogenetic 
when these levels rise. Stimulation of muscarinic receptor has been shown to increase 
APP cleavage favouring the non-amyloidogenic pathway (Nitsch et al., 1992). However 
most of the regulatory mechanisms associated with the α-Secretase enzyme(s) are 
unknown. This is due to the difficulty in localising the enzyme and/or identifying the 
enzyme(s) with this α-Secretase activity. Varied results suggest that the enzyme could be 
either trans-golgi operating (Kuentzel et al., 1993) or membrane bound endoprotease on 
the cell surface (Lammich et al., 1999). These results aren’t necessarily conflicting results, 
it could mean that multiple enzymes have α-Secretase activity. In fact several disintegrin 
metalloprotease have been identified with this activity. In trying to identify enzymes that 
could have APP processing,  α-Secretase activity, two proteins within this class are the 
leading candidates ADAM10 and ADAM17 and (or TACE, TNF-α converting enzyme). 
ADAM17 has been characterised as cleaving pro-TNF-α, where the reaction is similar to 
that of APP cleavage. More striking evidence is the inhibiting of ADAM17 causes a 
decrease in sAPPα production, but a KO of ADAM17 does not fully inhibit α-Secretase 
cleavage. Phorbol esters has been shown to increase α-Secretase activity (Hung et al., 
1993), but this effect is not evident in the ADAM17 KO mice. This suggests that increase 
α-Secretase activity is due to their effect with ADAM17. As the ADAM17 KO still has some 
α-Secretase activity. It has been thought that there is a constitutive (ADAM10) and a 
regulatory form (ADAM17) of the enzyme.
ADAM-10 also increases α-Secretase cleavage of APP, resulting in an increase in sAPPα 
levels. Again a correlation has been observed in knock down in ADAM-10 (inactive mutant) 
and the concentration of sAPPα, but not fully inhibited (Lammich et al., 1999). It terms of 
localisation ADAM-10 is only activated at the plasma membrane, yet some sAPPα is 
produced within the cell. This is further evidence that both enzymes are needed in the 
production of sAPPα in different parts of the cells. These two enzymes have been 
identified to have α-Secretase activity at the correct site in APP and are localised in two 
places where the cleavage occurs, but they could be only two, of many enzymes of the 
ADAM class that act in this pathway.      
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TAPI1 (TNF-alpha proteas inhibitor-1) was used in my experiments as an inhibitor of α-
Secretase. TAPI1 acts as a potent inhibitor of matrix metalloproteinases, used to prevent 
de novo synthesis of sAPPα when testing neuroprotection in cell viability assays. Although 
used to inhibit sAPPα, it isn’t specific α-Secretase, thereby toxic to the cell with other vital 
enzymes such as TNF-α convertase inhibited (Sigma-Aldrich).      
1.13 β-Secretase
Most Secretase’s have some uncertainty involved in the identity of the enzyme(s) 
response for the cleavage event. However the evidence stating that BACE1 is the β-
Secretase is overwhelming, so much that the terms BACE1 and β-Secretase are often 
used interchangeably. The expression levels and patterns of BACE1 are constant with β-
Secretase activity as well as an increase in its expression of BACE1 leads to high β-
Secretase cleavage and its associated products (Vassar et al., 1999). BACE1 has high 
expression levels in neurones and some expression in the surrounding astrocytes. A 
variant of the enzyme found in the pancreas, but it is inactive and missing exon 9 and has 
unknown function. The BACE1 enzyme has two aspartic protease motifs or DIGS 
(residues 93-96) and DSGT (residues 289-292) that both result in the inactivation of β-
Secretase activity when substituted with the other amino acids (Hussain et al., 1999). The 
pH optimum for this enzyme is 4.5, suggesting that it is localised either in the Golgi 
apparatus or endosomes. 
BACE1 KO mice did not produce any Aβ nor did they develop any symptoms relating to 
Alzheimers, evidence used to support the amyloid hypothesis. At first these mice were 
shown to be free of any adverse side effects in regards to embryonic development, 
morphology and biochemical pathways. Memory deficits were also stated not to occur in 
BACE1-/- mice, suggesting that Aβ served no function (Luo et al., 2001). However more 
precise behavioural studies show now that knocking out BACE1 does cause cognitive 
abnormalities. Mice lacking any BACE1 showed impaired spatial and reference memories. 
BACE1 was shown to be required for normal hippocampal memory processing (Ohno et 
al., 2004). This is due to the production of Aβ, which, like the absences of BACE1 was not 
thought to have any functional consequence, but was there as an evolutionary byproduct 
(Yanker et al., 1989). However, as mentioned earlier (1.11), Aβ at low molar concentrations 
has function and its absence is likely the cause of the cognitive impairments in the 
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BACE1-/- mice. Mice with only one copy of the BACE1 gene, still showed significant 
impairment in cognitive ability, establishing the importance of this gene.  
An attractive approach to treatment of AD has been at to control the level of regulation of 
BACE1. Expression of BACE1 is regulated tightly at the transcription and translation level. 
It is worth noting that some of these are cell stress activated. It is possible that this has 
something to do with the underpinning cause of the disease, with increase stress levels in 
the brain in old age leading to the increase production of Aβ. Astrocytes and glial cells may 
also be more fundamental than originally thought in this process. Astrocytes and glial cells 
exhibit BACE1 expression, but far lower than in neurons. These neural cells outnumber 
neurons 10 to 1, which means a small increase in the expression of BACE1 in astrocytes/
glial could be far more significant than appears at first glance (Sambamurti et al., 2004). 
Astrocytes and glial cells may play more of a roll in AD pathology than originally thought, 
with their different between transcription factors and their regulation roles in these cells. 
NF𝛋B is a transcription factor usually associated with a stress response: it binds to BACE1 
and has an increase expression level in both aged and AD inflicted brains. The interesting 
point about this transcription factor is that it acts by conflicting mechanisms in neurons and 
in astrocytes/glial. In neurons NF𝛋B represses BACE1, while in astrocytes/glia it activates 
BACE1 (Bourne et al., 2007).  
1.14 𝛄-Secretase
Unlike some of the other secretases involved in APP cleavage, most of the proteins the 
function at the 𝛄 cleavage site are known. The interactions between the multiple proteins 
and the regulatory mechanisms are still not yet well understood well. However, four 
proteins that have been linked to the 𝛄-Secretase complex; presenilin 1 (PS1)/Presenilin 2 
(PS2), Nicastrin (Nct), Presenilin enhancer protein 2(PEN-2) and anterior pharynx-
defective 1 (ApH-1). Currently it is thought that these four proteins form a complex that 
allows 𝛄-Secretase activity, likely with other cofactors that are currently unknown (Takasugi 
et al., 2003). 
Presenilin 1 and 2 were the first discovered part of the 𝛄-Secretase complex due to their 
links with familial AD. PS’s are localised to sub cellular compartments such as the Golgi or 
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ER, which is thought to be the site where 𝛄-Secretase cleavage at least in part occurs 
(Hartmann et al., 1997). Furthermore KO of PS1 and PS2 individually in different cell lines 
causes inhibition of all 𝛄-Secretase activity suggesting that, neither acts as a redundant 
component  nor acts solely in a specific location (Hereman et al., 2000). Supporting this 
results for this idea have been obtained since mutations present in the aspartate residues 
of PS1 causes inhibition of 𝛄-Secretase activity. This suggests that PS1 has a catalytic 
moieties that could be via an aspartic protease mechanism (Capell et al., 2000). PS1 and 
PS2 variants have established negative correlation with familial AD. Some theories 
suggest it is the regulation by an endoproteolysis mechanism of PS1/2 responsible for the 
link with FAD. PS is stabilised by a proteolytic cleavage that produces two fragments, each 
having one of the of the aspartic acid residues in the 𝛄-Secretase complex (Thinakaran et 
al., 1996). One variant that has been linked to FAD is missing exon 9, which results in no 
endoproteolytic cleavage. As well as the mapped cleavage site of PS is where 58% of FAD 
mutations occurs, giving more evidence that the processing of PS is vital in a functional 𝛄-
Secretase complex. A protein Nct motioned later, has been linked in this process and 
reinforces the theory of how PS is processed. Overall most of the PS proteins likely act as 
regulatory proteins, but require processing and transport to operate properly. 
Another protein suggested to interact in the 𝛄-Secretase complex is nicastrin (Yu et al., 
2000). Nicastrin is a protein that has been found through co-immunoprecipitation 
experiments to be part of the 𝛄-Secretase complex. Nicastrin sequence does not share 
any homology with known proteases, suggesting it has more of a stabilising function than 
being active  in cleavage. Nicastrin has been shown to be important in the trafficking of PS 
to the cell surface and it is able to bind to both fragments of PS after its endoproteolytic 
cleavage. The trafficking function was suggested from two key experiments using Nct-KO 
and PS-KO. In the PS-KO cells, there was an accumulation of Nct in the ER, from where it 
is suggested to bind to PS. While in the Nct-KO, there is a decrease in the stabilised form 
of 𝛄-Secretase complexes (Strooper 2003). 
Further co-immunoprecipitation experiments reveals that another protein. PEN-2, is pulled 
down with PS1/PS2 and Nct. Only a small level of PEN-2 was co-precipitated, but far more 
after its denaturation, suggesting the majority of the protein is tightly incorporated into the 
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complex. Expression levels of PEN-2 correlate with expression levels of the other proteins 
in the complex. PS1/PS2 knockouts both decrease the level of expression of PEN-2, but to 
different degrees (Yu et al., 2000). Down regulation of PEN-2 causes a decrease level of 
steady-state 𝛄-Secretase complex- a trend seen in all of the protein the exist as part of the 
complex.  
The last important identified protein that is thought to be part of the 𝛄-Secretase complex is 
ApH-1. This protein was first recognised as a regulator of nicastrin localisation in the notch 
pathway (Goutte et al., 2002). ApH-1 was studied in transfected drosophila with emphasis 
on it’s roles in the 𝛄-Secretase complex (Takasugi et al., 2003). The presenilin holoproteins 
were more concentrated in the drosophila with over expressing proteins, ApH-1 or Nct. It 
was also shown that the presenilin protein was found in a higher concentration in factions 
of higher molecular mass, suggesting the existence of a complex dependent on a 
expression of ApH-1 and Nct. 
Further experiments suggest that ApH-1 acts as a stabilising factor for the   𝛄-Secretase 
complex, whereas the rest of the proteins are needed to keep a stable active complex. 
This was shown in by RNA interference (RNAi), which was used against mRNA for all 
proteins thought to be part of the 𝛄-Secretase complex- each drop in a subunit 
concentration inhibited all 𝛄-Secretase activity. The current models proposes that Psn-1 
forms a low molecular weight complex that is unstable, and can be degraded. ApH-1 and 
Nct bind to form a stable higher molecular weight complex, but is still inactive, then PEN-2 
binds to the complex and activates it. Over expressing all four increased Ps stability, Nct 
glycosylation and 𝛄-Secretase activity (Strooper et al., 2003). This is likely due to the 
stoichiometry of the complex requiring 1:1:1:1 ratio.           
1.15 𝛇-Secretase
The 𝛇-cleavage site is between 𝛄 and the ε cleavage site, it leads to the production of 
amyloid species 46 amino acids in length opposed to the more common Aβ40/42 (Zhao et 
al., 2004).  Interestingly 𝛄-Secretase can cleavage at multiple sites, so could be assume 
that Aβ46 species is produced as a rare event by the same enzyme(s). However 𝛇-species 
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Aβ46 is only detected when 𝛄-Secretase activity is inhibited, suggesting a different enzyme 
mediated the cleavage. Another puzzling fact is that this 𝛇-cleavage is presenilin 
dependent, which is the leading candidate for the 𝛄-Secretase enzyme(s). Leading to the 
enigma of 𝛇-Secretase, that requires the inhibition of 𝛄-Secretase, but is dependent on it 
for it’s own activity. This activity was shown in an experiment, where 𝛄-Secretase was 
inhibited, which showed increase 𝛇-cleavage activity. However in PS1 KO, there was no 
detection of the Aβ46 species was detected. 
It has been suggested that the identification of this new amyloid species was due to 
unnatural consequence of studying amplified pathways for amyloid species. However, 
interactions with known inhibitors give more evidence to the concept that 𝛇-Secretase and 
𝛄-Secretase are distinct enzymes. Inhibitors that are targeted at 𝛄-Secretase do not inhibit 
𝛇-Secretase activity. Evidence from transition state analogue inhibitors suggests that a 
similar substrate specificity, but different enzymes.  
The discovery of the Aβ46 species highlights an important facets in the amyloid hypothesis. 
A point within the hypothesis states that the longer and more hydrophobic the amyloid 
species the more amyloidogenic and toxic it is. If this is true, it highlights a consequences 
of the discovery of 𝛇-Secretase for therapeutic studies focusing on the inhibition of 𝛄-
Secretase. Inhibition of 𝛄-Secretase has shown to be needed to allow 𝛇-Secretase activity 
to occur. Therefore treatment targeting 𝛄-Secretase could consequently cause an increase 
in 𝛇-Secretase activity and increase production of toxic Aβ46 species. Speculating from a 
genetic point of view, 𝛇-Secretase could have been the original 𝛄-Secretase, but has been 
replaced by presenilin to produce a less toxic molecule and now is redundant. This would 
explain in part some of its characteristics, such as its production only in the absence of 𝛄-
Secretase activity.
The 𝛇-Secretase cleavage site is the same site as an identified in APP associated with 
familial AD. The mutation is called London mutation and gives a predisposition for early 
onset AD, but the mechanism of this is unknown. It could be that this mutation increases 
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the concentration of Aβ46 species resulting in an earlier form of AD than the higher 
prevalent sporadic AD. If this is true, then the 𝛄-Secretase inhibitors that are being 
investigated as AD treatments, which, have been shown to increase the concentration of 
Aβ46 could accelerate the progression of the disease rather than stop it.           
1.16 𝛉-Secretase
BACE2 is a homologous enzyme with BACE1 and shares 75% of their amino acid identity. 
BACE1 has β-Secretase activity, it would suggest that its homologue BACE2 would share 
a similar function. While the cleavage site of BACE2 is close to that of BACE1 in APP, its 
function may be regulatory. The 𝛉-Secretase site occurs within the Aβ fragment, preventing 
Aβ formation (Zhang et al., 2014). It is not yet known if this is regulatory mechanism for 
dampening Aβ formation or if these fragments produced are further processed by 
additional secretase’s. 
1.17 η-Secretase
A newly discovered Secretase that targets APP, but appears to generate fragments by a 
novel pathway that is not associated with either the amyloidogenic nor non-amyloidogenic 
pathways(Willem et al., 2015). Typically α-Secretase or β-Secretase targets APP first and 
then successive Secretase’s further cleave the C-terminal fragment. By contrast η-
Secretase cleaves APP nearer the N-terminus at amino acid 504-505 before either α-
Secretase or β-Secretase to produce a shorter N-terminal fragment termed sAPPη (Figure 
1.3). The C-terminal fragment is then further cleaved by α-Secretase forming a fragment 
Aηα (ηα) or alternatively cleaved by β-Secretase to produce Aηβ (ηβ). Although all of 
these fragments have been identified, no function has yet been established. 
Immunochemical analysis was used to determine if the fragments produced by η-
Secretase existed within the core of the amyloid plaques.  Neither ηα or ηβ were found 
within the core, but the CTF-η was found in the plaques halo. Inhibition of BACE1 
increased most of the fragments produced by η-Secretase, as well as the non-
amyloidogenic pathway. One fragment that showed a significant increase was Aηα, which 
gave a significant decrease reduction in hippocampal LTP; although it was not clear if this 
was caused by the BACE1 inhibitor or the small peptide itself.  
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1.18 Available treatments of symptoms 
There is still many gaps in the complexity of knowledge of AD, and that is why developing a 
treatment is so difficult. In New Zealand a daily dose of 5-10mg of donepezil hydrochloride can be 
prescribed to enhance cholinergic function in the cerebral cortex, an activity that is decreased in 
AD. Donepezil functions by inhibiting acetylcholinesterase (AchE) activity, thereby increasing 
acetylcholine concentration. Butyrcholinesterase has the same function (1.3.1), but is 100 times 
less potent than the drug donepezil (Medsafe, 2014). There are other acetylcholinesterase 
inhibitors on the market that offer a similar temporary relief to cognitive impairment, but do not 
compare in their statistical effectiveness and each come with various side effects. However even in 
the best circumstances the clinical significance of these treatments are sporadic and typically not 
substantial. Other treatments have been used with low levels of successes, but do provide a level 
of relief in specific cases (Birks, J., 2006). Memantine, an inhibitor of NMDA receptors, can be used 
in combination with donepezil and can increase cognitive ability by acting decreasing glutamatergic 
activity (McShane et al 2006). Selegiline acts as a monoamine oxidase type b inhibitor, but is not 
yet approved for clinical use (Birks, J and Flicker, L 2003). A more comprehensible list of drugs that 
have been implied includes antipsychotics to reduce associated behavioural difficulties of people 
experiencing the difficulties of dealing with AD and altered testosterone. While the drugs mentioned 
above have had a level of relief in some of the symptoms in some patients, they do not treat the 
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Figure 1.4: Alternative processing of APP
Newly discovered Amyloid Precursor Protein (APP) processing pathway. Produces the shorter 
sAPPη through η- Secretase activity. Further processing by other secretases produces ηα and ηβ.  
disease or effectively deal with the symptoms. Other areas of investigation are examining removal 
of excess Aβ, secretase inhibitors or metal completing agents, none of these approaches have 
been developed into clinical treatment. 
1.18.1 Endocannabinoid as candidate drug
Another study looks at the activation of endocannabinoid receptors by cannabinoids, which have 
demonstrated a neuroprotective property against Aβ. Exogenous addition of endocannabinoids 
such as AEA, 2-AG and noladin have shown to increase viability of neurons after exposure to toxic 
levels of Aβ (Aso and Ferrer 2014). The neuroprotection was demonstrated in both cell culture and 
in transgenic animal models (Chen et al., 2011; 2013). Addition to the increase viability, these 
endocannabinoids have been shown to act in a similar way to current medication. Any approved 
drug currently on the market are acetylcholine esterase inhibitors, they increase the availability of 
acetylcholine. The compound Δ9-THC competitively inhibits AchE, it increases Ach level in the 
same way. Although there activity is lower than donepezil, it does open a new revenue of chemical 
compounds that could be developed in combatting AD. The structure of cannabinoids are also 
being investigated in the MTDL approach.           
1.18.2 Multi-targeted-directed ligand approach for AD
As treatment for AD is still only symptomatic and no huge strides have been made in a therapeutic 
treatment of the cause. Multi-target-directed Ligand (MTDL) is being investigated with aims to treat 
AD at multiple targets. Majority of these new structures are acetylcholineterase inhibitors modified 
to give a variety of additional properties. The list of additional properties is extensive, some of them 
include anti-Aβ aggregation, anti-oxidation, metal chelating and β-Secretase inhibition. Triazole 
derivate is one example of this new approach. The structure of tryptoline was shown to have β-
Secretase inhibition activity, with other structural moieties attached that have anti-Aβ aggregation 
and metal chelating activity. The combination of these different chemical structures produced 
compound 26, which displayed all of these functions. There are multiple compounds that 
demonstrate multi-functionality using this MTDL drug design approach. Of the selection, some out 
preform others and are candidates for further research (Guzior et al., 2015).  
1.19 Targets the APP lifecycle
There are multiple targets in the APP metabolic pathways of Aβ that are potential targets for 
therapeutic molecules. Each target has its difficulties since blocking  specific protein functions can 
have off target effects. The next few paragraphs illustrates some areas that have been investigated 
and the difficulties that can arise. 
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1.19.1 𝛄-Secretase as a potential target
The 𝛄-Secretase is particularly important in AD, since it cleaves APP to produce one end of Aβ. 𝛄-
Secretase acts in a complex and can cleave at different residues i.e. 40 or 42, with the 42 amino 
acids from the β cleavage site, with the 42 residue product more neurotoxic, but both associated 
with Aβ plaques formation (Tanzi and Bertram 2005). Inhibitors of this process have been 
proposed, acting as an intervention for the accumulation of Aβ, but the issue is 𝛄-Secretase is 
fundamental in other biochemical processes, notably the Notch pathway, a pathway essential for 
early development and neuronal function. This means the inhibition of this enzyme must not have 
off target effects, but be specificity for the APP pathway as to avoid conflict with other important 
pathways.   
1.19.2 Metal chelators as drug candidates
Once accumulated, Aβ can form aggregates and fall out of solution as insoluble plaques (however 
no correlation has been determined between levels of soluble Aβ and progression to insoluble 
aggregates). Furthermore it is thought that zinc and copper are vital in this process (Cherny et al., 
2001). Aβ plaques in AD patients have been found to have enriched levels of Cu and Zn, due to Aβ 
binding sites with varied affinity to both Cu2+ and Zn2+, which confers a level of protease resistance 
to Aβ and a barrier to prevent precipitation of the amyloid plaque (Artwood et al., 1998, 2000). Cu/
Zn chelators were shown to solubilise Aβ plaques from postmortem AD patients, but for a 
therapeutic agent to be a drug candidate, it must also be able to pass through the blood brain 
barrier. Clioquinol (CQ, iodochlorhyfroxyquin, 5-chloro-7-iodo-8-hydroxyquinoline) is a good 
example of a possible candidate, it binds Zn2+ and Cu2+ with higher affinity than Ca2+  and Mg2+ and 
is hydrophobic, which allows it to pass through the blood brain barrier (Padmanabhan et al., 1989) 
The effects of CQ were examined by NMR spectrometry, in particular the metal binding sites of Aβ 
(3 histidine residues). Cu2+ was added to the Aβ sample, which gave a specific spectrum. Addition 
of CQ showed a significant restoration of the original absorbance spectrum of Aβ without Cu2+ nor 
CQ. This suggest that CQ was able to function as a metal chelator and liberate some of the bound 
copper. CQ was given to APP2576 mice (transgenic mice that over expressing APP) as an oral 
dose of 30mg/kg/d for a 9 week period, which significantly decreased insoluble Aβ compared to 
controls. 770.0μg/g wet weight of controls against 395μg/g wet weight for CQ treated mice (Cherny 
et al., 1985). CQ is also quickly absorbed through the gut and nearly completely removed within 
hours of dosage due to its short half life (Toyokura et al., 1985). CQ has be used as an antibiotic 
(Richards, 1971) , but was withdrawn due to neurological side effects, although they are believed 
to be prevented by B12 supplements (Yassin et al., 2000). With this is mind CQ could be a 
possible candidate for clinical trials. 
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An additional point worth mentioning is that APP itself has been documented to have high affinity 
for both copper and zinc, in an alternatively site than the Aβ binding site (Dahms et al., 2012). The 
E2 domain within the APP molecule (Figure 4.1) is a high affinity binding site of copper and zinc, it 
is located in the middle of APP and exist in sAPPα, but not Aβ. The binding of metal ions to this 
domain within APP induces large conformation changes, which has been shown to occur at 
physiological concentrations of copper and zinc. The functional differences of metal free and metal 
bound conformations of APP isn’t known. Metal chelator treatment as discussed in previous 
paragraph, could be beneficial or harmful depending on the functions of metal bound and metal 
free conformations of APP.   
1.19.3 Ultrasound as possible treatment 
 Another treatment that has been quite successful in mice is the use of ultrasound to remove 
amyloid plaques. Using an ultrasound set to 0.7MPa peak refraction, 10Hz pulse repetition 
frequency and 6s sonification time frequency caused significant differences in amyloid plaque and 
memory function (Leinenga and Gotz 2015). The mice in the experiment were transgenic with 
excess APP production and were treated five times over a 6 week period. After this treatment, the 
mice brains were observed post-mortem with a silver stain, the cortical area occupied by plaque 
were reduced by 56% and the average amount of plaques per section was reduced by 52%. 
Antibody histochemistry was used to confirm the silver staining. It was also shown that the 
population of Aβ species has a lower molecular weight i.e. Aβ1-40 oppose to Aβ1-42. A behavioural 
test that measured time mice spent at a shock pad was lower in mice that had the treatment, 
compare with a placebo group. This suggests there is a restoration in memory of the effected mice 
(Leinenga and Gotz  2015). It was evident that the levels of Aβ species and the size of the amyloid 
plaques had both decreased as a result of the treatment, but the mechanism of clearing was not 
known. In the microglial lysosomes there was an increase in Aβ species as has been seen in 
passive Aβ immunization, suggesting the change could was by increased activation of microglials. 
1.19.4 Antibody treatment against Aβ 
Passive Aβ immunization uses antibodies targeting Aβ species to direct the body’s immune system 
to the amyloid plaques. The study used transgenic mice with human APP, which at 6 months had a 
significant Aβ plaque population. These mice were given weekly injections of Aβ antibody, against 
controls, and had a 28% decrease in Aβ42 levels and a 12% decrease in amyloid plaque surface 
area compared to the controls. It was also seen that the amyloid plaques left were stripped or most 
of the amyloid species, leaving just the plaque core (Wang et al., 2011). A second experiment used 
transgenic mice where the APP gene could be activated later in development. This second 
experiment therefore looked at slightly older mice, 18 months compared with 6 months of the 
previous experiment. There was a 47% decrease in Aβ42 species and a 72% decrease in amyloid 
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surface area in the older mice (Wang et al., 2011). The increase performance of the treatment 
better displays human AD as the plaque production is late onset, like in humans. Although the 
results are dramatic, the mechanism of how this works is not fully understood. In measuring the 
levels of antibodies in the brain 6h after incubation, less than 0.2% of the antibodies were found, 
which would not account for the results seen in the experiment. A suggested possibility is that the 
plaques act as a sponge for the antibodies as the antibodies have been found on the surface. The 
plaques would sequester the antibodies in the brain allowing the antibodies to bind to the 
aggregated Aβ despite the small level of antibodies.    
Stopping the accumulation of Aβ or stopping the aggregation process may prove to be an effective 
way of treating AD. Another option is to look more closely at the biological process of APP in 
general, rather than just the problem area of Aβ. APP is cleaved by three Secretase enzymes in at 
least two different biochemical pathways. One pathway produces sAPPα via α-Secretase 
cleavage, while the other pathway has two cleavage sites β-Secretase and 𝛄-Secretase 
respectively that produces Aβ (Fig1.2). As stated previously (1.8), the amyloid hypothesis suggest 
that the accumulation of Aβ causes disease, while the sAPPα protein has been shown to be 
neuroprotective (Levities et al., 2003, Turner et al., 2007, Taylor et al., 2008, Singh, 2009). These 
two proteins have 16 amino acids in common and could be a mechanism by which sAPPα 
regulates Aβ. While the downstream pathways of sAPPα are not yet fully established, it is thought 
that these 16 amino acids are fundamental for its neuroprotective properties and therefore ideal 
candidates for development of a peptidomimetic to confer neuroprotection for suffers of AD.  
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1.20 Research aims
My project follows on from the work of many previous students working with sAPPα as a potential 
therapeutic protein for the treatment of Alzheimers disease. Above I have described the different 
roles of Aβ and sAPPα play in AD pathology, soluble Aβ aggregates are believed to be the 
causative factor based on the amyloid hypothesis, while sAPPα has been shown to have 
neuroprotective properties. Potentially smaller peptides based on sAPPα could mimic the same 
neuroprotective properties. The peptides are based on the 16 amino acid difference between the 
sAPPβ and sAPPα (fig1.2) as the sAPPα has be shown to give neuroprotective properties, while 
the sAPPβ is 1/100 of the activity (Turner et al., 2007, Furukawa et al., 1996b). This implies that 
the 16 amino acid (16mer) difference between the peptides greatly affected the neuroprotective 
capabilities. The RER peptide within the E2 domain of sAPPα also demonstrates neuroprotective 
ability, but suggested to function distinct to the 16mer. 
My aims were to: 
i. Asses if sAPPα’s neuroprotective abilities are partially if not fully existing in subsections of the 
full protein (16mer/RER)
ii. Show that sAPPα causes changes in de novo protein synthesis that allows neurons to combat 
stress
iii. Show that the proteome of neuroblastoma cells change over a time course when incubated 
with sAPPα  
iv. The subsections of sAPPα protein (16mer/RER) elicit a change in protein expression







 2.1 Approvals and conditions
Development of Genetically Modified Organisms were carried out under the conditions and 
approval obtained by Environmental Risk Management Authority (ERMA). Approval for routine 
cloning in E.coli; GMD101715. Approval for protein over-expression in E.coli strains; GM101717 
and approval for use of human cell lines under PC2 conditions; GMD101730.
 
2.2 Cell culture techniques
All cell culture techniques were preformed in ESCO Class type Ⅱ A2 Fume Hood (Labculture®, 
USA). Prior to use all equipment and surfaces were sterilised with 70% ethanol and placed in the 
fume hood. Glass equipment used was baked at 200℃ for 4h and all pipette tips were autoclaved 
(J. Mercher and Sons ltd.), to prevent contamination of mammalian cell lines. Other plasticware 
used was from sealed sterilised containers to avoid contamination. Waste material from cells was 
removed by an aspirator system part of the fume hood. Glass Pasteur pipettes (Hirscmann®) are 
attached to the aspirator to remove waste, the removed waste was collected in a 5L Pyrex conical 
flask. After the fume hood session, the aspirator was rinsed with water, then rinsed with pure 
ethanol in a secondary 5L Pyrex conical flask. Glass Pasteur pipettes were disposed of in a 
biohazard bucket. The collected waste was autoclaved and disposed of once it reaches 2L.
Cells were grown in 250ml (T75) flasks with filter tops in a model 371 Steri-cycle CO2 incubator 
(Thermo Fischer Scientific, USA) at 37℃ with 5% CO2 and 95% humidity. Mammalian cell lines 
were grown and maintained in D5796 Dubecco’s Modified Eagle Medium (DMEM, Gibco® 
Invitrogen Corporation, USA) with 10% Foetal bovine serum (FBS, Gibco® Invitrogen corporation, 
USA). The cells were monitored using Nikon Eclipse TS100 (Japan) microscope for confluence 
and trace of contamination by bacteria or fungus. 
Cell media and reagents were pre warmed in a Grant SUB Aqua 12 water bath to 37℃ before use. 
Media change depending on the confluence of the cells. Phenol red in the DMEM indicates when 
the media is becoming toxic for the cells by a colour change based on pH. A healthy red cell media 
will become orange/yellow if the nutrients are depleted and waste accumulates. 
2.2.1 Seeding from frozen stock
Frozen SH-SY5Y cells were stored in cyrotubes at -80℃ or liquid nitrogen in freezing media. 
Freezing media contains 1:10 dilution of FBS with 10% dimethyl sulfoxide (DMSO). Seeding from 
frozen requires rapid thawing of seeds to prevent toxicity of DMSO. Thawed cell solutions were 
then resuspended in DMEM and centrifuged at 1000rpm for 4min in a CL-10 centrifuge with a G26 
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rotor (Thermo Fisher Scientific Inc, USA). Supernatant was aspirated off to leave cell pallet, which 
was resuspended in DMEM with 10% FBS and 1% antibiotic-antimycotic (Thermo Fischer Inc, 
USA) which consists of 10,000 units/ml of Penicillin, 10,000µg/ml of Streptomycin and 25µg/ml of 
Fungizone® antimycotic. The resuspended cells were put into a T75 flask and grown to reach a 
high enough confluence level to be passaged (70-80%). Passage number must be 2-3 before cells 
can be used in experiments to make sure cells tested are not part of the freeze/thaw population. 
2.2.2 Passaging cells
When cells reached a high confluence level they were passaged into another flask. SH-SY5Y cells 
have a mixed population of adhered and suspended cells, which means this must be taken into 
account when passaging. The media from the T75 flasks that have SH-SY5Y cells, was removed 
and put into 15ml falcon tube and centrifuged at 100rpm for 4min in a  CL-10 centrifuge, with a 
G26 rotor (Thermo Fisher Scientific Inc, USA). The supernatant from the 15ml falcon tube was 
aspirated off and a cell pallet is left. The T75 flask with media removed was rinsed with 5ml of 
1xPBS and then aspirated off, the rinse was repeated twice. After the rinse 1ml of trypsin was 
added to the cells and incubated at 37℃ in model 371 Steri-cycle CO2 incubator (Thermo Fischer 
Scientific, USA) for 4-7min. 10ml of DMEM with 5% FBS was added to the T75 flask with trypsin, to 
suspend the removed adhered cells. DMEM and trypsin was removed from the T75 flask and 
added to a 15ml falcon tube with a cell pallet of suspended cells. The 15ml falcon tube was 
centrifuged at 1000rmp for 4min in a  CL-10 centrifuge with a G26 rotor (Thermo Fisher Scientific 
Inc, USA). The supernatant from the 15ml falcon tube was aspirated off and the cell pallet was 
resuspended with 10ml of DMEM with 5% FBS. The resuspended cells were placed into a new 
T75 flask. Name, lab number, passage number, date and cell type were written on the flask and 
stored in model 371 Steri-cycle CO2 incubator (Thermo Fischer Scientific, USA). 
2.2.3 Counting cells
Passage cells were suspended in 10ml solution of DMEM. 10μl of the suspended cells was taken 
and put into a 1.5ml microfuge tube. 10μl of Trypan blue stain (0.4%, Gibco®) was added to the 
1.5ml microfuge tube and mixed with the suspended cell solution.10μl from the microfuge tube was 
taken and put on a haemocytometer (Hawksley counting chamber 1/400mm2). The amount of cells 
in 5 separate grids were counted and the average was taken. The average number of cell per grid 
was multiplied by the dilution factor to give cells/ml. Dilutions or concentrations could be done from 
here to get a desired cell concentration of the solution.  
2.2.4 Seeding cells into 96 well plates
When the cells were at a high enough confluence, approximately 80-90%, they were passaged 
(2.2.3) and counted (2.2.4). The cells were then diluted to give a cell concentration of 1x106 per ml, 
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100μl of the suspended cells were taken and put into each well of the 96 well plate (Costar® tissue 
culture treated). The outer most wells (surrounding the cell containing wells) have plain media, as 
they were more susceptible to evaporation than the centre wells. The cells were left overnight at 
37℃ in a model 371 Steri-cycle CO2 incubator (Thermo Fischer Scientific, USA) to settle before 
experimental work.  
2.2.5 Treating cells with TAPI-1
Cells were plated on a 96 well plate (2.2.4) and left overnight to settle. The media in the wells was 
then aspirated off carefully, not to disrupt the cells.The media was replaced with new media that 
contains 5μM of TAPI-1 (Slack, B.E., et al 2001) and incubated for 48 h. The cells subsequently 
went through the MTT assay (2.2.6). 
2.2.6 MTT cell viability assay
MTT is a colorimetrix assay that gives an indirect measure of cell viability (Sieuwerts et al., 1995). 
MTT stands for 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium, which is a yellow tetrazolium 
dye, which is soluble in the cell media (DMEM). MTT diffuses into the cell and is reduced by 
mitochondria enzymes to produces formazan. Formazan is an insoluble purple crystal that can be 
detected by spectrometry 562nm (once dissolved), which gives an indication of the cell viability 
after a specific treatment. MTT was made up as a stock solution of 4mg/ml in 1xPBS, which was 
then filter sterilised through a 0.2µm (ReliaPreTM) syringe filter. After the stress inducing incubation, 
7.5μl of MTT stock solution (4mg/ml) was added to each well that contained 100μl of media to give 
a final concentration of 300µg/ml. The MTT was then incubated in the wells for 2h in a model 371 
Steri-cycle CO2 incubator (Thermo Fischer Scientific, USA) at 37℃. The media from the wells was 
then removed by a 1ml syringe with extreme care as to avoid sucking up any of the formazan 
crystals. After the media was removed from the wells, 100μl of DMSO:EtOH(4:1) was added to 
each well to solubilise the crystals. The cells were left overnight on a rocking station (RockIt Select 
BioProducts) to allow the crystals to be fully dissolved in the solution. The absorbance of the wells 
was then measured at 562nm with a ELx808® Ultra Micro plate reader (Bio-Tek Instruments Inc, 
USA). Data was then compared with controls and analysis preformed using PRISM. 
Basic MTT assay used a glucose containing media (D6429-4500mg/L) and a glucose deprived 
media (D5030) both with 6-10 biological replicates as the standard. A rescuing effect is shown 
when the experimental wells fall in-between these two standards.The cells used are SH-SY5Y, 
which are neuroblastoma cells, therefore any rescuing effect shown was said to be 
neuroprotective. Treatment with TAPI-1 was required 48h before sAPPα incubation (2.2.5) as well 
as a pre-treatment with sAPPα. Two hours prior to glucose deprivation, the media was removed 
from all wells. The standards (glucose containing and glucose deprived) have glucose containing 
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media added, the other wells have glucose containing media with sAPPα (1nM) added. The cells 
were then left to incubate at 37℃ for 2h. The media of all wells was then carefully aspirated off. 
100μl of glucose containing media was added to the positive standards, 100μl of glucose deprived 
media was added to the negative standards and 100μl of glucose containing media with sAPPα 
was added to the experimental wells. Alternatively other proteins/peptides were added in 
substitution of sAPPα to measure their neuroprotective capabilities.   
2.2.6.1 pH method
Alternative method used variation in pH rather than glucose deprivation, derived from (Eagle et al., 
1973). This method required TAPI-1 treatment as well as pre-treatment the same as previously 
stated. The pre-treatment media was carefully aspirated off. 100μl of normal pH(pH.6-7) media 
was added to the positive standards, 100μl of low pH (5.5) media was added to the positive 
standards and 100μl of low pH (5.5) with sAPPα [1nM] was added to the experimental wells. The 
cells were incubated for 8-10h and absorbance measured the same as glucose deprivation 
method. 
2.2.6.2 CuSO4 method
CuSO4 concentrations derived from a protocol in a paper (O’Brien et al., 2000) was also tested. 
TAPI-1 and pre-treatment with sAPPα [1nM] would give best chance for success, therefore also 
used in combination with this method. Pre-treatment method was carefully aspirated off. 100μL of 
CuSO4  absent media (standard DMEM) was added to the positive standards and 100μL DMEM 
media with 1μM CuSO4  added to the negative standards. 100μL DMEM media with 1μM CuSO4 
and 1nM of sAPPα was added to the experimental wells. The cells were incubated for 8-10h and 
absorbance measured the same way as the glucose deprivation method.    
2.2.7 Alamar blue
Alamar blue is a fluorescent cell viability assay which measures oxidative-reductive level (O’Brien 
et al., 2000). It is a dye called Resazurin which fluoresces weakly, but can be irreversibly reduced 
to resorufin, which has a high level of fluorescent. Similar to that of the MTT assay (2.2.6) the dye 
is reduced by the mitochondria (NADH dehydrogenase). Excitation was at 530nm and emission 
measured at 590nm.  Resazurin was available as a salt which was made to a concentration of 
5mg.ml-1 and 20µl is to each of the 96 well plate that contained 100µl of media giving a final 
concentration of 500µg.ml-1 per well. The wells were then placed back into the model 371 Steri-
cycle CO2 incubator (Thermo Fischer Scientific, USA) for 2h. The Alamar blue was added after the 
stress induced incubation, same as with MTT, but did not require removing any media before 
measurements. 
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2.2.8 Statistics analysis of viability assay
Each experiment consisted of 6+ biological replicates (excluding MTT optimisation experiments). 
Grubbs test was preformed on data sets from MTT/alamar blue experiments to remove any 
outliers. The data was then put into PRISM (GraphPad), multiple comparisons were complied, 
comparing the mean of each group with the mean of all other groups. ANOVA was used to 
measure significant differences between the group, with significance set to p<0.05.  
2.2.9 Preparation of SILAC media
SILAC (Stable Isotope Labelling Amino Acid in Cell Culture) system used lysine and arginine 
isotopes that were integrated into de novo protein synthesis (Ong et al., 2002). Different types of 
media were required for this technique to work. The base media (SILAC DMEM; ThermoFisher) is 
deprived of the amino acids lysine and arginine, that were added separately, either light, medium 
or heavy isotopes depending the media type. FBS was also added, but it must be dialysed first to 
remove amino acids.  
2.2.9.1 Light
43.35ml of SILAC DMEM was put into a 50ml falcon tube with 50µl of light lysine, 50µl of light 
arginine and 50µl of proline. This solution was then filtered through a 0.2µm filter (ReliaPreTM) into 
a second 50ml falcon tube. 1ml of L-glutamine (ThermoFisher), 500µl of Pen anti-biotic and 5ml of 
dFBS (dialysed) was added to the second falcon tube. This tube was then stored at 4℃ ready for 
use.    
2.2.9.2 medium
43.35ml of SILAC DMEM was put into a 50ml falcon tube with 50µl of medium lysine, 50µl of 
medium arginine and 50µl of proline. This solution was then filtered through a 0.2µm filter 
(ReliaPreTM) into a second 50ml falcon tube. 1ml of L-glutamine (ThermoFisher), 500µl of Pen anti-
biotic and 5ml of dFBS (dialysed) was added to the second falcon tube. This tube was then stored 
at 4℃ ready for use.
2.2.9.3 heavy
43.35ml of SILAC DMEM was put into a 50ml falcon tube with 50µl of heavy lysine, 50µl of heavy 
arginine and 50µl of proline. This solution was then filtered through a 0.2µm filter (ReliaPreTM) into 
a second 50ml falcon tube. 1ml of L-glutamine (ThermoFisher), 500µl of Pen anti-biotic and 5ml of 
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dFBS (dialysed) was added to the second falcon tube. This tube was then stored at 4℃ ready for 
use.
2.2.10 Stable Isotope Amino acid Labelling in Cell culture
The cells growing in the T75 flask had to adjust to SILAC light (2.2.7.1) media before the SILAC 
experiment. The cells were passaged (2.2.3) and resuspended in SILAC light media and placed 
into a T75 flask and left to adjust to the new media for two weeks. Once the cells adjusted to the 
new media (light media), they were passaged using light media. The cells were then counted 
(2.2.4), then 10ml of media at a cell concentration of 5x104cells.ml-1 was plated on three 
100mmx20mm petri dishes (Cellstar®). The cells were incubated at 37℃ in a model 371 Steri-
cycle CO2 incubator (Thermo Fischer Scientific, USA) to reach 80% confluence. The media was 
then aspirated from the petri dishes and replaced with light, medium or heavy media. The negative 
control was then given 10ml of light media. Second negative control was given 10ml of medium 
media with PBS equivalent to amount of sAPPα. sAPPα (1nM) was added with 10ml of heavy 
media. The cells were then incubated for 12h at 37℃ in a model 371 Steri-cycle CO2 incubator 
(Thermo Fischer Scientific, USA). 
Additional experiment incubated the cells with 1nM concentration of the 16mer peptide in the 
heavy media for 6h. The RER peptide at a 1nM concentration was incubated for 6h in a heavy 
media sample. For the 6h incubation time, sAPPα, 16mer and RER were in three seperate heavy 
cell populations to be used in mass spec. 
2.2.10.1 SILAC cell lysis 
The media from the petri dishes was removed and autoclaved. The cells were then rinsed in ice 
cold PBS that was then aspirated off. 2.5ml of ice cold PBS was added to the petri dish, the cells 
were then removed by a cell scraper (FisherbrandTm), the scraped cells were pipetted into a 15ml 
falcon tube. This was done two more times, resulting with 7.5ml of scrapped cells, suspended in 
PBS. The cells in the falcon tube were spun for 10min at 600g at 4℃ (Avanti® J-26xp), prior to 
spinning, the rotor (Jsp F50c) was stored at 4℃ for 30min. The supernatant was removed and 
250µl of RIPA buffer was added. This solution kept on ice for 20min, vortexing every 5min. The 
solution was transferred to a 1.5ml microfuge tube and spun at full speed (Heraeus Biofuge Pico) 
for 10min at 4℃. The supernatant was removed and put into a 0.6ml microfuge tube, which was 




Sodium dodecyl sulphate Polyacrylamide gel electrophoresis (SDS-PAGE) was used to analyse 
protein from cell lysates of SH-SY5Y cells. 0.75mm, 10% polyacrylamide gels were used for all 
protein analysis, made using the Mini-PROTEAN® 3 system (Bio-Rad Laboratories Inc, USA). 
Separating gel solution was added between the two 1.5mm glass plates. 200µl of water was 
carefully pipetted on top to create smooth layer of separating gel. Separating gel solution was left 
to set (30min). Once set, the water was drained off the top of the gel. Stacking gel was then 
pipetted on to the top of the separating gel and a comb was inserted, the gel was then left to set. 
Protein samples were mixed with cracking buffer at a 3:1 ratio respectively. The protein was then 
denatured by heating to 95℃ for 5min, then iced(1min) and centrifuged(30s)(Heraeus Biofuge 
Pico). The gel was placed in a gel tank (BioRad mini-trans blot), with an inner buffer and outer 
buffer added to the gel tank system. The samples were then loaded into the wells, with the total 
protein amount adjusted to 100μg using the concentration worked out through BCA (2.3.3). Along 
with the samples, 5µl of broad range SDS-PAGE Molecular Weight Standard (Bio-Rad 
Laboratories Inc, USA) diluted with cracking buffer (1:20) was added. Samples and a molecular 
weight marker was run in a model 200/2.0 power supply gel electrophoresis machine for 1.5h at 
200V. The gel was then stained with coomasie blue dye for 1h, coomasie dye was then removed 
and destain was added for 1h. The destain was removed and replaced with MilliQ and left 
overnight. 
2.3.2 Denaturing polyacrylamide/urea gel electrophoresis 
0.75mm Urea PAGE gels were made with 10-20% acrylamide depending on resolution needs. 
Urea was added to a 8M final concentration with 10x TBE buffer. A 40ml solution for a 10% 
acrylamide gel consists of 19.2g of Urea dissolved in 4ml of 10x TBE buffer and 10ml of 20% 
acrylamide. The solution was made up to 40ml with MilliQ. Dissolving the urea was an endothermic 
reaction, therefore was heated slightly to allow the urea to fully dissolve. After the solution was 
made up to 40ml, 40μl of TEMED was added and mixed by swirling the flask. Immediately 
following, 400μl of 10% APS was added and mixed by swirling the flask. The solution was poured 
quickly into the glass plates with a comb as the setting time was short. Also note, the solution was 
kept at room temperature, higher temperatures would have caused the solution to set before 
adding it to the plates. 
 
Due to urea concentration the gels had to be pre-run before loading the samples. 0.5 xTBE buffer 
was heated to 55℃ and poured into the inner and outer chambers. The gel was run at 90v for 30 
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minutes using the Mini-PROTEAN® 3 system. After the pre-run, the wells were rinsed with 
pipetting due to urea settling in the bottom of the wells . The samples were prepared by adding 1μl 
of sample with 1μl of loading dye and heated to 70℃ for 1minute. 2μl of each sample was loaded 
in to a well. The gel was run at 70v for 3h or 20v for 18h depending on your resolution needs. After 
run, the gel was soak in 0.5x TBE for 15 minutes and then 0.5μg.ml-1 ethidium bromide for 10 
minutes. The gel was visualised under UV light (Bio-Rad gel doc™ XR+). 
2.3.3 BCA assay
Reagent A’ consists of 20µl of reagent S for each 1ml of reagent A, 5µl of reagent A’ was added to 
each standard and sample being tested. The BSA protein standard is 10mg.ml-1, which was diluted 
through serial dilutions to produce protein concentrations of 10mg.ml-1, 5mg.ml-1, 2.5mg.ml-1, 
1.25mg.ml-1, 0.625mg.ml-1 and 0.3mg.ml-1 to get an adequate range of concentrations to measure 
any given sample. The assay was preformed in a 96 well plate, with triplicate replicates for each 
standard. 5µl of the standard/sample was put into a well with 25µl of reagent A’ and 200µl of 
reagent B. The 96 well plate was then placed on a rocking table (RockIt Select BioProducts) for 
15min. Absorbance was then read at 750nm on a ELx808® Ultra Micro plate reader (Bio-Tek 
Instruments Inc, USA).   
2.3.4 Production of λ marker
Typically a XIV marker (Sigma-Aldrich) was used in an agarose gels to give a accurate estimation 
of sizes of fragments that are running. This marker worked well for DNA fragments that were under 
1000bp; larger fragments than this needed an alternative marker. λ DNA can be used with 











Fig 2.1 λ marker
λ DNA cut by endonuclease EcoR1 and HindⅢ 
and run on a 1% agarose gel. Fragment sizes 
are marked to the right and are in base pairs 
(bp); range from 564-21,226bp.  
restriction enzymes used. One of the fragments I am cloning is 1500bp, therefore I produced a λ/
Hind/Eco marker (figure 2.1) by incubating λ DNA with EcoR1 and HindⅢ with an appropriate 
buffer that is suitable for both restriction enzymes. 
2.3.5 Heat shock transformation 
The plasmid vector was amplified in bacteria culture DH5α, E.Coli cells. I used the plasmids pMal-
C2 for ηα, ηβ cloning and pcDNA3.1D for sAPPη cloning. Plasmids were added to 200µl of DH5α 
cells mixed and then iced (30min), then heated at 42℃ for 45 seconds. Cell were iced (1min) and 
then suspended in 800µl of 2TY media. The cells were then incubated at 37℃ on the shaker 
(RockIt Select BioProducts) for 45 to 60 minutes.100µl of the cells were spread onto agar plates 
with ampicillin antibiotic at 100µg/ml and then incubated at 37℃ overnight facedown.  
2.3.6 Growing colonies and isolating plasmids
Colonies grown on the ampicillin plates will be ampicillin resistant, likely due to successful 
transformation of the plasmid. Individual colonies were picked and grown in 5ml of LB and placed 
in a 37℃ shaker overnight. After overnight incubation, the plasmids were isolated from the culture 





In my experiment we were looking to clone DNA fragments that were based around the newly 
discovered η-secretase (1.16). η-secretase cuts alternatively and close to β-secretase to produce 
two fragments; sAPPη and CTF-η. CTF-η is then further processed by either α-secretase or β-
secretase to produce ηα and ηβ respectively. Therefore the scope of my experiments was to clone 
the fragments sAPPη, ηα and ηβ; the primers are thereby designed to amplify these segments, 
resulting in three sets of forward and reverse primers (Appendix Ⅱ). APP695NM_201414 from 
GenBank is the base sequence used for all primer sets
2.4.1.1 ηα and ηβ primer design
The η cut site was determined to be between amino acids 504-505 in the APP695 sequence as 
stated in ‘η-Secretase processing of APP inhibits neuronal activity in the hippocampus’ by Willem 
et al., 2015. The α and β cut sites are between 612-613 and 596-597 respectively; producing a 108 








2.4.1.2 sAPPη primer design 
sAPPη fragment is from the N-terminus to the η-secretase cleavage site at 504-505 in the APP695 










The mRNA sequence for each of these amino acid sequences was found in the APP695 and 
primer pairs were designed for each sequence through the use of primer-BLAST from 
NCBI. The forward and reverse primers were tested with various bp lengths; the optimal 
length of primers was 22-30 amino acids with a melting temperature between 60-68℃, as 
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well as each primer within 4℃ of its primer pair. Once primers were shown to produce one 
product of the correct length through primer-BLAST analysis, they were tested through an 
online multiple primer analyser software by thermofisher; to identify possible hairpins, 
cross-dimerisation, self dimers and primer pairing. The end products, that met all of these 
regulations are shown below. 
2.4.2 PCR fragments 
10μM of forward and reverse primer was used with 10ng of APP695 clone DNA for PCR 
amplification. Concentrations of Taq polymerase, polymerase buffer, dNTP’s and MgCl2 used 
followed the protocol of Platinum Taq; High fidelity polymerase (invitrogen; Life technologies). 
Samples were then run through pre-set protocol for PCR amplification on Bio-Rad C1000-themo 
cycler. Samples initially heated to 95℃ for 5 minutes, then 60℃ for 1 minutes for annealing of 
primers, heated to 68℃ for 30 seconds for polymerase binding and amplification. These three 
steps were repeated 35 times, then the temperature was left at 4℃ to keep the DNA stable. The 
annealing step temperature may be altered depending on the Tm of the primers. The replication 
stage time may also change depending on the length of PCR fragment to be copied; typically 
extension time is 1 minute per kb of DNA amplification.  
2.4.2.1 PCR clean up 
The solution from the PCR reaction will contain primers, enzymes and small DNA fragments 
besides the desired PCR product. Cleaning up this solution so that only the desired PCR products 
remained was done through the use of a QIAquick PCR Purification Kit.  
2.4.3 Agarose gel electrophoresis
Both amplified DNA products and vectors were run on a 2% and 1% agarose gels with ethidium 
bromide respectively. Samples were mixed with loading dye at a 3:1 ratio and run at 90v for 1 hour 
with 0.5x TBE buffer. Gels also included a size appropriate ladder to allow estimation of the size of 
the fragments; XIV(Sigma-Aldrich) was used for fragments under 1000bp and λ/HindⅢ/EcoR1 
marker was used for the vectors. The bands present in the cell were visualised and photographed 
through UV illumination gel doc imager (BioRad Laboratories Inc., USA).  



















































































































































































































































































































































































































PCR products ηα, ηβ and sAPPη primer’s were designed to include a restriction enzyme 
sequence that matched the chosen cloning vector. ηα and ηβ were to be cloned into the vector 
Pmal-C2 with the restriction enzymes HindⅢ and BamH1, for this to occur the primers used to 
amplify ηα and ηβ incorporated HindⅢ and BamH1 cutting sequence into the primers. sAPPη 
used restriction enzymes HindⅢ and EcoR1, thereby their cutting sequence was incorporated into 
the sAPPη primers. The vector was manufactured with MCS, with both vectors including the 
associated restriction enzyme. sAPPη used the vector pcDNA3.1D, while ηα and ηβ used the 
vector Pmal-C2. Figures 2.2 and 2.3 illustrates the PCR fragment and vector ligation together. 
The restriction enzyme digest used 1μl of each needed restriction enzyme with 3μl of appropriate 
buffer for each μg of DNA. Restriction enzymes EcoR1, HindⅢ and BamH1 all preformed at 100% 
efficiency with buffer type B. The solution was made up to 30μl with MilliQ and then incubated for 
1.5h at 37℃ in a water bath (Grant SUB Aqua 12). After the incubation, the solution can be either 
heat inactivated (70℃ for 2min) or can be PCR purified (2.4.2.1)
2.4.5 Ligation
After both PCR and vectors were digested by the attended restriction enzymes, they were ligated 
back together using a standard ligation protocol. A ratio of vector to insert is worked out using the 
size of each in kb. The ratio of vector to insert was established in moles, which depends on the 
size of both vector and insert, typically a 3:1 (vector:insert) ratio is used. 
The ligation solution contained 50ng of vector and 16ng of insert following the 3:1 ratio. The rest of 
the solution had 2μl of T4 DNA ligase buffer (10x), and 1μl of T4 ligase added. The final volume 
was made up to 20μl with MilliQ. The ligation solution was then incubated at 16℃ overnight or at 
room temperature for 10 minutes. 
2.4.6 Dephosphorylation of DNA
Vector pcDNA3.1D was treated with Calf intestine phosphatase (CIP) to remove phosphate groups 
from the vector ends after restriction digest. 1µl of CIP was added to 1pmol of DNA ends with CIP 
buffer and made to 20μl with MilliQ. The solution was incubated for 30min at 37℃, then put 
through a PCR clean (2.4.2.1) up to remove CIP.
2.4.7 Growing on plates 
Following transformation protocol (2.3.5), 200μl of the transformation solution was spread on an 
agar plate with an appropriate antibiotic. All plasmids I used were ampicillin resistant, thereby the 
plate I used had an ampicillin concentration of 100μg.ml-1 as a selective marker of a successful 
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transformation of my plasmid. Once the cells were spread onto the plates, they were incubated 
overnight at 37℃ (Conthorn incubator).   
2.4.8 Colony screen 
Successful transformation resulted in colony growth on the ampicillin plates. A PCR reaction was 
carried out on the colonies to determine which of the colonies carried our genetic construct, rather 
than a false positive. A master plate was set up with a grid that was numbered for each of the 
colonies to be streaked onto. A given colony was mixed with 6μl of LB media, some of this media 
was streaked onto a master plate. 3μl of the LB media was added to 10μl of 0.5% Tween-20 (filter 
sterilised) to break open the bacteria from the colony. 1μl of the Tween-20 mixture was added to a 
PCR mixture designed to amplify our construct within the plasmid. The forward primer is one that 
binds to the plasmid, while the reverse binds to the insert. Therefore amplification will only occur is 
insert is in plasmid and will not amplify stray fragments of the insert.   
2.4.9 Sequencing
Samples were sent away for sequencing by genetic analysis services at Otago University, the 
samples were set up in 0.2ml strip tubes (BioRad). Forward and reverse primers were set up in 
seperate tubes at a concentration of 3.2μM. 150ng of the DNA to be sequenced was added to the 
tubes. The solution was made up to 5μl and sent to be sequenced.  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2.5 Mass spectrometry 
Protein lysate from SILAC cell lysis (2.2.10.1) was run on a protein gel (2.3.1). The gel was cut and 
run in 10 fractions  for each band. The fractions were put through shotgun proteomics via nano-
uHPLC (ultra high performance liquid chromatography) coupled with ESI (electro-spray ionisation) 
tandem mass spectrometry. Tandem mass spectrometry refers to a full analysis of peptide species 
that then progress through a second mass spec after peptides are fragmented. The fragments can 
then be complied to workout the sequence of amino acids from the peptide (Schwanhausser et al., 
2008).    
2.5.1 SILAC analysis using proteome discoverer
The peptides found through mass spec were analysed through proteome discoverer 1.4 (Thermo-
Fischer). Multiple runs measuring the mass spec data were analysed simultaneously to increase 
the statistical power. All peptides discovered were loaded into the program and matched to a 
specific protein, each protein thereby has a number of peptides associated to it. The peptides 
associated to each protein consist of either heavy or medium isotopes giving different molecular 
weights. Each protein had a ratio of heavy/medium peptides (assuming multiple peptides), which 
showed up or down regulation, depending on the conditions of the heavy and medium media i.e. if 
heavy was the sample and medium was the control then a higher ratio of medium/high would 
signify down regulation and vice versa. Further processing of the data was done before looking at 
which proteins were up regulated. Multiple filters were applied to the data set, so that the results 
were significant. 
Filters applied
1. Peptide confidence: This applied a false discover rate (FDR) of 1%  to the peptides. FDR is 
‘Number of false peptides/ all peptides’, with false peptides calculated by running peptides 
through a nonsense database and calculate how many hits a given peptides has on this 
nonsense database. Typically a reverse of peptides or a scrambled database is used as the 
nonsense database. 
2. Variability of proteins: This was set to 20%; it scored the similarities of peptides linked to the 
same protein. If the peptides were too dissimilar, it was unlikely that they are for the same 
protein. 
3. Data normalisation: Between medium and heavy protein samples, some protein can be 
assumed to have the same expression levels. Actin, GAPDH and tubulin should have a 
medium to heavy ratio of 1, showing no expression change. If a different ratio was observed, 
then the data set can be normalised to 1 for any of these proteins. 
4. Peptide number: A minimum of 2 peptides per protein was selected. Under this would have 
meant the protein wasn’t significant enough within the dataset to be fairly represented
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5. Unique protein number: A minimum of 2 unique peptide was selected. This was to prevent the 
same peptide being counted twice towards a specific protein. 






   3.1 Experimental context 
Secreted Amyloid Precursor Protein alpha (sAPPα) has been shown to have a number of effects 
on neurons. Increased neurite length and branching are some of the documented morphological 
changes (Li et al., 1998). A related protein Secreted Amyloid Precursor Protein beta (sAPPβ) lacks 
the 16 amino acids at the C-terminus of sAPPα and is far less active. Both are processed from 
Amyloid Precursor Protein (APP), but by exclusive pathways for their production. The fact that the 
neuroprotective capabilities of these two proteins vary considerably, implies directly or indirectly 
the 16 amino acids, now termed the 16mer is responsible.
One aim of this study was to determine the neuroprotective capabilities of sAPPα through a cell 
viability assay and to identify wether the 16mer could mimic the effects that are exhibited by 
sAPPα and compare how any correlations between the two sAPPs influence gene expression. 
Additionally to these two sAPPα variants, a new variant sAPPη, and its processing enzyme 
(η Secretase) was discovered (Willem et al., 2015). Another aim was to clone the fragments 
sAPPη and the shorter fragments ηα and ηβ from this new processing pathway to better 
understand the activity of APP processing products. 
3.2 Cell viability optimisation
The first step was to examine at the neuroprotective capabilities of sAPPα, and if successful the 
same assay should be able to show the 16mer and variants neuroprotection. For this reason the 
assay must be sensitive to determine the neuroprotection of sAPPα and the 16mers, which may 
have a decreased effect like with the sAPPβ.
The MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay is a colorimetric 
assay that measures the anti-oxidant level of a cell population that is used as a  proxy for cell 
viability (Sieuwerts et al., 1995). MTT is a soluble yellow dye that is taken up by the cells and then 
reduced by a mitochondrial reductase within the cell. An insoluble purple crystal is the product that 
accumulates in the culture in an amount corresponding to the viability of the cell population. These 
crystals are dissolved in a solution such as DMSO, (full methods available- section 2.2.6). 
Absorbance can then be recorded at 562nm using a ELx808® Ultra Micro plate reader (Bio-Tek 
Instruments Inc, USA). Differences between extent of crystal formation in the cell populations 
results in a variation in the recorded absorbance at a specific wavelength, and gives a measure of 
cell viability. Anything than can increase the absorbance level would be considered neuroprotective 
, whereas a decrease would be neurotoxic, assuming statistical significance. 
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Some evidence has been shown for the neuroprotective capabilities of sAPPα (Li et al., 1998). 
Optimisation of the MTT assay was required before effects of sAPPα could be observed.
3.2.1 Data analysis
The following results based on the MTT assay requires both technical and biological replicates for 
statistical significants. Typically three technical replicate is the minimum number for each 
experiment. But because of the variation of the MTT assay, even after optimisation, six technical 
replicates were always used as stated in the figure legend. Additionally biological replicates derived 
from independent batches of cells in culture were used for statistical biological significance. Each 
experiment for MTT has at least one biological replicate unless stated otherwise.
3.2.2 Determining the optimal cell density
For the MTT assay used a DMEM media that has a high glucose (4.5g.L-1 D-glucose) was used as 
a positive starting condition and a glucose deprived DMEM media as a stress condition. The 
greatest difference between these two conditions would provide a sufficient range to measure a 
neuroprotective effect. The first adjustment for the MTT protocol was the cell density in each 96 
well plate. 
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Figure 3.1: Effect of cell density on formazen production
Absorbance measurements (562nm) of SH-SY5Y cells with 4mg/ml of MTT after 4 hour glucose 
deprivation test and solubilisation with DMSO treatment. Variation of cell density plated in the 96 well plate; 
glucose n=10; Non-Glucose n=10. Error bars are SD while significance is **p<0.01,***p<0.001 using 
ANOVA statistical test.
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This optimisation for the MTT assay shown in figure 3.1, with cell densities per well of a 96 well 
plate shown here ranging from 1.25x104 to 2x105. Used a 4mg.ml-1 concentration of MTT as stated 
in section 2.2.6. With the exception of 104 (not shown in graph) an increase in cell density gave an 
increase in formazen production and thereby higher absorbance. At the lowest cell densities the 
difference between media with and without glucose and no glucose was not significant, although 
differences were observed. At the cell density 5x104, a significance p value <0.01was obtained. 
With a large difference between the two tested variables, it could be used as a suitable cell density 
for further testing. Variation between replicate wells and thereby error bars are larger as the cell 
density increases, suggesting that with more cells per well lead to greater variation in formazen 
production. There may also be an increase in losses when aspirating media prior to solubilising the 
formazen crystals with increased concentration of this product. Nevertheless the highest cell 
density, 2x105 per well has the most significant results with a p value <0.001 and thereby would be 
the optimal cell density. However, in the 96 well plates, the cell confluence may be too high and in 
such close proximity to each other, so that the results may be affected when sAPPα is added. The 
next set of experiments used both the 5x104 and, 105 for investigation with different conditions. The 
105 cells/well was chosen as the optimal cell density and used for all MTT experiments from this 
point onwards.   
3.3.3 Determining cell incubation time 
Figure 3.2 shows a range of incubation times with no glucose from the starting time of 4 h to 24 h 
at the pre-determined cell density. Glucose deprivation is a method previously shown to cause cell 
stress, and so it was reasoned, a longer time might increase the differential level of formazen 
production between with or without glucose.  The larger the significance between glucose and non-
glucose conditions the easier it would be to measure neuroprotection with sAPPα. Figure 3.2 
shows that not all incubation are suitable. In this experiment shown in figure 3.2, 4h incubation 
gave only a small difference between the two variables. By contrast 8h and 16h both showed 
significant differences, with the 8h incubation time having slightly smaller error bars. At 24 hours pf 
glucose deprivation, this difference between glucose and non-glucose, had diminished. 
Paradoxically the cells have been shown to become apoptotic after such lengthy glucose 
deprivation, but this cell death would expect to cause, higher losses of formazen production and 
thereby increase the deficit between glucose containing and glucose deprived cells. However, by 
24h incubation cells with media containing glucose showed a decrease in formazen production, 
suggesting that the cells regardless of glucose concentration become less viable in the 96 well 
plate after such a long incubation time. The shorter 8h incubation time of was chosen as the time 
of choice due to the significant difference between glucose conditions and the small error bars. 
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This time is also well  before cells start dying from, a state neuroprotection would not be able to 
overcome.
3.3.4 Determining MTT concentration
Initial concentration of MTT reflects the amount of soluble dye that is able to be reduced by the 
cells and should be saturating (2.2.6). An insufficient level of dye (MTT), would mean that both the 
glucose and glucose-deprived cells could feasibly reduce all of the dye and consequently show no 
difference. Ideally the concentration of dye in the cell populations would remain in surplus during 
the 2h incubation.
Figure 3.3 shows varied concentrations of MTT concentration from 200 - 500μg/ml. The lower 
concentration 200μg/ml shows a significant differential between the glucose conditions that is 
significant. A concentration of 300μg/ml gave the most significant difference between the two 
conditions with tighter replicates. Surprisingly 500μg/ml the difference between was not significant, 
and the absolute absorbance with glucose was not as high. Higher concentrations could be 
causing a toxic to the cells, diminishing their ability to reduce the dye.      
 55
Figure 3.2: Effect of incubation time on formazen production
Absorbance measurements (562nm) of SH-SY5Y cells with 4mg/ml of MTT with a cell density of 105 per 
well and solubilisation with DMSO treatment after timed glucose deprivation. Glucose n=10; Non-Glucose 
n=10. Error bars are SD while significance is *p<0.05 using ANOVA statistical test.
3.4 Glucose deprivation effects on cell morphology
The earlier experiments described above established that glucose deprivation reduced cell viability, 
but did not assess morphological changes. Mitochondrial function may be a good measure for cell 
health, but does not fully describe how the cells respond to stress. Undifferentiated cells in the 
population may respond differently to the differential neuroblastoma cell, too long under glucose 
deprivation may preclude recovery facilitated by neuroprotective peptide. Cell viability must not 
only show a difference in between glucose free cell populations and those in glucose, but these 
cells must have the ability to recover, and any morphological changes should reverse as well. 
Figure 3.4 examines morphological changes in cells over a glucose free period of up to 24h. Key 
characteristics in the neuroblastoma cell populations are axon development, straight/non-rounded 
bodies and fully differentiated cells with no aggregation masses. It is clear from the Figure 3.4 that 
even after 18h of glucose deprivation, the key characteristics remain unchanged. By 24h the cells 
populations began to show some aggregation, seen as overlapping cells with little or no axon 
definition. Although this is subtle, even at long incubation times, it is unclear how influential the 
changes of morphology is on the viability of the cells. Regardless, the optimal incubation time in 
glucose free media was 8-10h and at this time point no morphological changes were evident.  
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Figure 3.3: Effect of MTT concentration on formazen production
Absorbance measurements (562nm) of SH-SY5Y cells at a cell density of 105/well, with or without 8h 
glucose incubation and solubilisation of formazen product with DMSO. Variation of MTT concentrations 
ranged from 200μg/ml, 300μg/ml, 400μg/ml and 500μg/ml were tested in the 96 well plate; glucose n=8; 
Non-Glucose n=8. Error bars are SD while significance is *p<0.05, **p<0.01 using ANOVA statistical test.
(μg/ml)
3.5 Testing sAPPα in MTT viability assay 
Optimisation of the cell viability assay (MTT), established a significant difference in reductive 
potential between the two conditions that was large enough to be detect recovery and thereby 
neuroprotection. The larger the difference the higher the sensitivity of the assay. Furthermore for a 
peptide/substrate to show neuroprotection then it should reproducibly show a significant protection 
from the glucose deprived. 
Despite optimisation of the MTT assay, sAPPα did not protect against the effects of glucose 
deprivation. Figure 3.5 shows the first sAPPα experiment results with a range of protein 
concentrations. Although there was a significant difference between glucose treated and glucose 
deprived cells, the addition of sAPPα to the glucose deprived cells, did not facilitate protection. In 
this experiment I used 8 technical replicates for each sAPPα concentration tested, suggesting that 
the lack of effect was not from lack of statistical power. Furthermore biological replicates of this 
experiment yielded the same results, indicating that these conditions the sAPPα protein did not 
show neuroprotective capabilities. With the amount of optimisation of this assay, it is unlikely that 
neuroprotection was occurring but couldn’t be detected. As in figure 3.4 the cells kept in glucose 
had a higher absorbance as expected than the glucose deprived cells. However regardless of the 
concentration of sAPPα no change was observed. Establishing neuroprotective ability of sAPPα as 
shown by (Li et al., 1998) was vital before testing other substrates. Therefore other variations in the 
conditions of the assay, such as pre-treatment of samples with sAPPα, and the addition of an α-
secretase inhibitor (TAPI-1)(2.2.5) (Slack, B.E., et al. 2001), to prevent endogenous production of 
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Fig. 3.4 Effects of glucose deprivation on cell morphology  
Cells were plated at a cell density of 25x105 in 24 well plates in glucose deprived (Gibco) DMEM media with 10% 
FBS
24 h
sAPPα, alternative MTT methods (2.2.6.1-2.2.6.2) and alternative cell viability assays were 
trialled(2.2.7).  
3.5.1 Testing pre-treatment with sAPPα
The first experiment included pre-treatment for 2h with sAPPα, thereby allowing the cells to take up 
sAPPα before being under stress. After the pre-treatment, the cells underwent the same protocol 
as previously used (2.2.6). Unfortunately no significant difference was seen in as a result of sAPPα 
as before.  
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Figure 3.5: sAPPα neuroprotection
Absorbance measurements (562nm) of SH-SY5Y cells at a cell density of 105cells/well, 8h 
glucose deprivation incubation, 300μg/ml of MTT and solubilisation of formazen with DMSO. 
Variation of sAPPα concentrations ranged from 1nM to 10nM and were tested in the 96 well 
plate; glucose n=6; Non-Glucose n=6; sAPPα 1-10 n=8. Error bars are SD while significance is 































3.5.2 Treatment with TAPI
SH-SY5Y cells, a neuronal cell line, processing APP with endogenous α-secretase activity. Cellular 
endogenous levels of sAPPα might protect partially from the stress from the glucose deprivation. 
Yet, it should be acknowledged a clear difference in reductive potential was seen when glucose 
was absent, as observed.
To test the intrinsic ability of endogenous sAPPα to compete with exogenous sAPPα for 
neuroprotection, an α-secretase inhibitor TAPI (TNF-alpha protease inhibitor) was used. TAPI is a 
potent inhibitor of metalloproteinases such as α-secretase (Slack et al.. 2001)(1.12). One such 
experiment was to add TAPI to glucose deprived cells and compare them to cells without TAPI. 
One limitation is that TAPI is not a specific inhibitor of sAPPα production and is toxic to cells at 
>10μM. Hence a drop in absorbance, an apparent reductive power in TAPI treated cells could be 
caused by either the loss of sAPPα production or toxic effect of TAPI. I pre-treated cells with TAPI 
(5μm) for 48h before adding sAPPα to preventing any effects from endogenous sAPPα. The 
experiment then followed the protocol as stated in the methods (2.2.6).
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Figure 3.6: TAPI treated cells (24h)
Absorbance measurements (562nm) of SH-SY5Y cells at a cell density of 1.00E+06, 8h glucose 
deprivation incubation, 300μm/ml of MTT and solubilisation of formazen product with DMSO. Pre-
treated with 5μm of TAPI 24h previous. glucose n=6; Non-Glucose n=6; sAPPα 1nm n=6. Error bars 


















Firstly, the effect of TAPI treatment is shown in figure 3.6, which used a 24h pre-incubation with 
5μm of TAPI before sAPPα was added and glucose withdrawn. The first results between glucose 
deprived and sAPPα treated groups were promising. When treated for 24h with TAPI, a small 
increase in average absorbance is seen with the addition of 1nM sAPPα treated cells. This is more 
evident when you look at the significance compared with the glucose standard. The difference in 
cell viability between cell viability between cells in glucose compared with the glucose free cells 
has a higher significance than when sAPPα is present. These results suggest that adding TAPI, did 
inhibit sAPPα endogenous synthesis leading to an greater sensitivity to added sAPPα
3.6 TAPI morphology experiment
Figure 3.7 illustrates the morphological effects of TAPI-1 on neuroblastoma cells over an extended 
incubation time. Some of the morphological changes that a key to understanding if the cells are 
healthy is axon formation, non-rounded bodies and separate cells rather than clumped 
aggregations. Without TAPI-1, no changes were detected over the 60h time frame of the study, 
with axons formed and no sign of aggregations, TAPI-1 (12.5μM) showed the same result with no 
changes over the 60h time frame. At 25μM concentration of TAPI-1 some signs of degradation or 
differentiation were seen at 48h. The axons still had developed, but the cells were clumped and 
showing aggregation. At 50μM TAPI-1 concentration, toxic effects are apparent at 24h, with very 
little axon development and significant aggregation. The experiment demonstrated that the 
increase time of incubation with TAPI-1 at higher concentrations, could cause a change in the cell 
morphology. Using TAPI-1 for 24h did not alter the cell morphology. The next experiment repeat the 
previous TAPI-1 MTT experiment but with 48h incubation. 
This experiment with TAPI experiment shows significant neuroprotection with sAPPα. There is a 
significant difference between media with glucose and glucose free media, as expected. However, 
additionally there is a significant difference between glucose free and the same conditions when 
sAPPα is added. By varying the conditions of the assay and treatments of the cells I was able to 
show significant results for the protection against glucose deprived stress by sAPPα. Unfortunately 
later experiments were inconsistent and made it difficult to examine the effects of other sAPPα 
variants and peptides. Alternative methodology and assays were examined to look at a more 




































































































































































































































3.7 Alternative methods for MTT
The lack of consistency in the MTT assay meant that changes to the MTT. Instead of using the 
glucose deprivation as a stressor, I tried a low pH. The rationale behind this change is from a paper 
that looked at optimal pH conditions for cell growth and the pH limits of cells (Eagle, 1973). 
3.7.1 pH method for MTT assay
Firstly the compatibility with the MTT viability assay was examined, (figure 3.9) while second 
effects on the cell morphology caused by the alternative stress technique were investigated (figure 
3.10). Both approaches were fundamental to development of the an alternative MTT assay. The 
cells needed to show a significant decrease in reduction power, but the impaired functionality of the 
cells must be able to be rescued. 
For the modified method I kept the same optimisation conditions that I previously established, but 
varied the pH of glucose containing media. Figure 3.9 shows physiological pH of 7.4 maintaining 
the reductive power of the cell populations with glucose present. Two other two conditions; Low pH 
of 5.5 and Medium pH of 6.5, are standard media with pH adjusted with dilute HCl. Figure 3.9 
shows that both the medium and low pH show a significant difference compared with that of the 
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Figure 3.8: TAPI treated cells (48h)
Absorbance measurements (562nm) of SH-SY5Y cells at a cell density of 1.00E+06, 8h glucose 
deprivation incubation, 300μm/ml of MTT and solubilisation of formazen products with DMSO 
treatment after; Pre-treated with 5μm of TAPI 48h previous. glucose n=6; Non-Glucose n=6; 


















standard media (Normal 7.4). The medium pH difference mimics the effects seen with glucose free 
media in earlier experiments. The low pH media facilitated greater loss of reductive potential. 
Additionally the altered pH method has the ability for refinement unlike the glucose deprivation.
3.7.1.1 Morphology of low pH treated cells
The cell morphology caused by a varied pH conditions was examined in figure 3.10. The initial cell 
morphology experiment used a broad range pH 4-7 to establish an acidity level in which cells can 
survive. Any cells in pH below 4 were killed instantly, at pH5 the majority of cells survived, but 
some level of cell death. This was the lower limit of pH for the second experiment shown in figure 
3.10, were a refined pH range from 5-7 was up to 10h. 
 
At pH 5, at 2h and 6h, there was no cell death. By 10h incubation, cells were lost with poor 
adhesion to the plate, and axon formation was decreased. At 10h incubation there was significant 
cell death, thereby it was concluded the pH was too extreme for the cells to survive during the MTT 
assay. However at pH 5.5, the images after 2h up to 10h were very similar, although by 10h there 
was less axon formation. There were small morphological changes in the pH 5.5. This pH was 
clearly at the limit, but might have the highest chance for rescue with sAPPα. 
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Figure 3.9: MTT assay with varied pH 
Absorbance measurements (562nm) of SH-SY5Y cells at a cell density of 105cells/well, 8h low/ medium pH 
incubation, 300μg/ml of MTT and after solubilisation of formazen with DMSO. Normal pH n=6; Low pH n=6; 
medium pH n=6. Error bars are SD while significance is **p<0.01, ****p<0.0001 using ANOVA statistical 
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Fig. 3.10 Cells in various pH adjusted media
Cells were plated at a cell density of 5x105 cells/ml in dishes with media at pH from 7-5 and photos 
taken at time points 3,4,6,8 and 10h. 
3.7.1.2 sAPPα treated cells with low pH 
Figure 3.11 shows an experiment with sAPPα and pH stress. It shows a significant difference 
between the standard media pH of 7.2 and a low pH of 5.5. The significant difference between the 
low pH with and without the addition of sAPPα, shows evidence for neuroprotection of sAPPα. 
However the results must be consistently replicated, to allow sAPPα to be used as a 
neuroprotective control to compare other proteins to. Unfortunately like with the glucose 
deprivation method, consistency was a problem, with technical replicates not showing 
neuroprotection.
3.7.2 MTT assay with varied CuSO4 concentrations
Figure 3.12 shows the results showing the viability of cells exposed to various 
concentration of  CuSO4 (O’Brien et al., 2000). CuSO4 was trialled as an alternative stress 
to glucose deprivations, as elaborated in the discussion (4.2.3). There is a significant 
difference between the normal media (DMEM) and that to which CuSO4 has been added 
at all concentrations tested. There was a inverse linear regression of cell viability to the 
increase in CuSO4 concentration. The largest significant change between the positive 
control and a given specific CuSO4 concentration is desired, but without compromising the 
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Figure 3.11: sAPPα MTT assay with low pH
Absorbance measurements (562nm) of SH-SY5Y cells at a cell density of 105cells/well, 8h low 
pH incubation, 300μg/ml of MTT. Formazen was solubilised with DMSO. Normal pH n=6; Low 
pH n=6; low pH + 1nm sAPPα n=6. Error bars are SD while significance is *p<0.05, ***p<0.001 
















ability for the cells to be able to recover. Therefore the 8μM concentration of CuSO4  while 
having the greatest effect and most significant may not be the best condition as rescue 
may not be possible at such a high level of cell viability reduction (~80%). The cell 
morphology is shown in figure 3.13, on the premise is that a cell population that undergoes 
extensive morphological change would be unlikely to recover, even if treated with an 
effective protective agent. The MTT assay range was from 1μm to 8μm, it showed an 
inverse relationship between CuSO4 concentration and cell viability. Based on the literature 
by O’Brien, this concentration might be problematic. Since the CuSO4 [1μM] showed a 
significant decrease in viability at the lowest concentration used compared to the positive 
control, then this concentration was used to examine the morphology of the cells.  
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Figure 3.12 MTT assay with varied CuSO4 concentrations  
Absorbance measurements (562nm) of SH-SY5Y cells at a cell density of 105cells/well, 8h incubation, 
300μg/ml of MTT and solubilisation of formazen products with DMSO. Normal media n=6; 1-8μM n=6. 














3.7.2.1 Morphology of cells exposed to 1μM  CuSO4 concentration 
Viability was shown to decrease as expected with an increase time of exposure to CuSO4 
but would this able to be rescued? Figure 3.13 shows the cell morphology of 
neuroblastoma cells two concentrations of CuSO4. At 0h the cells have developed axons 
and straight and not rounded bodies, as typical for neuroblastoma cells. At time points 4h 
and 10h in both concentrations, there did not appear to be any morphological changes, 
despite significant levels of decreased viability. This was less disruptive than seen in the 
pH morphology experiment, which showed varied axon lengths and rounded bodies. This 
experiment shows a morphological neutral CuSO4 concentration, which is sufficient to 
decrease cell viability. This is the ideal conditions for the next experiments with sAPPα 
uses against CuSO4 stress.  
3.7.2.2 sAPPα treated cells with cells incubated with CuSO4
The CuSO4 treatment showed a significant decrease in viability of the cells, optimised to show a 
decrease in MTT absorbance, but without any observed morphology changes to the cells. Despite 
this, the addition of sAPPα (1nM) did not show any significant restoration of viability. In figure 3.14 
you can see a suggested increase in absorbance in both cell populations with sAPPα compared 
with when sAPPα was absent. These increases however, is not statistically significant. 









Fig 3.13 CuSO4 incubation at various concentrations
Cells were plated at a cell density of 5x105 per mL in dishes with DMEM (Gibco) media with 10% FBS. Cells were 
incubated at varied concentrations ranging from 0.5μM-1μM over 10h; photos taken at time points 2,4,8 and 10h. 
Additional images can be found in appendix III. 
Although the effects of the CuSO4 treatment for the cells was the most reliable method, in terms of 
replicability. It still was not reversible, even with the use of TAPI-1 an endogenous inhibitor of the 
synthesis of sAPPα in the cells. An alternative to MTT may more easily provide evidence of 
neuroprotective property of sAPPα.  
3.7.3 Alamar blue alternative cell viability assay 
Alamar blue (resazurin) is an alternative cell viability assay in which characteristics of the key 
compound in analogous to that of MTT (O’Brien et al., 2000). Both compose of a reducible 
compound and their reduced form able to be measured as a proxy of cell viability. MTT is a 
colorimetric assay that uses a salt that becomes insoluble (2.2.6). While alamar blue is a dye that 
fluoresces when reduced by NADH dehydrogenase (2.2.7). The method follows closely to that of 
the MTT assay. The cells are treated with either glucose containing media or glucose deprived 
media for the standards and left to incubate at 37℃ for 8h, resazurin dye is then added for 2h. 
Differences in RFU (Relative Fluorescence units) between the two conditions gives the measurable 
 68
Figure 3.14 CuSO4 MTT assay with sAPPα
Absorbance measurements (562nm) of SH-SY5Y cells at a cell density of 105cells/well, 8h incubation, 300μg/
ml of MTT and solubilisation of formazen products with DMSO. Normal media n=6; 1μM and 4μM n=6; 1μM 
and 4μM with 1nM sAPPα n=6. Error bars are SD while significance is from using ANOVA statistical test.
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difference in the assay. Suspected neuroprotective proteins would be incubated with glucose 
deprived cells. RFU above the lower glucose deprived reading will be said to reflect 
neuroprotection as long as the results are significant.
First proof of concept type experiment for alamar blue (figure 3.15), showed a significant difference 
between glucose treated cells and glucose deprived cells. The cell viability assay, while different 
rom the MTT assay, has similar fundamental principles, therefore the optimisation experiments for 
the MTT method are applicable to the alamar blue assay. For example cell density and the glucose 
deprivation time, are likely to reflect the cell conditions in a 96 well plate rather than the nature of 
the reducible agent used to calculate the drop in the cell population viability. 
3.7.3.1 Alamar blue with sAPPα
Previous experiments showed a significant difference could be obtained between the 
glucose positive and negative conditions. However, with the addition of sAPPα, no 
changed was observed (Figure 3.16). A significant difference is seen between glucose and 
glucose deprived cells. At this stage, it appears that there is nothing fundamentally wrong 
with the experimental system, but that effects of sAPPα in this system are different from 
expected and may be a reflection of the cells, this point is elaborated in my discussion 
(4.2.2)  
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Figure 3.15 Alamar blue cell viability assay
Emission 590nm and excitation at 530nm, 8h incubation with glucose deprivation, then 4h incubation with 
10% (w/v) Alamar blue added to each well (20μl). Glucose n=10; No-Glucose n=10. Error bars are SD 




Figure 3.16 Alamar blue with sAPPα
Emission 590nm and excitation at 530nm, 8h incubation with glucose deprivation, then 4h incubation with 
10% (w/v) Alamar blue added to each well (20μl). Glucose n=10; No-Glucose n=10; No Glucose +1nM 
sAPPα n=10. Error bars are SD while significance is ***p<0.001, ****p<0.0001 using ANOVA statistical test.
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3.8 SILAC protein synthesis 
SILAC (Stable Isotope Labelled Amino acids in Cell culture) can be used to examine differential 
protein expression by using amino acids with heavy isotopes of carbon and nitrogen as markers. 
Lysine and arginine are labelled and incorporated into de novo protein synthesis, they have C13 in 
their structure for ‘medium’ media and 13C and 15N for ‘heavy’ media (figure 3.17). The heavier 
isotopes in the amino acid structure increases its molecular weight, but does not alter its 
biochemical interactions. This allows us to isolate proteins synthesised under different conditions 
grown in light, medium and heavy media due to the different isotopes, without causing stress to the 
cells. 
Light weight media was used as the control in which the amino acids had the normal dominant 
isotopes with 12C and 14N. The cells in ‘light’ media acted as a study state base level of proteins for 
comparison with newly synthesised proteins according to the specific conditions of the experiment. 
The ‘heavy’ media had sAPPα added and the proteins synthesised were compared to the ‘medium’ 
media that had only sAPPα buffer so that de novo protein synthesis caused sAPPα could be 
determined.
In the first experiment the cell proteins extracts were made and the protein concentrations were 
between 3-4mg/ml for both the ‘medium’ and ‘heavy’ media cells (measured using BSA method 
2.3.3). This was deemed not sufficient for mass spectrometry analysis of the proteins. This was 
most likely due to the cells not adjusting to the specific new media (normally requiring 5 - 7 days). 
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Figure 3.17 SILAC Amino Acids
Chemical structure of L-lysine and L-Arginine amino acids. 
Red asterisk indicate incorporation of C13 isotopes and N15. 
(ThermoFisher Scientific-metabolic labelling strategies) 
In the next set of experiments the cells were adjusted to the ‘light’ media for two weeks before they 
were switched to the ‘medium’ or ‘heavy’ media (2.2.10).
3.8.1 Protein gel of 12 hour sAPPα incubation
Figure 3.18 shows the protein lysate on a SDS-PAGE (2.3.1) of the SILAC protein lysate for the 
12h incubation with sAPPα. The concentration of protein from the ‘medium’ and ‘heavy’ isotope 
treated cells was high enough to fractionate 100mg on a gel with the ration of ‘medium’ to ‘heavy’ 
isolates in a ratio of 50/50. As often happens with high concentration of protein, there was some 
streaking.
3.8.2 Protein gel of 6 hour incubation
Second set of experiments used a 6h incubation time instead of a 12h incubation, as to compare 
the newly synthesised proteins specifically influenced by sAPPα at two time points, i.e. to 
determine if there is a different set of genes expressed at 12 h than the genes expressed at 6h. In 
this second SILAC experiment the expression patterns with of sAPPα, and two ‘active’ peptides 
from within it sequence are investigated. These are the 16mer from the C-terminus (1.19;4.2.1) 
and the tripeptide RER from a N terminal domain (4.2.1). In comparing the expression pattern of 
these subsections of sAPPα we could identify or allude to why these variants have been shown to 
show a similar level of neuroprotection as sAPPα.
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Figure 3.18  PAGE of 12h SILAC protein lysates 
Lane 1: PBS Buffer Control (Medium) and sAPPα (Heavy) 
protein lysate mixture; Lane 2: ‘Light’ protein lysate; Lane 3: 
Broad range protein marker (Bio-Rad). Gel’s stained with 
Colloidal Coomassie Brilliant blue.    
1 2 3
The second set of SILAC experiments, the neuroblastoma cells were incubated with either sAPPα, 
or RER or 16mer for 6 hours in the ‘heavy’ media, and the control cells incubated with PBS in 
‘medium’ media. The first protein gels of the SILAC lysates showed streaking, therefore an 
additional 4℃ spin for 1 h, was carried out. This decreased the streaking, bit it was still evident. 
Figure 3.19, show the broad bands where the samples were loaded; dark bands that ran vertically 
through the entire gel may be caused by precipitation, despite the pre centrifugation step. The gels 
showed multiple protein bands running the entire length of the gel, with clear migration from the 
wells. In each of the images, I included a broad range protein marker lane, to allow for 
comparisons between gels and to show that all samples ran consistently. Nevertheless the proteins 
extracts from the 16mer experiment showed a different pattern, which may be caused to gel 
running slower. In the 16mer experiment, you can see the bottom two bands of the ladder, which 
are absent in the other two images, showing that the proteins are less spread out than the other 
two gels. The images of the three samples can not readily be compared, but the markers for each 
match up perfectly, showing that all the gels ran the same distance. The mass spectrometry results 
should be able to be compared between the different sample conditions.  
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A. B. C.
Figure 3.19  PAGE of 6h SILAC protein lysates 
Image A. Broad lane on left: PBS Buffer Control (Medium) and sAPPα (Heavy) protein lysate mixture; Thin lane on the 
right: Broad range protein marker (Bio-Rad). Image B. Broad lane of left: Control (Medium) and RER (Heavy) protein 
lysate mixture; Thin lane of right: Broad lane protein marker; Image C. Broad lane on left: Control (Medium) and 16mer 
(Heavy) protein lysate mixture. Protein lysates were first centrifuged at 4℃ for 1h, gel’s stained with Colloidal 
Coomassie Brilliant blue.    
3.9 SILAC protein expression
There were a high number of proteins that were down regulated and up regulated after a 12h 
incubation with 1nM sAPPα compared with the PBS buffer. Although some of these proteins do not 
have known interactions with other proteins that with altered expression level they may still be part 
if an important mechanism involved with sAPPα, they are less obvious than the proteins that show 
known interactions with each other. In figures 3.20-3.23 non-interaction proteins are illustrated by 
single node that have been shown to have altered expression levels, but no known interactions 
with other proteins.. Proteins that have known/predicted interactions with other proteins with 
altered expression levels, are shown by that are colour coded link between nodes. 
3.9.1 Up regulated proteins from 12h sAPPα incubation
3.9.1.1 RNA processing proteins
Protein interaction pathways that are significantly up regulated are shown by nodes with multiple 
connections in figure 3.20. FTSJ3 has multiple interactions with other up regulated protein. FTSJ3 
is predicted to be a methyltransferase involved in ribosomal RNA processing and in 40S ribosomal 
subunit formation. FTSJ3 has known interactions (determined experimentally) with both EIF2AK2 
and NOB1, as well as a predicted interaction with TRMT10C. EIF2AK2 (eukaryotic translation 
initiation factor 2-alpha kinase 2) is a interferon induced dsRNA-dependent kinase, which is 
involved in the regulation of signal transduction, apoptosis and cell proliferation. NOB1 function is 
not well understood, it is suggested to play a role in mRNA degradation. TRMT10C (tRNA 
methyltransferase 10 homolog C) functions as in mitochondria tRNA maturation factor. None of 
these functions are apparently specific to sAPPα alone, but they do link to a key metabolic 
pathway. These proteins are up regulated together through known predicted interactions we can 
start to deduce a picture of the metabloic changes mediated by sAPPα. These proteins are 
involved in RNA processing functions. From this web of interactions, sAPPα appears to cause an 
increase in RNA processing.
Another set of proteins up regulated was CDK11B and RBM25, which have been experimentally 
shown to interact. CDK11B is a cyclin dependent kinase and RBM25 is a RNA binding protein, 
although the exact function is unknown. An increase level of CDK11B could suggest alterations in 
the cell cycle, which may link to increase cell growth and proliferation. It is worth noting that 
CDK11B (GeneCards®) has been shown to be altered or deleted in neuroblastoma cells. 
Nevertheless the increase in CDK11B should not be an artefact since it is not present in the 
‘medium’ PBS buffer protein extracts as well.
 74
3.9.1.2 mRNA Export
DDX19A was up regulated, fully known as DEAD box polypeptide 19A, it is an ATP-dependent 
helicase. It functions to remove nuclear mRNA binding proteins and allow cytoplasmic mRNA 
binding proteins. In linking with other up regulated proteins, this protein increases the availability of 
mRNA allowed for translation. DDX19A also links to the first interaction web, that was centred 
around RNA processing. AN increase in helices function could facilitate and increase in RNA 
processing. There was no reported link between this protein and the RNA processing pathway, 
however this doesn’t mean DDX19A isn’t functionally beneficial. The function of DDX19A is non-
specifically, it allows an increase in mRNA export from the nucleus regardless of the mRNA 
function. 
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Figure 3.20 Up regulated proteins after 12h incubation with (1nM) sAPPα. With interactions map and key 
3.9.1.3 mRNA translation and stability
PUM1 (pumilio homolog 1) Is a RNA binding protein that regulates translation and mRNA stability. 
The function of this protein is general and could be applied to many pathways. PUM1 fits well with 
the proteins I have mentioned so far that have functions in RNA processing and translation. The 
protein discussed so far suggest an overall increase in protein synthesis caused by the addition of 
sAPPα. It indicates that sAPPα may be up regulating translation as a general response to the 
stress that the cell is under for its neuroprotective role.  
3.9.1.4 Changes in glycolysis
C12ORF5 (chromosome 12 open reading frame 5) inhibits glycolysis by reducing fructose-2,6- 
bisphosphate levels, and has been suggested to protect cells against reactive oxygen species and 
apoptosis induced by TP53. This protein was up regulated in the 12h incubation with sAPPα. This 
could be associated with a more direct mechanism of the neuroprotective measures of sAPPα. 
C12ORF5 is suggested to protect cells against apoptosis, thereby a neuroprotective mechanism of 
sAPPα cold be through the increase expression of C12ORF5
AKR7A2 is another protein that is could be associated with a more direct action of sAPPα. 
AKR7A2 (aflatoxin aldehyde reductase) catalyses the reduction of succinic semialdehyde to 
gamma-hydrozybutyrate via a NADPH-dependent reaction. Importantly gamma-hydrozybutyrate 
(GHB) is a neurotransmitter that binds to GHB receptors in the brain(Gamma-hydroxybutyric acid, 
Wikipedia). An increase AKR7A2 protein, will likely cause in increase in GHB. Therefore it sAPPα 
expression is linked to an increase in GHB levels this may correlate with the neuroprotetive 
properties of sAPPα. GHB has been shown to be neuroprotective against hypoxia in brain cells 
(Ottani et al., 2003), thereby could be a mechanism in which sAPPα acts. Nevertheless, the 
precise function of GHB in the body is still be elucidate and the ability for GHB to protect against 
hypoxia may not translate to other types of neuroprotection, such as the neuroprotection from 
sAPPα.
NDUFS2 (NADH dehydrogenase (ubiquinone) Fe-S protein 2) is a protein associated with 
mitochondrial function. NDUFS2 is a part of a core subunit in the electron transport chain. It is 
located in complex 1 and allows for NADH to offload electrons to coenzymeQ to generate the 
proton motive force to generate ATP. Mitochondria dysfunction has been linked to Alzheimer’s 
disease and an increased level of NDUFS2 would suggest increased mitochondria function, is part 
of the of larger picture of sAPPα related neuroprotection against mitochondrial stress.
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3.9.1.5 DNA repair
TTI2 (TELO2 interacting protein 2) is a very important protein in DNA damage response (DDR). 
This protein is part of the TTT complex that is vital for cellular protection from DNA damaging 
stresses. Despite this protein not linked to other proteins shown to be unregulated, it is a good 
candidate for a mechanism of sAPPα neuroprotective capabilities. One of the ways sAPPα could 
alter cellular expression to illicit neuroprotection is through an increased level of DNA protection. 
DNA damage is very destructive to a cell and increased damage caused by toxic amyloid beta 
aggregates or insoluble amyloid plaques could increase sAPPα production, in turn increasing TTI2 
production in response to this DNA damge.
3.9.1.6 Other notable proteins
IFIT5 (interferon-induced protein with tetratricopeptide repeats 5) is an interferon induced RNA 
binding protein. Interferons are signalling proteins that typically deal with pathogens from viral 
infections to tumour cells. This specific protein functions to bind to RNA bearing a 5’-triphosphate 
group, which is a characteristic of viral RNA. Unfortunately it may be that this protein is not linked 
directly to sAPPα, as acting to increase expression level of a protein that deals with viral infection 
as defence against endogenous stress seems counterintuitive.  Nevertheless, IFIT5 is interferon 
induced, which could mean that sAPPα may increase interferon expression allowing for other 
responses, discussed later (4.3.1). 
3.9.1.7 Conclusions
Overall there were a few proteins that showed significant increase levels after a 12h incubation 
with sAPPα. There were some proteins that had a more logical link with sAPPα such as TTI2 and 
AKR7A2. Other proteins did not have an apparent link with any other up regulated proteins, 
therefore have not been discussed above (full list in appendix Ⅲ). The majority of the proteins 
however, did have functions that could be linked, with some of the main up regulated activities 
linked to increased RNA processing, mitochondria function and cell growth/proliferation (4.3.2).
3.9.2 Down regulated proteins from 12h sAPPα incubation
The down regulated proteins in figure 3.21 show proteins that are significantly lower than the 
proteins in the ‘medium’ cell protein extracts. A full list of the proteins is in the appendix Ⅲ, with the 
proteins that are more significant or relative discussed in further detail below. In the down regulated 
proteins there were three interaction pathways. Of the down regulated proteins, there were three 
interaction pathways, each with three or four interacting nodes. 
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3.9.2.1 Pre-mRNA processing
The pathway with four nodes connected starts with LUC7L, a protein of unknown primary function 
is unknown, but that is suggested to bind to RNA via Arg/Ser-rich domains. The second node is 
TCERG1, which is experimentally shown to interact and is co-expressed with LUC7L. TCERG1 
(transcription elongation regulator 1) is a transcription factor that binds RNA polymerase Ⅱ and 
inhibits elongation of transcripts from targeted promotors. The next protein, CPSF6 (cleavage and 
polyadenylation specific factor 6) functions as the cleavage subunit of the ‘Im’ complex, which 
plays a key role in pre-mRNA processing and the polyadenylation of the 3’ end of the mRNA. 
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Figure 3.21 Down regulated proteins after 12h incubation with (1nM) sAPPα. With interactions map and key below. 
Linked to CPSF6 is FIP1L1, which is a pre-mRNA 3’ end processing factor.  The pathway has a 
clear function focusing on pre-mRNA processing. Unfortunately some of the proteins in this 
interaction map have functions that are unknown. Decreasing this interaction pathway may lead to 
an up regulation of transcription. 
3.9.2.2 Nicastrin
The second interaction pathway shown to be significantly down regulated starts with NCSTN 
(nicastrin). Nicastrin functions as a stabilizing subunit of the 𝛄-Secretase complex, which 
processes  APP as mentioned in the introduction(1.13). 𝛄-Secretase is typically the second 
secretase in both the amyloidogenic and non-amyloidogenic pathway. A decrease in this protein 
will likely result in a decrease in 𝛄-secretase. Inevitably this would lead to a decreased level in both 
Aβ, but not sAPPα. This is an exciting protein to see a change in synthesis level as it has a direct 
relation with the toxic product of APP processing balance by sAPPα. The other proteins in this 
interaction map; UTP14A and LSG1 have functions that are not similar to that of nicastrin. UTP14A 
(U3 small nucleolar ribonucleoprotein, homolog A) is experimentally linked to nicastrin, and 
suggested to function in ribosome biogenesis. LSG1 (large subunit GTPase 1 homolog), co-
expressed with UTP14A is  predicted to mediated the export of 60S ribosomal subunit. Thereby the 
rest of this interaction pathway suggest a down regulation of ribosome synthesis. Quite dissimilar 
to the function of nicastrin, nevertheless their down regulation suggest a stressed cell is restricting 
translation and the energy committed to that due to a decrease in ribosome synthesis. 
3.9.2.3 Mitochondria function
The ‘mitochondria function’ interaction pathway was down regulated in the 12h sAPPα incubation 
and starts with SMC4 (structural maintenance of chromosomes 4). This protein is in a core subunit 
of the condensen complex, which is vital for the conversion of interphase chromatin into 
condensed chromosome in preparation for proliferation. SMC4 is experimentally determined to 
interact with PMPCB (peptidase (mitochondrial processing) beta) that cleaves the mitochondria 
presequence. Although this protein has been shown experimentally to be linked its role is not clear. 
The protein connected to the next node in the interaction pathway are more similar. PMPCB is 
linked to SDHB (succinate dehydrogenase complex, subunit B) through co-expression. This 
enzyme is involved in the succinate dehydrogenase of complex Ⅱ in the electron transport chain, it 
is responsible for offloading electrons from FADH2 to coenzymeQ. This raise two interesting points; 
(i). Previously we have seen that NDUFS2 was up regulated, a proteins that functions to increase 
NADH reduction in mitochondria’s complex Ⅰ. While SDHB is down regulated, a protein that 
functions to increase FADH2 reduction in mitochondria’s complex Ⅱ. Both systems reduce not 
dissimilarly, electron carries (NADH and FADH2) to release electrons through the same pathway. 
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(ii). Is there something inherently different about NADH and FADH2 that results in their function 
being regulated differently? The proteins in this pathway are difficult to group, an overall function 
suggest mitochondrial function(4.3.4).
MBD3 (methyl-CpG binding domain protein 3) acts as a transcription repressor by recruiting 
histone deacetylases and DNA methyltransferases. This protein plays a role in gene silencing, 
which is required in many circumstances. One of the proteins with a similar function was SMC4 
that was involved in chromosome condensation, which alters DNA to form heterochromatin, a 
similar premise to that of gene silencing. However no other proteins were shown to have functions 
around gene or chromatin silencing.
3.9.2.4 Other notable proteins
PPM1B (protein phosphatase, Mg2+/Mn2+ dependent, 1B) functions as to dephosphorylate cyclin 
dependent kinase 2 and 6. Cyclin-CDK complexes are required to allow transition through the cell 
cycle. Dephosphorylation of CDK2/6 would inhibit cell cycle progression through the cell cycle, 
down regulation of CDK phosphatase’s would allow increased level of cell cycle progression. There 
were no specific interaction pathways shown in the study in regards to proliferation, but there have 
been a number of proteins, like this one that have functions that are linked to proliferation (4.3.2).  
ACOX1 (acyl-CoA oxidase 1) is the first enzyme in beta-oxidation processing. Down regulation of 
this protein would result in lower levels of fatty acid break down that may be associated with lower 
level of mitochondria function. Neuroblastoma (and brain cells) should use predominantly glucose 
as an energy source so this protein should not be expressing in high levels. Nevertheless fatty 
acids oxidation as a fuel source in the brain, is thought to be exclusive to astrocytes and not 
neurons (Panov et al., 2014). Additionally the ‘mitochondria function’ interaction pathway including 
PMPCB and SDHB, linked to mitochondrial processing and activity respectively, was also shown to 
be down regulated. These proteins in this third interaction pathway are localised to the 
mitochondria matrix or inter membrane and are involved in energy producing pathways. This 
suggest a decrease in the cells ability to produce energy through mitochondria function, mediated 
by the addition of sAPPα. This is puzzling. 
CNNM3 (cyclin M3), is a suggested metal transporter. Metal ions have been thought to be a 
possible cause of Alzheimers disease with metal chelator investigated as a possible treatment 
(1.18.2). Paradoxically, a metal transporter might be increased if metal ions were shown to be a 
significant cause of the disease. On the other hand metal ions like Zn may also protect against the 
toxicity of amyloid beta aggregates. 
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TSNAX (translin-associated factor X) activates the RNA-induced silencing complex (RISC). 
Previous proteins have suggested roles in gene silencing (or viral infections). It is unknown how 
this contributes to the mechanism of sAPPα, but a decrease in this protein would suggest an 
increase mRNA transcription and less regulation at the translation level; a common theme in the 
proteins identified.  RFC1 (replication factor C1) binds to the primer-template junction to allow 
elongation and likely plays a role in DNA transcript regulation and repair. This protein could also 
link to the idea of an overall increase in transcription and translation. 
PGM3 (phosphoglucomutase 3) mediates both glycogen formation and conversion of glucose-1-
phosphate (G1P) to glucose-6-phosphate (G6P). Conversion of G1P to G6P allows glucose to go 
through glycolysis and then the citric acid cycle. Down relegation of this protein would decrease the 
availability of glucose and consequently a decrease level of ATP production. There are multiple 
proteins shown to be down regulated that are active in energy production. Whether this is the 
actions of sAPPα or some other mechanisms is unknown.   
3.9.2.5 Conclusions
Overall most of the proteins that were shown to have altered synthesis levels could be linked to a 
cellular pathway that is beneficial for the cell. Notwithstanding there were a few proteins that had a 
function that was unknown or did not match the conventional ideas surrounding sAPPα mechanism 
of action. ACOX1 was one of these proteins, although it had similarities with other down regulated 
proteins, it itself should not play a role in neuroblastoma cell survival. Another point that is worth 
making, is the down regulation of ATP generating proteins. This was not directly, but a few 
metabolism proteins were down regulated and the reason for this is puzzling.    
 3.10 sAPPα 6h incubation
The second SILAC experiment used a time frame of 6 hours to measure specific protein 
expression reflecting sAPPα, 16mer and RER.  A shorter time frame meant that the heavy and 
medium isotopes are more difficult to detect over the background of the more dominant light amino 
acids. Yet was hoped to reflect significant changes nearer to the time sAPPα was added.
Shorter times (6h) are desirable for detecting protein changes with added reagent, but the SILAC 
methodology needs sufficient time for heavy isotope amino acids to be incorporated for accurate 
detection of protein changes. 
In the 6 hour time frame, the addition of sAPPα showed one large network of interacting proteins. 
There were other additional proteins that did show some interactions, however due to the large 
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number of proteins shown to be up regulated and the smaller changes between light and medium/
heavy labelled isotopes, I will only focus on the large interaction network (figure 3.22).
3.10.1 Up regulated proteins in the 6h incubation with sAPPα
CACNA2D1 is the first protein in the network shown in figure 3.22, it is a voltage gated calcium 
channel. It is linked to transducin, that is important in phototransduction. These two proteins have 
been suggested to be up regulated, however their function not easily related to sAPPα. The next 
protein in this network is WDR12, which is required for the maturation of ribosomes. Followed by 
EIF3I, a component in the translation initiation complex. These two suggest a central function of 
translation. Additionally, EIF3I links to both RPS15 and RPL37A, both of which are ribosomal 
proteins. This shows that this interaction pathway’s main function is mRNA translation. The next 
two proteins in the chain are U2AF2 and NUP155, both function in exporting mRNA from the 
nucleus. U2AF2 is necessary for splicing of mRNA and is required for the exportation of mRNA out 
of the nucleus. While NUP155 is a nucleoporin and is part of the nuclear pore complex, it regulates 
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Figure 3.22 Up regulated proteins after 6h incubation with (1nM) sAPPα. With interactions map and key below. 
the transport of molecules from within the nucleus to the cytoplasm and vice versa. Reflecting on 
this interacting pathway as a whole, the function appears to facilitate and increase level of mRNA 
processing and exportation followed by translation.
3.10.1.1 Translation 
Another pair of proteins that are linked are UBE2N and POLD1, their function are also associated 
with transcription. UBE2N functions in the process of polyubiquitination, however unlike the 
majority of ubiquitination pathways, this does not lead to protein degradation. Rather it mediates 
transcription of targeted genes. UBE2N has been suggested to play a role in cell cycle progression 
as well as DNA-repair. POLD1 is required for leading strand synthesis, required for transcription. 
Thereby, these two proteins both facilitate and increase in transcription. 
3.10.1.2 Conclusions
The selection of proteins up regulated, propose an increase in cell growth/proliferation. PUM1 is an 
RNA binding protein, with a predicted role to support proliferation. DIAPH1, binds to actin and 
allows for cytokinesis to occur. TMPO helps to in the assembly of the nuclear envelop after 
cytokinesis and ANXA11 is required for terminal progression of cytokinesis. All are evidence for an 
increase in proliferation. There was connected interaction pathway that showed an increase in cell 
growth and proliferation, yet there was a selection of proteins identified that weren’t linked together, 
but were active in this process. Showing the addition of sAPPα could illicit this type of response, 
suggesting the cells were going through a growth stage due to the addition of sAPPα.
3.10.2 Down regulated proteins in sAPPα 6h incubation 
The down regulated proteins in the 6 h sAPPα experiment showed two major interaction pathways 
and numerous smaller ones. Each of the SILAC lysates are processed through mass spectrometry 
twice as a replicate. Despite this, there was still a large level of proteins identified to be down 
regulated, none of the lone protein were discussed below.  
3.10.2.1 Processing of RNA
PNPT1 is one protein that is shown to be down regulated, it is central in one of the interacting 
pathways seen in figure 3.23. It is required for the correct processing and polyadenylation of 
mitochondria mRNA. Linked to this protein is TRNT1 and DDX50. TRNT1 allows for the 
attachment of amino acids to tRNA, while DDX50 is an RNA helices involved in formation of 
secondary RNA structures such as tRNA. These functions both contribute to the formation of tRNA. 
SNRPA is the next protein in the chain, it is proposed to facilitates pre-mRNA’s splicing and 
polyadenylation. SNRPA interacts with both PABPN1 and ELAVL1, which function to polyadenylate 
and stabilise mRNA respectively. There are more proteins shown to be interacting in this pathway, 
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however the function of the pathway is clearly RNA processing. This process isn’t clear with 
respect to sAPPα activity. All of these proteins were shown to have a significant change in protein 
levels, however the low quality data may have led to a broader set of results, resulting in lower 
statistical strength in the list of proteins found. The other possibility is that the results are correct 
and sAPPα caused a decrease in RNA processing at a 6 hour time point. 
3.10.2.2 Protein degradation
The next interaction pathway has proteasome proteins in the centre, with PSMD14 and PSMB4 
shown. These two proteins are subunits that work together as a proteasome for targeted protein 
degradation. The next protein in the interaction pathway is GPS1, which has multiple functions, 
one that links to other protein as part of the CSN complex, that regulates ubiquitination of proteins. 
There are additional proteins in this pathway, but their functions are less well known or the 
interactions are not as significant. Overall the pathway is about protein degradation. The function is 
more applicable to sAPPα since for the up regulated protein, there was an increase in mRNA 
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Figure 3.23 Down regulated proteins after 6h incubation with (1nM) sAPPα. With interactions map and key below. 
processing in terms of transcription and translation ability of the cell. Thereby it would stand to 
reason that protein degradation may also be decreased.
3.10.2.3 Conclusions
A number of other proteins were shown to be down regulated, with 46 proteins in total shown to 
have a decreased expression level. The majority of these proteins did not link to any other proteins 
in terms of interactions and not discussed. There were no proteins that were known to have a 
specific role in APP metabolism, with most of the protein functions having a not easily explained 
interaction with neuroprotection role or any neurone specific role. The high ratio of light isotopes to 
medium and heavy can result in broader results. This principle is shown in comparisons between 
sAPPα 6 hour incubation with the sAPPα 12 incubation. There were less result in the 12 hour 
incubation, but the result were more specific. For future experiments there is a need to increase 
ratio of medium and heavy isotopes over light isotope incorporated proteins in order to more 
accurately gauge the change in protein expressions.
3.11 16mer and RER protein expression
The same issue was seen in the sAPPα 6 hour incubation was also seen in the 16mer and RER 
results. There was a higher level of light isotopes and the level of medium and heavy isotopes 
were too low. The specificity of 16mer and RER was worse than for the sAPPα 6 hour incubation. 
The 16mer and RER did however, show some changes in protein expression, but only down 
regulated proteins were specifically discussed. In spite of a replicate run through mass 
spectrometry, the majority or close to it, of the proteins detected had shown an increase level of 
expression. This suggests that the 16mer and RER had increased transcription and translation in 
the cells, thereby many of the proteins identified through mass spectrometry were shown to be up 
regulated. Although the large sum of increase protein expression may be an artefact of the low 
ration of medium/heavy isotopes to the light.  
There were only a few proteins that were shown to be significantly down regulated across multiple 
studies. PSMD14 was shown to be down regulated in the sAPPα and the RER experiments, which 
is involved in proteasome function. PTK7 was also shown to be down regulated in the 16mer and 
sAPPα, though its function is not known. One protein linking the expression pattern of 16mer/RER 
and sAPPα isn’t significant enough to state that the 16mer or the RER caused the same 
expression as the sAPPα. 
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3.12 Cloning experiments
There were three fragments based around the newly discovered APP processing pathway 
involving the eta (η) secretase that I was aiming to clone. I designed PCR primers that targeted the 
processing sites that produced the new η fragments from APP. These were amplified from an 
available APP695 clone, as explained in more depth in methods (2.4.1).
3.12.1 sAPPη PCR
The first lane in image B, figure 3.24 is a λ-marker lane cut by EcoR1 and HindⅢ, followed by a 
negative control of master mix and primers (lane 2). The third lane shows the PCR amplification of 
sAPPη, the band is of a size between marker bands 1,375 and 1,904bp. The theoretical fragment 
size is suppose to be 1,512bp, within the estimated size range of the fragments. This means that 
this amplification of this N Terminal fragments derived from APP was successful and can be used 
for the later experiments.
3.12.2 ηα and ηβ PCR 
Figure 2.25 on the following page illustrates the amplification of smaller fragments ηα and ηβ 
through PCR. Lane 1 shows the XIV marker, which is used for identifying fragments under 1000bp. 
Lane 2 is a negative control, which had a faint band, possibly due to contamination from adjacent 
lanes. Lane 3 is the PCR product of ηα, the expected size of the fragment is 324bp, comparable to 
the band just above the 300bp marker band. The last lane shows the ηβ PCR product, with an 
expected fragment size of 276 bp, the experimentally derived fragments falls just below the 300bp 











Fig. 3.24 sAPPη PCR
Image A shows λ-marker cut by EcoR1 and HindⅢ with accompanying band sizes (bp) on 
1% agarose gel. Image B shows in lane 1: λ-marker lane cut by EcoR1 and HindⅢ; Lane 2: 
negative control; Lane 3: sAPPη. On 1% agarose gel 
A. B.
    1             2              3 
size, suggesting both ηα and ηβ are the correct fragments and can be used for cloning into the 
pMal vector.     
Fig 2.26 shows all three PCR samples after purification; the three fragments in order are sAPPη, 
ηα and ηβ. The ηα and ηβ bands appear fainter due to differences in running these small 
fragments on lower percentage gel and poorer ethidium bromide staining at the lower part of this 
gel. Despite this, all of the fragments have been run clearly on the gel and at the correct sizes. The 







Fig. 3.25 ηα and ηβ PCR
Lane 1: XIV marker with band sizes annotated on the left (bp); Lane 2: 
Negative control; Lane 3: ηα PCR results; Lane 4: ηβ PCR results










Fig. 3.26 PCR Clean up of all fragments
Image A shows λ-marker cut by EcoR1 and HindⅢ with accompanying band 
sizes (bp) on 1% agarose gel. Image B, lane 1: λ-marker cut by EcoR1 and 
HindⅢ; Lane 2: shows sAPPη; Lane 3; ηα PCR fragment; Lane 4: ηβ PCR 
fragment. On 1% agarose gel. 
A. B.
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3.12.3 Plasmid restriction digest 
The restriction digests of the plasmids with the respective enzymes for both of the cloning 
constructs are shown in figure 3.27. Image A is the prokaryotic pMal vector digest; image B is the 
eukaryotic pcDNA3.1D vector digest. pMal vector is an easier vector to deal with for the cloning 
experiments. Lanes 3 and 4 showed a linear band, the same size as the double cut lanes 6-8 with 
each individual enzyme. This means that the each restriction enzyme is functioning efficiently and 
completely cutting the DNA. Therefore there can be a simple ligation of cut PCR product into 
purified cut plasmids. 
The second cloning experiments for the care sAPPα-type gene fragment uses a pcDNA3.1D. The 
vector used had an insert that needed to be removed. This is seen in image B (figure 3.27) with 
lanes 3 and 4 (single cut) having a larger band than the double cut band in lane 6 and 7. In lanes 6 
and 7 there are two bands, showing the separation of the insert and the vector. The top band is the 
vector, while the lower band shows the unwanted insert. To clone my fragment, the vector band 
without the insert needs to be purified. The purified vector and the sAPPη were ligated at a 1:3 and 
1:6 ratio of vector to insert. This ligation mixture was then transformed into cells and the colonies 
grown were tested via a colony screen (2.4.7). 
Unfortunately the gel extraction wasn’t efficient, each experiment using the gel extraction method 
resulted in no colonies. Any colonies that did grow were the original unwanted insert re-ligated 
back into the vector, therefore an alternative approach was taken. 
 88
Fig. 3.27 Vector gel extraction 
Image A shows pMal vector. Lane 1: λ-marker; Lane 2: Uncut pMal vector; Lane 3: pMal cut with BamH1; Lane 4: pMal cut with 
HindⅢ; Lane 5: Empty; Lane 6-7/8: pMal cut with BamH1 and HindⅢ. Image B shows pcDNA3.1D vector. Lane 1: λ-marker; Lane 
2: Uncut pcDNA3.1D; Lane 3: pcDNA3.1D cut with EcoR1; Lane 4: pcDNA3.1D cut with HindⅢ; Lane 5: empty; Lane 6-7: 
pcDNA3.1D cut with EcoR1 and HindⅢ. Image C shows λ-marker cut by EcoR1 and HindⅢ with annotated band sizes (bp), 
shown as a clarification of Lane 1 in images in A and B. All images are run on a 1% agarose gel.    
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3.12.4 Alkaline phosphatase treatment
With the gel extraction method not producing colonies and the background of the unwanted insert 
re-ligation back into the plasmid remaining high, it was difficult to attain a single colony with my 
insert with unpurified vector. To clone the sAPPη fragment I had to decrease the level of 
background of the unwanted insert. This was done through the use of CIP; a phosphatase that was 
incubated with the vector (and old insert) after the restriction digest. CIP removes the phosphates 
from the ends of both the vector and the old insert. A phosphate group is required for a successful 
ligation, removing this phosphate group from the vector and old insert prevents re-ligation. This 
significantly decreased the background of my sAPPη ligation experiment. Figure 3.28 illustrates a 
colony screen of colonies after the CIP treatment. The primers for the PCR amplification are 
primers T7 and BGH reverse (commercially available) that amplify over the MRS (multiple 
restriction site). The original insert is 2,694bp, was removed by this procedure. My insert is 
1,515bp, the bands shown in Figure 3.28 appear to be about this size. Both colonies were sent for 
sequencing to confirm the correct my insert had be cloned.  
3.12.5 αη and αβ cloning 
While the αη and αβ fragments were technically easier to clone, as the vector did not have an 
insert already in it. However there were still some difficulties involved in cloning the fragments into 
the pMal vector. Previous experiments used a forward primer from the vector and a reverse primer 
from the insert (ηα or ηβ). In this case, the different length and annealing temperature of the primer 
combination, proved incompatible together. The vector primers are relatively small and less 
specific with a low annealing temperature. While ηα and ηβ primers required large primers that are 
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Fig. 3.28 sAPPη colony screen
Lane 1: XIV marker with band sizes annotated on the left (bp); Lane 




more specific, thereby have much higher annealing temperature. For primers to work together 
ideally their Tm’s should be within 5℃ of each other. The primers thereby didn’t successfully work 
together. New primers were developed to identify successful colonies as shown in table below.   
The new primers amplified the insert section of the pMal vector, they are illustrated in methods 
figure 2.2. The pMal-2nd_F is an additional primer for sequencing purposes, but wasn’t used in the 
colony screen. pMal-Ins_F and pMal-Ins_R work in combination to amplify the insert area of the 
plasmid. A re-ligation of plasmid would give one size, while the ligation of the insert will give 
another larger size, thereby this can be used to identify a successful ligation. 
3.12.6 ηα and ηβ colony screen
The new primer work together to form a band regardless of a successful ligation. The different size 
fragments will show if the insert is incorporated or not. Theoretically any different size fragment 
should be the incorporate PCR product, in reality this isn’t quite the case. With the most common 
alternative sized band around 6000bp, showing that the vector had ligated to another vector. Often 
the pMal vector ligated back together and a band just under 500bp was formed. However in one 
colony there was a band between 700bp and 800bp, this band is likely to be ηβ insertion, as it the 
New Primer set for Pmal
Name: pMal-Ins_F pMal-Ins_R pMal-2nd_F
Sequence: CGACCTTCAAGGGTCAACCA TAAGTTGGGTAACGCCAGGG CCTGAAAGACGCGCAGACTA
Tm (℃): 57.3 57.1 57.1
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Fig. 3.29 ηβ colony screen 
Lane 1: XIV DNA marker with annotated band sizes (bp); Lane 
2-11: Colony screen PCR amplification of pMal_F and pMal_R. 
Images was run on a 2% agarose gel with ethidium bromide.    
correct band size should be 785bp. Unfortunately, no successful ηα clones were produced over the 
cloning experiments. The ηβ cloned was discovered after 100+ colonies screens, a similar number 
of ηα were also screened, but was not found. Unlike with the case of sAPPη, there was no obvious 
reason why this was the case and perhaps an ηα would be found in the next set of experiments, 
but due to time restraints this was not done.      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3.13 Sequencing
3.13.1 ηβ sequencing data
Figure 3.30 shows the sequence from a ηβ clone that was a promising candidate. Unfortunately, 
the sequence quality was poor despite sequencing the clone multiple times. This may have been 
due to the small size of the ηβ insert. Regardless, the top image (figure 3.30) shows the clone’s 
sequence, that is matched to sequence of ηβ. The bottom image is a sequence alignment from 
BLAST to the APP sequence containing the ηβ fragment. The sequencing data shows the 
successful insertion of the ηβ insert into the pMal vector.   
3.13.2 sAPPη sequencing data
The colonies from the alkaline phosphate treatment were sent away for sequencing, which is 
shown in figure 3.31. The primers used were T7 and BGH reverse. In the figure above is the 
sequence from the first colony only, as both colonies had near identical sequences. The top image 
in figure 3.31 is the sequence from the T7 primer, which shows a match to the sAPPη sequence 
starting at position 31. The T7 primer starts 20bp before the HindⅢ cut site, so a match at position 
31 is expected. The rest of the T7 primer sequence matches with sAPPη shown by the query 
alignment image (bottom left figure 3.31). The BGH reverse primer sequence of colony 1 matches 
sAPPη from position 66. The previous insert is an additional 1000bp longer, thereby if that insert 
had re-ligated as it has previously, then the match with sAPPη from the reverse primer would not 
have occurred until after 1000bp’s. The sequencing data proves that it was the sAPPη insert in my 
clones and not the previous insert.
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Figure 3.30 Sequence data from ηβ
Top image; Sequence data from pMal-Ins_F primer of successful colony from ηβ colony screen: Bottom Image; 
Query alignment of ηβ colony sequence to sAPPη sequence 
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Fig. 3.31 Sequence data from sAPPη 
Top image is sequencing data from the T7 primer of colony 1 from a sAPPη colony screen; 
For_sAPPeta_pcDNA3.1D primer sequence highlighted in light blue. Middle image is sequencing data 
from the BGH reverse primer of colony 1 form a sAPPη colony screen; beginning of matched sequence 
to sAPPη shown in light blue. Bottom left shows sequence match between T7 forward sequence and 





4.1 My beginning 
My master in biochemistry initially consisted of two main themes 1). Neuroprotection by sAPPα 
and variants, and 2). de novo protein synthesis resulting from sAPPα mediated signaling. During 
the project a ‘Nature’ paper described a new processing pathway for APP and later I initiated a 
study that will ultimately evaluate the physiological role of the products of this pathway.
4.2 Hypothesis: Neuroprotective abilities are mimicked by fragments of sAPP
4.2.2 My inconclusive results of sAPPα for its protective role of neurones
One of the pillars for the beginning of my thesis, was the principle that sAPPα has a 
neuroprotective role. Others previously in the laboratory had shown the addition of exogenous 
sAPPα, to an in vitro system under stress, could increase viability of the stressed cells (Mukadam 
2009, Morris 2011). I was able to show neuroprotection (Figure 3.8 and 3.11), but not consistently. 
While my experience is contradictory to the earlier research, recent studies by other students with 
sAPPα in the MTT assay have also shown mixed results (Prendergast 2016).This inconsistency 
meant my first hypothesis could not be tested with fragments of sAPPα that I hoped to show were 
peptidomimetics of the apparent molecule. The 16mer and RER fragments were used in other 
experiments, but were never able to be tested in a cell viability for efficacy compared with sAPPα. 
4.2.3 sAPPα neuroprotection in the literature
Originally the MTT method used a stress of glucose deprivation. This method consistently showed 
decrease viability of the glucose deprived cells. A rescue of viability in the glucose deprived cells 
with the addition of exogenous sAPPα would show neuroprotection. No reproducible rescue with 
sAPPα was observed regardless of modifications made to the MTT assay. This assay has always 
been sensitive to the physiological state of the cells. For example, cells have been more robust to 
the applied stress and thereby the stress has to be applied for a longer time than expected. 
Perhaps this is because cells are suffering stress even in the glucose containing media that results 
in endogenous synthesis of sAPPα. Under these circumstances further addition of exogenous 
sAPPα would likely have no extra effect. Moreover there is likely to be a time window of glucose 
deprivation where the results of the stress can be rescued by the addition of sAPPα.   
Studies of sAPPα by Levities 2003 looked at expression of sAPP activated by the addition of (-)-
epigallocatechin-3-gallate (EGCG). The main findings were 1). EGCG stimulated sAPPα 
expression via a Protein kinase C mediated pathway 2). EGCG showed neuroprotection/ 
neurorescue of toxicity induced by Aβ. This study used both MTT and ELISA; both showed rescue 
with the addition of EGCG. Additionally this study showed EGCG stimulated sAPPα, thereby 
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suggesting the increase sAPPα expression protected from Aβ-induced toxicity. Fundamentally 
there were substantial differences between this study and my own. Levities used Aβ-induced 
toxicity for a viability, while my study used glucose deprivation (for the most part). With Levities 
study, EGCG was shown to stimulate expression of sAPPα, which in turn was suggested to 
alleviate the toxic effect caused by Aβ. sAPPα wasn’t specifically used an the neurorescue protein, 
but its stimulation lead to protection against Aβ toxicity. My study focused on a variation of Levities 
study with glucose deprivation, yet this study did not show any protection against such a stress. It 
has been suggested that polyphenol’s (EGCG) have anti-aggregation activity (1.8.5).This would 
mean that a toxic effect caused by aggregation of Aβ could be rescued by EGCG and perhaps 
sAPPα, but glucose deprivation could not with the state of my neuroblastoma cells. 
Aβ and glucose deprivation could alter the cells metabolism in different ways. As seen in my 
protein synthesis experiments, sAPPα altered the de novo protein synthesis of multiple proteins. 
This change, may allow for rescue of one stress i.e. Aβ, but not another i.e. glucose starvation. To 
demonstrate this point, nicastrin was a down regulated protein after a 12h sAPPα incubation. 
Nicastrin acts as a stabilizing protein of 𝛄-secretase (1.14) and would decrease Aβ  production if 
down regulated.  Although this isn't evidence for rescue, it does correlate with Aβ induced toxicity 
protection.  
A paper by Taylor et al 2008 from our group showed how secreted amyloid precursor protein-α 
regulated hippocampal NMDA receptor function, long-term potentiation and spatial memory. The 
premise of this paper is that sAPPα is diminished in AD patients and thereby the symptoms of 
alzheimers may result from a lowered sAPPα expression. This paper focused on Long Term 
Potentiation (LTP) the best model for mammalian memory. The evidence of this study was clear, 
LTP was increased with the addition of exogenous sAPPα. If the decrease in LTP is a mediator of 
AD, thereby sAPPα administration in AD patients may diminish some its symptoms. In this sense 
sAPPα could be said to be neuroprotective. This definition of neuroprotection should not be 
evidence for my MTT experiments. To elaborate on this; Taylor’s definition of neuroprotection for 
sAPPα is the increase in LTP in the whole live animal and conversely a decreased LTP is 
associated with AD.
The stress used in the original MTT method was glucose deprivation, although an alternative 
method was based around a paper by Eagle, H (1973). That examined the optimal pH for the 
growth of malignant cells. The principle for my alternative method was that a variance form the 
optimal pH in the media, would hinder the cell growth enough to show a decrease in viability. This 
method may be a more refined approach than the glucose deprivation method, while a different 
stress may also be more applicable to sAPPα neuroprotection. Another alternative stress used was 
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CuSO4 based on another paper that used MTT with this stress model (O’Brien et al., 2000). This 
method is more applicable to AD pathology and can be refined to a similar degree as the pH 
method. The APP protein family is thought to function in Copper homeostasis (Barnham et al., 
2015). AD patients have been shown to have elevated levels of Cu2+ possibly due to the Aβ having 
binding sites for Cu2+ (Artwood et al., 2000). In this way the MTT assay using CuSO4 is more 
applicable to the AD pathology than the other MTT stress models. Despite careful research into 
these alternative MTT methods, neither altered pH nor the CuSO4 lead to any consistent rescue by 
sAPPα. Perhaps using  Aβ like the Levities study may have produced positive results for sAPPα.          
sAPPα neuroprotection has been linked to its ability to extend neuritis, increase LTP, plasticity in 
neurones, and improve memory in behavioural studies, which has been translated to a broad term 
of neuroprotective. In suggesting this, these functions are shown with a more direct assays and I 
expect this is where some of the issues that I experienced when testing sAPPα in the MTT assay. 
An additional point is the degree of variability within technical replicates, they were typically high 
due to the difficulty of recovering all of the formazen. Thereby without sufficient technical replicates 
false positives could occur.
4.2.4 Future direction of the MTT assay
Knowing what I know now, I would have tackled the cell viability assay in a different way. Thomas 
Edison once said “I have not failed. I’ve just found 10,000 ways that won’t work”. Which is how I 
would summaries my experience with the MTT viability assay with sAPPα. Future work, I would 
use Aβ rather than any approaches I used. Additionally I would change the format of the assay, 
using larger welled plates. The 96 well plates are attractive due to the high throughput system with 
an ability to have multiple technical repeats with limited cells. Some level of quality is sacrificed for 
an increase in quantity. I would use a 24 well plates or 12 well plates, it would decrease the 
number of technical replicates for each experiment, but would hopefully decrease the error bars 
between the the these replicates. Restoring the consistency of MTT in response to sAPPα.   
4.3 Hypothesis: sAPPα causes specific de novo protein synthesis to combat stress. 
Earlier experiments from our group investigated changes in gene expression caused by the 
additional of sAPPα at a range of different time frames (Ryan et al., 2013). It is known that a 
changes in gene expression does not necessarily correlate with a change in protein expression 
(Vogel and Marcotte 2012). Thereby a change in protein synthesis was measured using SILAC 
with the addition of sAPPα. This was to show that sAPPα change in gene expression also caused 
de novo protein synthesis. The first experiment preformed by Katie Peppercorn was after a 2h 
incubation, a mid-time when RNA expression had been examined successfully (Ryan et al 2015). 
However, it was found 2h of incubation in a heavy isotope media did not produce sufficient 
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incorporation of heavy isotopes (3.8) into newly synthesised proteins. Thereby in my SILAC 
experiment I initially used a 12h incubation time, to ensure a high enough incorporation of heavy/
medium isotopes to be able to be detected significantly over the light isotope background. 
The 12h incubation with sAPPα gave data indicate specific de novo protein synthesis of a change 
in protein synthesis (3.9). Proteins identified to be up and down regulated, proving the first part of 
the hypothesis, that sAPPα causes changes in de novo protein synthesis. The next part is how 
these proteins shown to have altered expression levels might be connected with stress. The 
following paragraphs look at some of the proteins that have altered levels and how they may be 
linked to the neuroprotective role of sAPPα.          
4.3.1 Possible mechanism for neuroprotection
According to the amyloid hypothesis, the main cause for Alzheimers disease is the accumulation of 
Aβ (1.8), creating soluble aggregates and then insoluble plaques that lead to neuronal death. 
Thereby effective clearance of Aβ would alleviate Alzheimer symptoms and would be 
neuroprotective. In the 12h incubation two proteins were shown to have an increased expression 
levels that were linked to interferons. Interferons are a large family of signaling proteins that are 
produced by the host and released to the extracellular environment in response to various types of 
pathogens and stresses. The two proteins were EIF2AK2 and IFIT5, both which are induced by 
interferons and interact with RNA, their individual functions are discussed in the results (3.9.1) 
Interferons have been shown to recruit macrophages ‘Brummer et al., 1985’ with many interferons 
receptors located on macrophages. Thereby an increase level of interferons could be a mechanism 
to increase macrophage activity. Phagocytic behavior in glial cells are effective at clearing Aβ 
deposits, so enhanced mechanisms allowing sAPPα to recruit macrophages as a neuroprotective 
defense- is plausible. Additionally in Alzheimer's disease phagocytosis can be defective in the 
clearance ability of the wild type macrophages, thought to be due to poor differentiation from 
monocytes, stated in ‘Ineffective phagocytosis of amyloid-β by macrophages of Alzheimer's 
disease (AD) patients’ by Fiala et al., (2005) Another paper illustrates that sAPPα is able to induce 
significantly high levels of NF-kB after 90 minutes in microglia cells (neuronal monocyte lineage) 
‘Barger and Harmon (1997)’. Thereby macrophage activation by increased interferon production 
could be initiated. Unfortunately in the 12h sAPPα study, no increase in any interferons was found, 
rather only interferon induced proteins. This could be due to the long incubation time in respect to 
the Barger and Harmon study, the immune response was within 90 minutes. Thereby a 12h 
incubation, may miss the window of interferon up regulation. Regardless if macrophage activation 
is occurring via a mechanism caused by sAPPα, it would not be the only mechanism in place. As 
neuroprotection by sAPPα has been established using a cell viability assay (Levities et al., 2003), 
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then there must also exist a cell signaling cascade within the cell that deals with stress. Activation 
of macrophages is extracellular and will only benefit if there is foreign bodies to clear and would not 
be seen in a cell viability assay.    
4.3.2 Other sAPPα functions: Growth and proliferation
sAPPα functions to increase growth and proliferation of cells. There were no interaction maps that 
link proteins together that share this function. Nevertheless, there were a number of proteins that 
do suggest that growth and proliferation was altered in this experiment, with perhaps the wrong 
time frame diminishing the significance of the data set. There were 5 proteins that had functions 
that were associated with proliferation and growth. Papers by Ohsawa (Ohsawa et al., 1999) and 
Caille (Caille´ et al., 2004), both showed evidence that sAPP (sAPPα) stimulates proliferation of 
neural stem cells and adult subventricular zone respectively. The de novo protein synthesis seen 
with this experiment suggests a mechanism behind sAPPα function of growth and proliferation. 
Ohsawa study showed proliferation of neurons, significantly increased with the addition of full 
length sAPPα and N-terminal sAPP16-290. The C-terminal sAPP380-663 did not show a significant 
increase in proliferation of neurons suggesting that the same increase in growth and proliferation 
may be observed in the RER study, but not the 16mer study (figure 1.3). The up regulated proteins 
in my results with growth and proliferation function were NCAPH, TUBGCP2, MESDC2, CORO1B 
and PUM1. 
• NCAPH is part of the condensen complex, required for transition through cell cycles. 
• TUBGCP2 is necessary for microtubules formation for nucleation. 
• MESDC2 acts as a modulator of the Wnt pathway, responsible for polarity of a cell, perhaps 
allowing for neurite branching. 
• CORO1B suggested to be involved in cytokinesis in cell proliferation. 
• PUM1 suggested to function in support of cell proliferation.
My study had a different time frame than the Ohsawa study. The Oshawa study had only a 3h 
incubation. At this time frame a strong signal for proliferation factors were shown. My 12h 
incubation may have excluded some proliferation factors, as changes in the proteome was 
observed with the induction of sAPPα, as seen in my SILAC results and suggested by previous 
gene expression studies (Ryan et al., 2013). 
4.3.4 SILAC links to MTT assay
The next set of proteins worthy of an honorable mention, gives a small sense of cosmic irony. A 
group of proteins suggests an early experiment to be the first domino for the failing MTT assay. 
The 12h SILAC experiment shows a series of proteins with altered expression levels that may have 
altered how well the MTT could gauge the viability of the cells with glucose deprivation. C12OR5 
was an up regulated protein that inhibits glycolysis by reducing levels of fructose-1,6-biphosphate 
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(a glycolysis intermediate). The cells deprived of glucose would have a diminished viability due to 
decrease of ATP production. The addition of sAPPα could further decrease glucose availability as 
C12OR5 inhibits glycolysis and sAPPα increases C12OR5 expression. Meaning that the sAPPα 
cell population at the 12 h incubation time may be under more stress than the PBS buffer control 
counterparts. In other words, the sAPPα induced populations with a 2 h pre-treatment, had a total 
of 12h incubated with sAPPα, and at 12h of incubation, glucose breakdown appears to be reduced. 
Thereby the sAPPα induced cells had less ATP availability than the negative control. SDHB 
(Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial) was also shown to have 
altered synthesis levels. This protein was down regulated and reduces FADH2. Lower levels of 
SDHB would further decrease ATP production. Two proteins show decrease glucose metabolism 
after 12h induction with sAPPα. Whether this would alter the viability of the cells in the MTT assay, 
remains unknown. If so, it could be a reason why the glucose deprivation methodology for the MTT 
assay was inconsistent. Even the MTT methods that used other forms of stress could be 
influenced by these changes in protein expression.
4.4 Hypothesis: Neuroblastoma proteome changes with exposure time to sAPPα  
The initial SILAC experiment used a 12h incubation with endogenously added sAPPα, this gave a 
change in de novo protein expression confirming that sAPPα is able to change protein synthesis. 
Another point made in the Ryan paper (Ryan et al., 2013) was that the gene expression of the 
transcriptome changed over a time course. This is the basis for my next hypothesis, whether 
different incubation periods with sAPPα causes a different spectrum of proteins to be up and down 
regulated. A 6 h incubation was chosen to test this, however in hind-sight, a longer incubation (24h) 
might have been better. The same issue with the earlier 2h incubation occurred in the 6h 
incubation. There was more difficulty defining up and down regulated proteins over a high 
background of the steady state proteins. Despite this, the data was sufficient to address the 
hypothesis stated. 
Figures 3.20 and 3.22 illustrates this hypothesis best, there are no shared proteins between the 
two incubation time points (12h and 6h). The evidence does point towards a change in protein 
synthesis pattern from 6 hours to 12 hours. Between the 6h and 12h sAPPα SILAC experiments, 
only one protein was shown to have altered expression levels across both experiments 
(POGLUT1). The Ryan et al paper from this group showed three time periods, 15 min, 2h and 24h 
with 540, 415 and 241 genes, whose transcripts changes significantly, were identified for each time 
period respectively. Only one annotated gene identified was common in all three studies, although 
between two of the time periods (15min and 2h, or 2h and 24h) there were a modest number of 
genes in common. The lowest period of exposure was dominated by immediate early genes and 
transcription factors and most were up regulates, where there was a shift to response genes by 2h 
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with an equal number up regulated and down regulated, and then more were down regulated than 
up regulated at 24h. The two SILAC experiments identified credible pathways that were being 
regulated but the response times were intermediate between the 2h and 24h used for gene 
expression. A 6h time for the SILAC strategy showed there was insufficient incorporation of ‘heavy’ 
isotopes to easily identify the newly synthesized protein relating to the sAPPα exposure. 
Nevertheless this time for protein expression would equate more to the 15 min of the transcript 
study and the 12h change in proteome study would be more equivalent to the 2h transcript study. It 
is somewhat surprising there is such a different profile of protein changes between the different 
incubation times that are relatively close together. Additional exposure times to extend the time 
course in both directions would be informative.
4.4.1 Exceptions to the hypothesis
The one protein shown with a lower expression level at both the 6h and 12h. POGLUT1 (protein O-
glucosyltransferase) allows for the post-translation modification of EGF-like repeats (Fernandez-
Valdivia et al., 2011). Absence of O-glucosylation in Notch EGF-like repeats is embryonically lethal 
before embryonic day 10. Previously established, Notch signaling pathway has multiple similarities 
to APP pathways, notably 𝛄-Secretase that cleaves both Notch and APP. Nicastrin a key subunit in 
𝛄-Secretase, was shown to be down regulated in the 12h incubation. 
POGLUT1 is a second protein identified, that also regulates Notch signaling. Although POGLUT1 
does not regulate APP in the same manner as the Notch pathways (APP does not have EGF-like 
repeats like Notch), but may do so indirectly. APP is regulated by Fibulin-1, which itself has EGF-
like repeats (Ohsawa et al., 2001). Fibulin-1 is an extracellular protein that binds to the E1 domain 
of APP via the EGF-like repeats. Fibulin-1 has a consensus O-glucosylation sequence (Argraves et 
al., 1990), required for its function. Fibulin-1 in Ohsawa’s study demonstrates an ability to inhibit 
sAPPα-mediated cell proliferation. This proposes that POGLUT1 activates Fibulin-1, which in turn 
decreases sAPPα-mediated cell proliferation. An increase level of cellular proliferation would occur 
as a consequence of a down regulated inhibitor (Fibulin-1). This links back to an earlier point 
(4.3.2), the 12h incubation showed up regulation of proteins that functions in cell growth and 
proliferation.  
4.4.2 Future hypothesis: Function of APP dimerisation
Additionally the down regulation of POGLUT1, may lead to an increase in sAPPα dimerisation. 
Fibulin-1 binds to the E1 domain of APP, the E1 domain allows for a hairpin induced dimerisation of 
APP (Dahms et al., 2011). If Fibulin-1 is bound to the E1 domain, no dimerisation would occur. This 
is a possible mechanism of how Fibulin-1 prevents sAPPα-mediated cell proliferation. The function 
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of APP dimers has yet to be elucidated it has been proposed to be involved in cell-cell mediated 
signaling. From my data, we know sAPPα down regulates POGLUT1, which in turn decrease 
Fibulin-1, likely allowing for an increase level of APP dimerisation. We also know APP acts as a 
ligand for LRP (LDL receptor-related protein)(Trommsdorff et al., 1998). LRP is a receptor on 
macrophages and has been defined as a monocyte differentiation antigen (Krieger and Herz 
1994). One possibility is that the increased dimerisation of APP increases macrophage activity via 
cell-cell signaling. As an additional point, elevated level of APP in neurons increase microglia/
macrophage activity (Shigematsu et al., 1992). Nicastrin also shown to be down regulated, would 
cause an increase in APP concentration because a to lower 𝛄-Secretase processing activity.
4.5 Hypothesis: Fragments of sAPPα elicit a change in protein expression
As previously discussed one of the original aims of studying the C terminal ‘16mer’ of sAPPα and 
N terminal tripeptide RER, was to demonstrate neuroprotection (4.2.2). Nevertheless these 
fragments of the full sAPPα protein were able to address another hypothesis utilizing SILAC. The 
16mer is the only sequence difference between sAPPα and sAPPβ, and is thought to be 
responsible for the 100 fold difference in neuroprotection efficiency of these two proteins. The RER 
by contrast is within an established active site (Roch et al., 1992) that exists in both sAPPα and 
sAPPβ. With this in mind, an expectation was that sAPPα derivatives each would direct the 
synthesis of different set of proteins, but each would have some proteins in common with those 
whose synthesis is directed by sAPPα.   
Unfortunately the 6 h incubation time frame, in which both the 16mer and RER were investigated, 
had low signals for ‘heavy’ isotopes (newly synthesized) over the ‘light’ (steady state). A 
consequence is that the conclusions are less definitive. Nevertheless both the 16mer and RER 
experiments showed a relatively large number of up regulation proteins, 100+. This could suggest 
a general increase in translation. Nevertheless, it means that the up regulated proteins can not 
easily be used to compare protein expression pattern, which makes it difficult to address the above 
hypothesis. This was addressed by proteins that were down regulated in response to the peptides. 
4.5.1 Differences between RER and the 16mer
The RER is located in the central E2 domain of sAPPα, while the 16mer is at the C-terminal end of 
sAPPα (figure 1.3). Each proposed to have separate function (1.10), thereby as a secondary 
hypothesis, I would propose that the 16mer and RER would not likely share proteins with altered 
levels of expression, but will share proteins in common with the full length sAPPα. In the down 
regulated proteins there were no shared proteins identified between the 16mer and the RER, 
reinforcing that each have a separate function within sAPPα. Second, both RER and the 16mer 
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have proteins that are indeed shared with sAPPα. RER and sAPPα both down regulate PSMD14, 
a proteasome subunit, while the 16mer and sAPPα, down regulate PTK7, that has an unknown 
function. This reinforces the underlying premise of the hypothesis that the peptides would behave 
independently but have some commonality of function with sAPPα. The quality of the data is better 
with sAPPα than the two variants, suggesting the small peptides did not facilitate de novo  protein 
synthesis as efficiently in the SILAC analysis. This means that the data may not have 
encompassed all the proteins were affected.     
4.6 Future direction of SILAC
The SILAC method is a powerful method to look at de novo protein synthesis in cells. The reason 
is because it measures differences in proteins synthesis rather than changes in gene expression 
transcripts. It has been clearly established that the change in gene expression does not correlate 
with a change in de novo protein synthesis (Vogel and Marcotte 2012). SILAC as explained 
previously (3.8) can identify  in combined samples changes in protein synthesis using isotopes of 
common elements. The SILAC system is not without limitations however, gene expression 
changes in transcripts are able to identified within minutes of exposure to a reagent like sAPPα. 
SILAC is not able to do this, it requires sufficient time for incorporation of isotopes into proteins. 
This is harder to detect for multiple reasons, first it detects one or two isotope (lysine and arginine) 
changes out of 20 amino acids. Second it is for de novo protein synthesis, meaning there is a huge 
background of light isotopes from the steady state protein. The later issue is the most problematic 
with shorter time frames. The 12 h incubation had sufficient incorporation of isotopes to be able to 
detect changes in protein expression with the heavy isotope. However the shorter time frame point 
of 6h I used, marked a limit of usefulness of this technique.
The next experiment I would suggest with sAPPα incubation would be longer than 12 hours. It 
would still function to satisfy the same hypothesis; that sAPPα protein expression is time 
dependent and changes accordingly. A secondary hypothesis could also be satisfied with the 
longer incubation time; do the sAPPα derivates, the 16mer and RER elicit a similar protein 
expression as sAPPα, but vary between themselves? An alternative time, between 6h and 12h 
could be used, with more definitive results nearer 12h incubation. If a shorter time frame was 
desired, an alternative technique would have to be used, such as chemical labelling rather than 
metabolic labelling. 
4.7 Additional work: Cloning of sAPPη
The discovery a new APP processing pathway and accompanying proteolytic enzyme, η-Secretase 
was reported in October 2015 and I investigate the significance of this report with my work cloning 
sAPPη, started late in 2016. For this reason, a hypothesis for functional relevance has not yet 
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been tested. Rather my work attempted to clone the gene fragment encoding sAPPη so it can be 
used by others in the group to transform human embryonic kidney cells and create a stable cell line 
that will enable the group to produce the protein as it does sAPPα. This work gave me skills and 
experience in molecular genetic techniques that are very common and invaluable in biochemistry 
research.  
4.7.1 sAPPη background
Multiple secretase’s have been discovered, with each producing specific products from APP 
relevant to its overall metabolism. These protein variants have displayed different functions, for 
example levels of neuroprotection, with sAPPβ shown to be 1/100th that of sAPPα (Turner et al., 
2007, Furukawa et al., 1996b). The 16 amino acid difference between sAPPα and sAPPβ is 
fundamental for proper neuroprotection, which sparked one of my aims of my study. η-Secretase 
(Willem et al., 2015) was recently discovered in which APP processing results in different 
fragments (1.17). The main protein produced by η-Secretase is sAPPη, a shorter protein by 100 
amino acids than sAPPα. It will be interesting to test the functional activities of this protein such as 
in neuroprotection. A hypothesis could be constructed, that sAPPη might acts as in inhibitor of 
sAPPα.
APP when cleaved by η-Secretase can then be further processed by α-Secretase and β-Secretase 
to form additional small unique peptides ηα and ηβ, which are more similar in size to Aβ and the 
16mer respectively than other APP fragments. It is worth noting that the 16mer is never seen in 
vivo as a separate peptide, but the ηβ is similar in sequence. These fragments have two possible 
origins 1). they may be simply a byproduct of evolution, like Aβ was once thought to be and 2). 
they could provide yet another layer of function and regulation of the APP molecule. Intriguingly 
both these fragments ηα and ηβ, contain sequence from both sAPPα and Aβ, though the amount 
of share sequence varied. With shared sequence common to both sAPPα and Aβ, will the 
fragments act in a neuroprotective or neurotoxic manner or inhibit either function? 
My experiment consisted of three sequence to clone; sAPPη, ηα and ηβ. This was mostly 
successful, with 2 out of 3 of the constructs cloned successfully. The sAPPη fragment was difficult 
to clone due to the vector used, that had previously been used to clone a similar APP fragment. 
This lead to a high level of false positives in earlier experiments, as the colony screen was not 
specific enough for sAPPη. The ηα and ηβ should have been straight forward to clone, as smaller 
fragments have a high chance of ligating to a vector. For an unknown reason, this was not the 
case, with more frequently vectors ligating together over successful insertion of either ηα and ηβ 
fragments. Regardless of this, the ηβ was successfully cloned into a pMal vector. However the ηα 
was never successfully cloned. The cloned sAPPη fragment could be tested in the SILAC 
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experiment as well as sAPPα. ηα and ηβ are also possible candidate peptides for this approach, 
but I would suggest using Aβ in SILAC, before looking at these other smaller peptides. 
4.8 Final note   
The prevalence of Alzheimer's disease is still rising and with that an increase in the economical 
burden is also expected. No cure or treatment is available for Alzheimer’s disease, but our 
understanding has increase with each successive experiment. This studies contribution to the 
understanding of AD’s pathology is small, but important. This study provided insight into protein 
expression of sAPPα. This gave a better understanding of the mechanism of sAPPα that could aid 
in the development of further therapeutic agents or peptidomimetics. Additionally the SILAC results 
gave additional proteins that work in combination with sAPPα that could also have pathological 
consequences. This information could benefit targeted therapeutic drug design and better genetic 
diagnosis with the disease, possibly allowing better prediction of late onset AD. 
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All chemicals used were of analytical grade. Solution prepared were with Milli-Q® Ultrapure H2O 
and stored in autoclaved glassware. Solution were prepared as required unless could be stored 
under sterilised conditions. Any solutions that required autoclaving were heated to 121℃ for 20 
minutes.  
AppliChem GmbH, Germany: Agarose, N,N,N’,N,N’-tetrmethyl-ethylenediamine (TEMED), urea
Axygen incorporate, USA: 0.6ml, 1.5ml microcentrifuge tubes
BD, USA: Disposable 1ml syringe, disposable 0.22μm filter, 10ml and 50ml serological pipettes, 
T175 filter culture flask
Biolab, Australia: ethanol
Bio-Rad Laboratories incorporated, USA: Acrylamide/Bis solution 37:5:1, Broad Range SDS-PAGE 
molecular weight standard
Corning Incorporate, USA: 96 well cell culture treated plate
Gibco®, USA: Dubecco’s Modified Eagle Medium (DMEM) with and without glucose, SILAC 
DMEM, Foetal bovine serum (FBS), penicillin streptomycin solution, Trypsin (0.25% w/v)
Greiner Bio-One, Germany: T25 cell culture flasks, T75 cell culture flasks
Invitrogen Corporation, USA: Ethidium bromide, 100bp DNA ladder
Koch-Light limited, UK: bromophenol blue
Lab Supply Ltd, New Zealand: bactotyptone, yeast extract, hydroxymethylaminomethane (Tris)
Life Technologies, USA: Trypan blue solution, 0.4%
Oxoid Limited, UK: phosphate buffered saline tablets (Dulbecco A)
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Peptides International, USA: TAPI-1
Qiagnen, Germany: Qiaprep® Spin Miniprep kit, QIquick®  PCR purification kit
Roche Applied Science, Germany: ampicillin, dNTPs, λ-DNA, restriction endonuclease (BamH1, 
EcoR1, HindⅢ) and there RE buffer B
Scharlau Chemie S.A, Spain: isopropanol, hydrochloric acid
Sigma-Aldrich Incorporated, USA: BCA reagents, β-mercaptoethanol, Brilliant Blue G, BSA protein, 
DMSO (cell culture grade), MTT, resazurin
USB Corporation, USA: Tween® 20





1% (w/v) yeast extract
0.5% (w/v) NaCl
Adjusted to pH7 with NaOH
Acrylamide Urea gel 15-20% 
10% (w/v) TBE buffer 10x




TBE buffer 0.5 x
Agarose 1-2% (w/v)
0.1% Ethidium bromide (v/v)
Coomassie blue stain 
10% (w/v) ammonium sulphate
0.1% (w/v) brilliant blue G
20% (v/v) ethanol





0.3% (w/v) bromophenol blue
DMEM cell media
Dulbecco's Modified Eagle Medium
10% FBS (v/v)
Antibiotic-Antrimycotic solution 1% (v/v)
Destaining solution
5% (v/v) methanol










0.5% (w/v) yeast extract
1% (w/v) NaCl
Outer running buffer 1x
0.3% (w/v) Tris
1.4%(w/v) Glycine 
PBS (phosphate buffer solution) 
1tablet of PBS dissolved in 100ml of 
ddH2O then autoclaved
SDS polyacrylamide stacking gel, 10%
1x Stacking gel buffer





SDS polyacrylamide resolving gel, 10%
1x stacking gel buffer
9.8% (v/v) acrylamide:biacrylamide  
(37:5:1)
0.09% (w/v) ammonium persulfate
0.075% (v/v) TEMED
SILAC Light Media
DMEM (customised SILAC) 43.35mL
Lysine (light) 50μL







DMEM (customised SILAC) 43.35mL
Lysine (Medium) 50μL







DMEM (customised SILAC) 43.35mL
Lysine (Heavy) 50μL






Separating gel buffer, 4x
36% (w/v) Tris
0.4% (w/v) SDS
pH adjusted t0 8.8 with HCl
Stacking gel buffer, 4x
6% (w/v) Tris
0.4% (w/v) SDS




5.5% (w/v) boric acid 
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Appendix Ⅱ: Primer catalogue






98305571 62.8 Forward primer for ηα and ηβ 





983955772 64 Reverse primer for ηα 





98305573 64.9 Reverse primer for ηβ 





98305569 68.1 Forward primer for sAPPη 






98305570 66.2 Reverse primer for sAPPη 
cloning into pcDNA3.1D 
vector 
pMal-Ins_F CGACCTTCAAGGGTCAACCA 98570472 57.3 Forward primer for pMal 
insert amplification
pMal-Ins_R TAAGTTGGGTAACGCCAGGG 98570472 57.1 Reverse primer for pMal 
insert amplification
pMal-2nd_F CCTGAAAGACGCGCAGACTA 98570474 57.1 Second forward primer for 
pMal insert amplification
T7 TAATACGACTCACTATAGGG 49 Forward primer for 
pcDNA3.1D vector
BGH Reverse TAGAAGGCACAGTCGAGG 54 Rorward primer for 
pcDNA3.1D vector
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Appendix Ⅳ: Full protein list
Up Regulated Proteins (12h sAPPα)
Gene name Full name Description
C12ORF5 chromosome 12 open 
reading frame 5
Fructose-bisphosphatase hydrolyzing fructose-2,6- 
bisphosphate as well as fructose-1,6-bisphosphate. 
Inhibits glycolysis by reducing cellular levels of 
fructose-2,6- bisphosphate. May protect cells against 
reactive oxygen species and against apoptosis induced 
by tp53
EXOSC5 exosome component 
5
Non-catalytic component of the RNA exosome complex 
which has 3’->5’ exoribonuclease activity and 
participates in a multitude of cellular RNA processing 
and degradation events. In the nucleus, the RNA 
exosome complex is involved in proper maturation of 
stable RNA species such as rRNA, snRNA and 
snoRNA, in the elimination of RNA processing by-
products and non-coding ’pervasive’ transcripts, such 
as antisense RNA species and promoter-upstream 
transcripts (PROMPTs), and of mRNAs with processing 
defects, thereby limiting or excluding their export to the 
cytoplasm.




protein kinase which plays a key role in the innate 
immune response to viral infection and is also involved 
in the regulation of signal transduction, apoptosis, cell 
proliferation and differentiation. Exerts its antiviral 
activity on a wide range of DNA and RNA viruses 
including hepatitis C virus (HCV), hepatitis B virus 
(HBV), measles virus (MV) and herpes simplex virus 1 
AKR7A2 aldo-keto reductase 
family 7, member A2 
(aflatoxin aldehyde 
reductase)
Catalyzes the NADPH-dependent reduction of succinic 
semialdehyde to gamma-hydroxybutyrate. May have an 
important role in producing the neuromodulator gamma-
hydroxybutyrate (GHB). Has broad substrate specificity. 
Has NADPH-dependent aldehyde reductase activity 
towards 2-carboxybenzaldehyde, 2- nitrobenzaldehyde 
and pyridine-2-aldehyde (in vitro). Can reduce 1,2-
naphthoquinone and 9,10-phenanthrenequinone (in 
vitro)
NCAPH non-SMC condensin I 
complex, subunit H
Regulatory subunit of the condensin complex, a 
complex required for conversion of interphase 
chromatin into mitotic-like condense chromosomes. The 
condensin complex probably introduces positive 
supercoils into relaxed DNA in the presence of type I 
topoisomerases and converts nicked DNA into positive 
knotted forms in the presence of type II topoisomerases
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TUBGCP2 tubulin, gamma 
complex associated 
protein 2
Gamma-tubulin complex is necessary for microtubule 




Chaperone specifically assisting the folding of beta- 
propeller/EGF modules within the family of low-density 
lipoprotein receptors (LDLRs). Acts as a modulator of 
the Wnt pathway through chaperoning the coreceptors 
of the canonical Wnt pathway, LRP5 and LRP6, to the 
plasma membrane. Essential for specification of 
embryonic polarity and mesoderm induction
RBM25 RNA binding motif 
protein 25
NOB1  NIN1/RPN12 binding 
protein 1 homolog (S. 
cerevisiae)




ATP1A1 ATPase, Na+/K+ 
transporting, alpha 1 
polypeptide
This is the catalytic component of the active enzyme, 
which catalyzes the hydrolysis of ATP coupled with the 
exchange of sodium and potassium ions across the 
plasma membrane. This action creates the 
electrochemical gradient of sodium and potassium ions, 
providing the energy for active transport of various 
nutrients
DDX19A DEAD (Asp-Glu-Ala-
Asp) box polypeptide 
19A
ATP-dependent RNA helicase involved in mRNA export 
from the nucleus. Rather than unwinding RNA 
duplexes, DDX19 functions as a remodeler of 
ribonucleoprotein particles, whereby proteins bound to 
nuclear mRNA are dissociated and replaced by 
cytoplasmic mRNA binding proteins
TRMT10C tRNA 
methyltransferase 10 
homolog C (S. 
cerevisiae)
Functions in mitochondrial tRNA maturation. Part of 
mitochondrial ribonuclease P, an enzyme composed of 
MRPP1/RG9MTD1, MRPP2/HSD17B10 and MRPP3/
KIAA0391, which cleaves tRNA molecules in their 5’-
ends (403 aa)
CORO1B coronin, actin binding 
protein, 1B
Regulates leading edge dynamics and cell motility in 
fibroblasts. May be involved in cytokinesis and signal 
transduction (By similarity)
Up Regulated Proteins (12h sAPPα)
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TTI2 TELO2 interacting 
protein 2
Regulator of the DNA damage response (DDR). Part of 
the TTT complex that is required to stabilize protein 
levels of the phosphatidylinositol 3-kinase-related 
protein kinase (PIKK) family proteins. The TTT complex 
is involved in the cellular resistance to DNA damage 
stresses, like ionizing radiation (IR), ultraviolet (UV) and 
mitomycin C (MMC). Together with the TTT complex 





protein 2, 49kDa 
(NADH-coenzyme Q 
reductase)
Core subunit of the mitochondrial membrane respiratory 
chain NADH dehydrogenase (Complex I) that is 
believed to belong to the minimal assembly required for 
catalysis. Complex I functions in the transfer of 
electrons from NADH to the respiratory chain. The 






interferon-induced RNA-binding protein that specifically 
binds single-stranded RNA bearing a 5’-triphosphate 
group (PPP- RNA), thereby acting as a sensor of viral 
single-stranded RNAs. Single-stranded PPP-RNAs, 
which lack 2’-O-methylation of the 5’ cap and bear a 5’-
triphosphate group instead, are specific from viruses, 
providing a molecular signature to distinguish between 
self and non-self mRNAs by the host during viral 
infection. Directly binds PPP-RNA in a non-sequence-




PUM1 pumilio homolog 1 
(Drosophila)
Sequence-specific RNA-binding protein that regulates 
translation and mRNA stability by binding the 3’-UTR of 
mRNA targets. May be required to support proliferation 
and self-renewal of stem cells
FTSJ3 FtsJ homolog 3 (E. 
coli)
Probable methyltransferase involved in the processing 




Up Regulated Proteins (12h sAPPα)
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Down Regulated Proteins (12h sAPPα)
Gene name Full name Description
FHL1 four and a half LIM 
domains 1
MBD3 methyl-CpG binding 
domain protein 3
Does not bind DNA by itself. Recruits histone 
deacetylases and DNA methyltransferases. Acts as 




Serine/threonine kinase which acts as an essential 
component of the MAP kinase signal transduction 
pathway. MAPK14 is one of the four p38 MAPKs which 
play an important role in the cascades of cellular 
responses evoked by extracellular stimuli such as 
proinflammatory cytokines or physical stress leading to 
direct activation of transcription factors. Accordingly, p38 
MAPKs phosphorylate a broad range of proteins and it 
has been estimated that they may have approximately 
200 to 300 substrates each.
IRF2BPL interferon regulatory 
factor 2 binding 
protein-like
May contribute to the control of female reproductive 
function (By similarity). May play a role in gene 





Cleaves presequences (transit peptides) from 
mitochondrial protein precursors
VAC14 Vac14 homolog (S. 
cerevisiae)
The PI(3,5)P2 regulatory complex regulates both the 
synthesis and turnover of phosphatidylinositol 3,5-
bisphosphate (PtdIns(3,5)P2). Acts as a positive 
activator of PIKfyve kinase activity. Also required to 
maintain normal levels of phosphatidylinositol 3-
phosphate (PtdIns(3)P) and phosphatidylinositol 5-
phosphate (PtdIns(5)P). Plays a role in the biogenesis of 
endosome carrier vesicles (ECV) / multivesicular bodies 
(MVB) transport intermediates from early endosomes
LSG1 large subunit 
GTPase 1 homolog 
(S. cerevisiae)
GTPase required for the XPO1/CRM1-mediated nuclear 
export of the 60S ribosomal subunit. Probably acts by 
mediating the release of NMD3 from the 60S ribosomal 
subunit after export into the cytoplasm
PPM1B protein phosphatase, 
Mg2+/Mn2+ 
dependent, 1B
Enzyme with a broad specificity. Dephosphorylates 
CDK2 and CDK6 in vitro
ACOX1 acyl-CoA oxidase 1, 
palmitoyl 
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LUC7L LUC7-like (S. 
cerevisiae)
May bind to RNA via its Arg/Ser-rich domain
NCSTN nicastrin Essential subunit of the gamma-secretase complex, an 
endoprotease complex that catalyzes the 
intramembrane cleavage of integral membrane proteins 
such as Notch receptors and APP (beta- amyloid 
precursor protein). It probably represents a stabilizing 








Transcription factor that binds RNA polymerase II and 
inhibits the elongation of transcripts from target 
promoters. Regulates transcription elongation in a TATA 
box-dependent manner. Necessary for TAT-dependent 
activation of the human immunodeficiency virus type 1 
(HIV-1) promoter
IKBIP IKBKB interacting 
protein
Target of p53/TP53 with pro-apoptotic function
CNNM3 cyclin M3 Probable metal transporter 
TRIP10 thyroid hormone 
receptor interactor 10
ZYX zyxin adhesion plaque protein. Binds alpha-actinin and the 
CRP protein. Important for targeting TES and ENA/VASP 
family members to focal adhesions and for the formation 
of actin-rich structures. May be a component of a signal 
transduction pathway that mediates adhesion-stimulated 
changes in gene expression




Central component of the condensin complex, a 
complex required for conversion of interphase chromatin 
into mitotic-like condense chromosomes. The condensin 
complex probably introduces positive supercoils into 
relaxed DNA in the presence of type I topoisomerases 
and converts nicked DNA into positive knotted forms in 
the presence of type II topoisomerases 
TSNAX translin-associated 
factor X
Acts in combination with TSN as an endonuclease 
involved in the activation of the RNA-induced silencing 
complex (RISC). Possible role in spermatogenesis
SH3GLB2 SH3-domain GRB2-
like endophilin B2




complex, subunit B, 
iron sulfur (Ip)
Iron-sulfur protein (IP) subunit of succinate 
dehydrogenase (SDH) that is involved in complex II of 
the mitochondrial electron transport chain and is 
responsible for transferring electrons from succinate to 
ubiquinone (coenzyme Q)
RFC1 eplication factor C 
(activator 1) 1, 
145kDa
the elongation of primed DNA templates by DNA 
polymerase delta and epsilon requires the action of the 
accessory proteins PCNA and activator 1. This subunit 
binds to the primer-template junction. Binds the PO-B 
transcription element as well as other GA rich DNA 
sequences. Could play a role in DNA transcription 
regulation as well as DNA replication and/or repair. Can 
bind single- or double-stranded DNA
CIAPIN1 cytokine induced 
apoptosis inhibitor 1
May be required for the maturation of extramitochondrial 
Fe/S proteins (By similarity). Has anti-apoptotic effects in 
the cell. Involved in negative control of cell death upon 
cytokine withdrawal. Promotes development of 
hematopoietic cells (By similarity) 




may be required for ribosome biogenesis 
ENSG Functions in trans to edit the amino acid moiety from 
incorrectly charged tRNA(Ala)
CPSF6 cleavage and 
polyadenylation 
specific factor 6, 
68kDa
Component of the cleavage factor Im complex (CFIm) 
that plays a key role in pre-mRNA 3’-processing. 
Involved in association with NUDT21/CPSF5 in pre-
MRNA 3’-end poly(A) site cleavage and poly(A) addition. 
CPSF6 binds to cleavage and polyadenylation RNA 
substrates and promotes RNA looping
PGM3 phosphoglucomutase 
3 
Down Regulated Proteins (12h sAPPα)
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Up Regulated Proteins (6h sAPPα)
Gene name Full name Description
GLA galactosidase, alpha
ABCF2 ATP-binding cassette, 
sub-family F
NUP155 nucleoporin Essential component of nuclear pore complex. 
Nucleoporins may be involved both in binding and 
translocating proteins during nucleocytoplasmic transport
WDR18 WD repeat domain 18 May play a role during development (By similarity). 
Functions as a component of the Five Friends of 
Methylated CHTOP (5FMC) complex; the 5FMC complex 
is recruited to ZNF148 by methylated CHTOP, leading to 
desumoylation of ZNF148 and subsequent 
transactivation of ZNF148 target genes
EXOC4 exocyst complex 
component 4
Component of the exocyst complex involved in the 
docking of exocytic vesicles with fusion sites on the 
plasma membrane
ORC3 origin recognition 
complex, subunit 3 
WDR12 WD repeat domain 12 Component of the PeBoW complex, which is required for 
maturation of 28S and 5.8S ribosomal RNAs and 
formation of the 60S ribosome
WIZ widely interspaced 
zinc finger motifs
RAB7A AB7A, member RAS 
oncogene family
key regulator in endo-lysosomal trafficking. Governs 
early-to-late endosomal maturation, microtubule minus-
end as well as plus-end directed endosomal migration 
and positioning, and endosome-lysosome transport 
through different protein-protein interaction cascades. 
Plays a central role, not only in endosomal traffic, but 
also in many other cellular and physiological events, 
such as growth-factor-mediated cell signaling, nutrient- 
transportor mediated nutrient uptake, neurotrophin 
transport in the axons of neurons and lipid metabolism.
RBM27 RNA binding motif 
protein 27
ANXA11 annexin A11 Binds specifically to calcyclin in a calcium-dependent 
manner (By similarity). Required for midbody formation 
and completion of the terminal phase of cytokinesis
TMPO thymopoietin May help direct the assembly of the nuclear lamina and 
thereby help maintain the structural organization of the 
nuclear envelope. Possible receptor for attachment of 
lamin filaments to the inner nuclear membrane. May be 
involved in the control of initiation of DNA replication 
through its interaction with NAKAP95
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Up Regulated Proteins (6h sAPPα)
Gene name Full name Description
EIF3I eukaryotic translation 
initiation factor 3
Component of the eukaryotic translation initiation factor 3 
(eIF-3) complex, which is required for several steps in 
the initiation of protein synthesis. The eIF-3 complex 
associates with the 40S ribosome and facilitates the 
recruitment of eIF-1, eIF-1A, eIF-2-GTP-methionyl-tRNAi 
and eIF-5 to form the 43S preinitiation complex (43S 
PIC). The eIF-3 complex stimulates mRNA recruitment to 
the 43S PIC and scanning of the mRNA for AUG 
recognition.
CLPB ClpB caseinolytic 
peptidase B homolog
May function as a regulatory ATPase and be related to 
secretion/protein trafficking process
SYNPO2 synaptopodin 2 Has an actin-binding and actin-bundling activity
TBL2 transducin
U2AF2 U2 small nuclear RNA 
auxiliary factor 2
Necessary for the splicing of pre-mRNA. Induces cardiac 
troponin-T (TNNT2) pre-mRNA exon inclusion in muscle. 
Regulates the TNNT2 exon 5 inclusion through 
competition with MBNL1. Binds preferentially to a single-
stranded structure within the polypyrimidine tract of 
TNNT2 intron 4 during spliceosome assembly. Required 
for the export of mRNA out of the nucleus, even if the 
mRNA is encoded by an intron-less gene. Represses the 





The UBE2V1-UBE2N and UBE2V2-UBE2N heterodimers 
catalyze the synthesis of non-canonical ’Lys-63’-linked 
polyubiquitin chains. This type of polyubiquitination does 
not lead to protein degradation by the proteasome. 
Mediates transcriptional activation of target genes. Plays 
a role in the control of progress through the cell cycle 
and differentiation. Plays a role in the error-free DNA 
repair pathway and contributes to the survival of cells 
after DNA damage.
DLG1 discs, large homolog 1 
CACNA2D1 alcium channel, 
voltage-dependent, 
alpha 2/delta subunit 
1
the alpha-2/delta subunit of voltage-dependent calcium 
channels regulates calcium current density and 
activation/inactivation kinetics of the calcium channel. 
Plays an important role in excitation-contraction coupling
RHOT1 ras homolog family 
member T1
Mitochondrial GTPase involved in mitochondrial 
trafficking
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Up Regulated Proteins (6h sAPPα)
Gene name Full name Description
SIN3A SIN3 transcription 
regulator homolog 
A
Acts as a transcriptional repressor. Corepressor for REST. 
Interacts with MXI1 to repress MYC responsive genes and 
antagonize MYC oncogenic activities. Also interacts with 
MXD1-MAX heterodimers to repress transcription by 
tethering SIN3A to DNA (By similarity). Acts cooperatively 
with OGT to repress transcription in parallel with histone 
deacetylation
KRT6A keratin 6A





Acts in a Rho-dependent manner to recruit PFY1 to the 
membrane. Required for the assembly of F-actin structures, 
such as actin cables and stress fibers. Nucleates actin 
filaments. Binds to the barbed end of the actin filament and 
slows down actin polymerization and depolymerization. 
Required for cytokinesis, and transcriptional activation of 
the serum response factor. DFR proteins couple Rho and 
Src tyrosine kinase during signaling and the regulation of 
actin dynamics
PUM1 pumilio homolog 1 Sequence-specific RNA-binding protein that regulates 
translation and mRNA stability by binding the 3’-UTR of 
mRNA targets. May be required to support proliferation and 
self-renewal of stem cells 
GPSM1 G-protein signaling 
modulator 1
Guanine nucleotide dissociation inhibitor (GDI) which 
functions as a receptor-independent activator of 
heterotrimeric G- protein signaling. Keeps G(i/o) alpha 
subunit in its GDP-bound form thus uncoupling 
heterotrimeric G-proteins signaling from G protein-coupled 
receptors. Controls spindle orientation and asymmetric cell 
fate of cerebral cortical progenitors. May also be involved in 
macroautophagy in intestinal cells. May play a role in drug 
addiction
POLD1 polymerase (DNA 
directed), delta 1, 
catalytic subunit
Possesses two enzymatic activities- DNA synthesis 
(polymerase) and an exonucleolytic activity that degrades 
single stranded DNA in the 3’- to 5’-direction. Required with 
its accessory proteins (proliferating cell nuclear antigen 
(PCNA) and replication factor C (RFC) or activator 1) for 
leading strand synthesis. Also involved in completing 
Okazaki fragments initiated by the DNA polymerase alpha/
primase complex
GOLIM4 golgi integral 
membrane protein 
4
plays a role in endosome to Golgi protein trafficking; 
mediates protein transport along the late endosome-bypass 
pathway from the early endosome to the Golgi
RPS15 ribosomal protein 
S15 
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Down Regulated Proteins (6h sAPPα)
Gene name Full name Description




calcium-dependent mitochondrial solute carrier. 
Mitochondrial solute carriers shuttle metabolites, 
nucleotides, and cofactors through the mitochondrial 
inner membrane. May act as a ATP-Mg/Pi exchanger 
that mediates the transport of Mg-ATP in exchange for 
phosphate, catalyzing the net uptake or efflux of adenine 
nucleotides into or from the mitochondria
RCN1 reticulocalbin 1, EF-
hand calcium binding 
domain
May regulate calcium-dependent activities in the 
endoplasmic reticulum lumen or post-ER compartment
ZW10 ZW10, kinetochore 
associated, homolog 
Essential component of the mitotic checkpoint, which 
prevents cells from prematurely exiting mitosis. Required 
for the assembly of the dynein-dynactin and MAD1-
MAD2 complexes onto kinetochores. Involved in 
regulation of membrane traffic between the Golgi and the 
endoplasmic reticulum
SLC25A1 solute carrier family 
25 
involved in citrate-H(+)/malate exchange. Important for 
the bioenergetics of hepatic cells as it provides a carbon 
source for fatty acid and sterol biosyntheses, and 
NAD(+) for the glycolytic pathway
PABPN1 poly(A) binding 
protein, nuclear 1
involved in the 3’-end formation of mRNA precursors 
(pre-mRNA) by the addition of a poly(A) tail of 200-250 nt 
to the upstream cleavage product. Stimulates poly(A) 
polymerase (PAPOLA) conferring processivity on the 
poly(A) tail elongation reaction and controls also the 
poly(A) tail length. Increases the affinity of poly(A) 
polymerase for RNA. Is also present at various stages of 
mRNA metabolism including nucleocytoplasmic 
trafficking and nonsense-mediated decay (NMD) of 
mRNA
PTK7 PTK7 protein tyrosine 
kinase 7
NUDCD1 NudC domain 
containing 1
SNRPA small nuclear 
ribonucleoprotein 
polypeptide A
binds stem loop II of U1 snRNA. It is the first snRNP to 
interact with pre-mRNA. This interaction is required for 
the subsequent binding of U2 snRNP and the U4/U6/U5 
tri-snRNP. In a snRNP-free form (SF-A) may be involved 
in coupled pre-mRNA splicing and polyadenylation 
process. Binds preferentially to the 5’-UGCAC-3’ motif in 
vitro
TRNT1 tRNA nucleotidyl 
transferase, CCA-
adding, 1
Isoform 1- Adds and repairs the conserved 3’-CCA 
sequence necessary for the attachment of amino acids 
to the 3’ terminus of tRNA molecules, using CTP and 
ATP as substrates
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Up Regulated Proteins (6h sAPPα)
Gene name Full name Description
GNS glucosamine (N-
acetyl)-6-sulfatase









the transhydrogenation between NADH and NADP is 
coupled to respiration and ATP hydrolysis and functions 
as a proton pump across the membrane. May play a role 
in reactive oxygen species (ROS) detoxification in the 
adrenal gland
PRKAR2A protein kinase, cAMP-
dependent, regulatory, 
type II, alpha
Regulatory subunit of the cAMP-dependent protein kinases 
involved in cAMP signaling in cells. Type II regulatory chains 
mediate membrane association by binding to anchoring proteins, 









subunit, beta type, 4
the proteasome is a multicatalytic proteinase complex 
which is characterized by its ability to cleave peptides 
with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving 
group at neutral or slightly basic pH. The proteasome 
has an ATP-dependent proteolytic activity. Mediates the 
lipopolysaccharide-induced signal macrophage 
proteasome (By similarity). SMAD1/OAZ1/PSMB4 






COG5 component of 
oligomeric golgi 
complex 5
Required for normal Golgi function
RAB1B RAB1B, member RAS 
oncogene family
Protein transport. Regulates vesicular transport between 











Up Regulated Proteins (6h sAPPα)
Gene name Full name Description
PPM1A protein phosphatase, 
Mg2+/Mn2+ 
dependent, 1A
Enzyme with a broad specificity. Negatively regulates 
TGF-beta signaling through dephosphorylating SMAD2 
and SMAD3, resulting in their dissociation from SMAD4, 
nuclear export of the SMADs and termination of the TGF-
beta-mediated signaling
RANBP1 RAN binding protein 1 inhibits GTP exchange on Ran. Forms a Ran-GTP-
RANBP1 trimeric complex. Increase GTP hydrolysis 
induced by the Ran GTPase activating protein 
RANGAP1. May act in an intracellular signaling pathway 
which may control the progression through the cell cycle 
by regulating the transport of protein and nucleic acids 
across the nuclear membrane
VPS33B vacuolar protein 
sorting 33 homolog B
May play a role in vesicle-mediated protein trafficking to 
lysosomal compartments and in membrane docking/
fusion reactions of late endosomes/lysosomes. Mediates 
phagolysosomal fusion in macrophages
LAMP1 lysosomal-associated 
membrane protein 1
Presents carbohydrate ligands to selectins. Also 
implicated in tumor cell metastasis
GPS1 G protein pathway 
suppressor 1
Essential component of the COP9 signalosome complex 
(CSN), a complex involved in various cellular and 
developmental processes. The CSN complex is an 
essential regulator of the ubiquitin (Ubl) conjugation 
pathway by mediating the deneddylation of the cullin 
subunits of SCF-type E3 ligase complexes, leading to 
decrease the Ubl ligase activity of SCF-type complexes 
such as SCF, CSA or DDB2. The complex is also 
involved in phosphorylation of p53/TP53, c-jun/JUN, 
IkappaBalpha/NFKBIA, ITPK1 and IRF8/ICSBP, possibly 
via its association with CK2 and PKD kinases
EIF2B3 eukaryotic translation 
initiation factor 2B, 
subunit 3 gamma, 
58kDa
Catalyzes the exchange of eukaryotic initiation factor 2-
bound GDP for GTP (452 aa)
RPL12 ribosomal protein L12 Binds directly to 26S ribosomal RNA
CNN3 calponin 3, acidic Thin filament-associated protein that is implicated in the 
regulation and modulation of smooth muscle contraction. 
It is capable of binding to actin, calmodulin, troponin C 
and tropomyosin. The interaction of calponin with actin 
inhibits the actomyosin Mg-ATPase activity
DDX50 DEAD (Asp-Glu-Ala-
Asp) box polypeptide 
50 (737 aa)
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Binds to the plus end of microtubules and regulates the 
dynamics of the microtubule cytoskeleton. Promotes 
cytoplasmic microtubule nucleation and elongation. May 
be involved in spindle function by stabilizing microtubules 
and anchoring them at centrosomes. May play a role in 
cell migration
CTTN cortactin Contributes to the organization of the actin cytoskeleton 
and cell structure. In complex with ABL1 and MYLK 
regulates cortical actin-based cytoskeletal rearrangement 
critical to sphingosine 1-phosphate (S1P)-mediated 
endothelial cell (EC) barrier enhancement. Plays a role in 
the regulation of cell migration. Plays a role in the 
invasiveness of cancer cells, and the formation of 
metastases 
PRDX4 peroxiredoxin 4 Probably involved in redox regulation of the cell. 
Regulates the activation of NF-kappa-B in the cytosol by 
a modulation of I-kappa-B-alpha phosphorylation
RBM17 RNA binding motif 
protein 17
plice factor that binds to the single stranded 3’AG at the 
exon/intron border and promotes its utilization in the 
second catalytic step. Involved in the regulation of 
alternative splicing and the utilization of cryptic splice 
sites. Promotes the utilization of a cryptic splice site 
created by the beta-110 mutation in the HBB gene. The 
resulting frameshift leads to sickle cell anemia
NADKD1 NAD kinase domain 
containing 1
Mitochondrial NAD(+) kinase that phosphorylates 
NAD(+) to yield NADP(+). Can use both ATP or inorganic 
polyphosphate as the phosphoryl donor. Also has weak 
NADH kinase activity in vitro; however NADH kinase 
activity is much weaker than the NAD(+) kinase activity 





ELAVL1 ELAV (embryonic 
lethal, abnormal 
vision, Drosophila)-
like 1 (Hu antigen R)
Involved in 3’-UTR ARE-mediated MYC stabilization. 
Binds avidly to the AU-rich element in FOS and IL3/
interleukin-3 mRNAs. In the case of the FOS AU-rich 
element, HUR binds to a core element of 27 nucleotides 
that contain AUUUA, AUUUUA and AUUUUUA motifs. 
Binds preferentially to the 5’-UUUU[AG]UUU-3’ motif in 
vitro
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Metalloprotease component of the 26S proteasome that 
specifically cleaves ’Lys-63’-linked polyubiquitin chains. 
The 26S proteasome is involved in the ATP-dependent 
degradation of ubiquitinated proteins. Plays a role in 
response to double-strand breaks (DSBs)- acts as a 
regulator of non-homologous end joining (NHEJ) by 
cleaving ’Lys-63’-linked polyubiquitin, thereby promoting 
retention of JMJD2A/KDM4A on chromatin and restricting 
TP53BP1 accumulation. Also involved in homologous 




RNA-binding protein implicated in numerous RNA 
metabolic processes. Hydrolyzes single-stranded 
polyribonucleotides processively in the 3’-to-5’ direction. 
Mitochondrial intermembrane factor with RNA-processing 
exoribonulease activity. Component of the mitochondrial 
degradosome (mtEXO) complex, that degrades 3’ 
overhang double-stranded RNA with a 3’-to-5’ 
directionality in an ATP-dependent manner. Required for 
correct processing and polyadenylation of mitochondrial 
mRNAs.
PPP1R9A protein phosphatase 
1, regulatory subunit 
9A
Binds to actin filaments (F-actin) and shows cross- 
linking activity. Binds along the sides of the F-actin. May 
be involved in neurite formation. Inhibits protein 
phosphatase 1- alpha activity
RAB3GAP1 RAB3 GTPase 
activating protein 
subunit 1
Probable catalytic subunit of a GTPase activating protein 
that has specificity for Rab3 subfamily (RAB3A, RAB3B, 
RAB3C and RAB3D). Rab3 proteins are involved in 
regulated exocytosis of neurotransmitters and hormones. 
Specifically converts active Rab3-GTP to the inactive 
form Rab3-GDP. Required for normal eye and brain 
development. May participate in neurodevelopmental 
processes such as proliferation, migration and 
differentiation before synapse formation, and non-
synaptic vesicular release of neurotransmitters




Implicated in a number of cellular processes, including 
proliferation, differentiation, caspase-dependent and 
caspase- independent apoptosis, suppression of 
transformation (tumor suppressor), inhibition of protein 
phosphatase 2A, regulation of mRNA trafficking and 
stability in association with ELAVL1, and inhibition of 
acetyltransferases as part of the INHAT (inhibitor of 
histone acetyltransferases) complex. Plays a role in 
E4F1- mediated transcriptional repression
PPP2R5D protein phosphatase 
2, regulatory subunit 
B’, delta
The B regulatory subunit might modulate substrate 
selectivity and catalytic activity, and also might direct the 
localization of the catalytic enzyme to a particular 
subcellular compartment
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Gene name Full name Description
EIF3M eukaryotic translation 
initiation factor 3, 
subunit M
Component of the eukaryotic translation initiation factor 3 
(eIF-3) complex, which is required for several steps in 
the initiation of protein synthesis. The eIF-3 complex 
associates with the 40S ribosome and facilitates the 
recruitment of eIF-1, eIF-1A, eIF-2-GTP-methionyl-tRNAi 
and eIF-5 to form the 43S preinitiation complex (43S 
PIC). The eIF-3 complex stimulates mRNA recruitment to 
the 43S PIC and scanning of the mRNA for AUG 
recognition
C6orf174 C6orf174 protein
NUP88 nucleoporin 88kDa Essential component of nuclear pore complex 
ALDH4A1 aldehyde 
dehydrogenase 4 
family, member A1
